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ABSTRACT 
Down’s syndrome is a classic chromosomal disorder with an incidence rate of one in every 
750 live births. Early detection of Down’s syndrome pregnancies through screening will 
provide the option of early termination of pregnancy and better obstetric care to women 
with affected pregnancies. Some of the screening policies which have been implemented in 
the  UK  are  second  trimester  double,  triple  or  quadruple  marker  tests,  first  trimester 
combined  ultrasound  and  biochemical  (CUB)  screening,  and  integrated  screening. 
Screening performance can be optimized by applying appropriate correction factors for 
variables such as maternal smoking, ethnicity and assisted conception. Typical screening 
performance  is  around  70%  detection  of  Down’s  syndrome  pregnancies  at  a  5%  false 
positive rate for second trimester quadruple marker screening, 90% detection at a 5% false 
positive  rate  for  CUB  screening  and  90%  detection  at  a  1-2%  false  positive  rate  for 
integrated screening. The NHS Fetal Anomaly Screening Programme Committee has set a 
current performance target for Down’s syndrome screening of at least 75% detection at a 
3% or lower false positive rate and this can be achieved by CUB or integrated testing by 
setting a threshold (cut-off) risk of 1 in 150 at term. However, further improvements in 
performance proposed by the Committee to meet a detection rate of 90% at a false positive 
rate of 2% or less are unlikely to be reached by single stage testing, and protocols which 
include  some  element  of  sequential  testing  are  required.  The  Health  Technology 
Assessment Programme is currently reviewing two new approaches to screening, namely, 
repeated measure and cross trimester testing to evaluate their potential to meet the more 
challenging standard.  Abstract 
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In the present study, using various combinations of maternal serum marker and ultrasound 
measurements, several screening strategies and refinements are explored to establish their 
potential  for  improving  detection  rates  and  reducing  false  positive  rates  in  Down’s 
syndrome screening. Extensive use has been made of routinely collected screening data 
from the west of Scotland Regional Screening programme for retrospective analysis using 
standard  Gaussian  methods,  statistical  modeling  and  SPSS  and  S-PLUS  statistical 
software.  The  performance  of  within-  and  across-trimester  contingent  screening 
programmes have been evaluated and the effects of ethnicity, maternal smoking habit and 
assisted reproductive technology (ART) on screening markers has been assessed using first 
and second trimester samples.  
Screening within the first trimester 
The  standard  approach  to  CUB  screening  is  to  carry  out  maternal  serum  marker 
measurements (PAPP-A and fβhCG) and ultrasound Nuchal Translucency measurements 
at  11-13+6  weeks  of  gestation.  This  study  had  also  shown  that  in  the  CUB  screened 
population  in  the  west  of  Scotland,  adopting  a  within-trimester  contingent  screening 
protocol  where  all  women  have  serum  marker  testing  but  only  those  women  with 
intermediate  risks  from  the  serum  markers  are  offered  NT,  would  have  achieved  a 
detection rate of 88.7% at a false positive rate of 5.8% with 29% of women requiring an 
NT measurement. Using LMP based gestational age this screening protocol would have 
achieved a detection rate of 83.3% at a false positive rate of 7.4% with 25.9% of women 
requiring an NT measurement. When analysis was performed only on pregnancies with 
certain LMP dates, the contingent screening protocol would have achieved a detection rate 
of  88.9%  at  a  false  positive  rate  of  7.0%  with  25.3%  of  women  requiring  an  NT 
measurement. Where ultrasound resources are scarce within-trimester contingent screening Abstract 
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has the potential to maintain screening performance whilst reducing the number of NT 
scans required. 
Across –trimester screening 
Evidence suggests that sequential testing strategies can improve screening performance. 
This  has  been  explored  in  this  study  by  statistical  modelling  using  S-PLUS.  Various 
combinations of markers were tested. It was estimated that optimal performance could be 
achieved by a cross-trimester contingent screening protocol with repeat measures of PAPP-
A (NT, PAPP-A, fβhCG in the first trimester followed by AFP, hCG, InhA, uE3, PAPP-A 
in the second trimester in a sub-set of women with intermediate risks). This could achieve 
a detection rate of 92.2% at a false positive rate of 1.4% but with only 9.7% of women 
requiring  a  second  trimester  screening  test.  This  meets  the  aspirational  performance 
standard proposed by the UK NSC. Without NT measurements (i.e. serum only screening), 
the model indicates that this screening protocol would achieve a detection rate of 86.2% at 
a false positive rate of 3.0% with 22.3% of women requiring a second trimester screening 
test. Therefore, the inclusion of NT measurement at the first stage of testing is necessary to 
achieve the desired performance. 
The Effects of Smoking and Ethnicity 
Many maternal and pregnancy factors are known to affect serum marker concentrations 
and small but useful improvements in screening performance can be made by correcting 
for these. Changes however, vary between trimesters and in this study paired first and 
second trimester samples have been used to measure the changes in serum marker levels in 
smokers and between different ethnic groups at each stage of pregnancy. 
 Abstract 
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In this study, the AFP level in smokers was increased in the first trimester by 16.3% when 
compared with the non-smokers. The hCG level in smokers was decreased by 27.6% and 
30.5% in the first and second trimesters respectively. The fβhCG level was decreased in 
smokers in the second trimester by 17.1% when compared with non-smokers. The PAPP-A 
level was decreased by 14% and 22.8% in first and second trimesters respectively when 
compared  with  non-smokers.  These  results  demonstrate  that  the  effect  of  smoking  is 
gestation dependant and without appropriate correction factors being applied, these serum 
marker changes would result in inappropriate risks being estimated for individual women. 
The study on the effect of ethnicity on screening markers has shown that South Asian 
women had higher hCG levels in the first trimester compared with Caucasian women. 
They also had lower fβhCG and PAPP-A in the second trimester. Oriental women had 
higher first and second trimester hCG levels when compared with Caucasian women. They 
also had higher fβhCG and PAPP-A levels in the first trimester. Middle East women had 
lower  first  trimester  AFP  when  compared  with  Caucasian  women.  Black  women  had 
higher hCG in the first trimester when compared with Caucasian women. In Black women, 
the PAPP-A level was also elevated in both trimesters. While this study confirms that 
correction for ethnicity is clearly indicated, appropriate correction factors are difficult to 
derive as there is likely to be some variation in the classification of ethnicity between 
studies.  
Assisted Reproductive Technology 
The growing use of ART in developed countries and the variety of different methods 
employed make accurate correction factors desirable but difficult to derive. In this study, 
women pregnant after ART had larger NT measurements compared with women who had 
conceived spontaneously. The PAPP-A level was lower in the IVF or ICSI with fresh eggs Abstract 
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group when compared with the controls. Among the ART treatment groups, the NT was 
higher in the IVF or ICSI with fresh eggs group when compared with the controls. The 
AFP  level  was  higher  in  the  IVF  with  donor’s  egg  group  when  compared  with  the 
controls. The hCG level was higher in the ART group overall when compared with the 
controls. Women pregnant after IVF or ICSI with fresh eggs and frozen eggs had higher 
hCG level. 
Smoking frequency, birthweight and prematurity 
In addition to its effects on serum marker concentrations, smoking in pregnancy is known 
to  be  associated  with  low  birth  weight  and  prematurity.  It  is  important  therefore  that 
maternal smoking is accurately recorded on screening request forms and in this study, the 
accuracy of self reported smoking status was assessed by analysis of cotinine in serum. 
Results  showed  that  the  percentage  of  self-reported  smokers  (24.1%)  at  booking  was 
significantly  lower  than  the  cotinine-validated  estimate  of  30.1%.  Also,  smoking  was 
associated with low birth weight,  delivery prior to 39 weeks, increased AFP level (3.1%) 
and reduced hCG level (28.7%) in the second trimester. An increasing AFP level (but not 
hCG level) was associated with lower birth weight and  delivery prior to 39 weeks in both 
smokers and non smokers but the effect was most marked in smokers. The difference in 
birth weight between the highest and the lowest AFP category for non-smokers was 448.3g 
and for smokers was 619.2g, suggesting that smoking exacerbates the effect of an elevated 
AFP  on  birth  weight.  Overall  the  difference  in  birth  weight  between  the  lowest  AFP 
category in non smokers and the highest AFP category in smokers was 931.6g. 
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Summary 
 In summary, this study has shown that a cross-trimester contingent screening protocol 
with repeat measures has the potential to meet the UK NSC aspirational standard of 90% 
detection of Down’s syndrome pregnancies with a screen positive rate of less than 2%. 
Around 90% of women would complete screening in the first trimester without the need 
for a second stage sequential test. Correcting for factors such as maternal smoking habits, 
ethnicity and ART would further improve screening performance. Also it has been shown 
that where ultrasound resources are scarce, within-trimester and across-trimester protocols 
can reduce the need for NT measurement in all women and still deliver excellent screening 
performance although this falls short of the higher performance standard. The potential of 
these new screening protocols now need to be tested in prospective multicentre trials to 
confirm their performance in prospective practice. Declaration 
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1.1 BACKGROUND 
Down’s  syndrome,  a  classic  chromosomal  disorder  resulting  in  mental  retardation  and 
severe  congenital  disorders,  was  the  first  medical  condition  to  be  associated  with  a 
chromosomal abnormality. With the incidence rate of one in every 750 live births, early 
detection  through  screening  is  imperative  to  help  in  prenatal  diagnosis  of  Down’s 
syndrome.  This  will  provide  the  option  of  early  termination  of  pregnancy  and  better 
obstetric care to the women with Down’s syndrome pregnancies (Gardner and Sutherland, 
2004; Roper and Reeves, 2006). 
The  Down’s  Syndrome  Screening  Programme  was  started  under  the  UK  National 
Screening  Committee  (NSC).  The  UK  NSC  sets  standards  and  oversees  the 
implementation of screening programmes in England. The committee was set up in 1996. 
The  recommended  screening  strategies  from  2007  are  the  first  trimester  combined 
ultrasound  and  biochemical  (CUB)  screening,  integrated  testing  and  serum  integrated 
testing. The Health Technology Assessment is currently reviewing two new strategies for 
screening, namely, repeated measure and cross trimester testing. These tests are expected 
to further improve the performance of Down’s syndrome screening programmes in the 
period after 2010 (NHS Fetal Anomaly Screening Programme, 2008). 
1.2 DOWN’S SYNDROME 
The earliest mention of this disorder was made by John Langdon Down in 1866. Down 
described this disorder as ‘Mongolian Idiocy’ in an essay classifying mental handicaps.  
However,  the  cause  of  the  disorder  remained  unknown  until  1959,  when  a  French 
cytogeneticist,  Jerome  Lejeune,  discovered  trisomy  21  as  the  cause  of  this  genetic Chapter 1 : Introduction 
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abnormality. Subsequently, the condition was renamed as ‘Down’s Syndrome’ in 1961, 
after John Langdon Down (Chudley and Chodirker, 2003)     
1.2.1 INCIDENCE RATE OF DOWN’S SYNDROME 
Down’s syndrome, a classic chromosomal disorder, was the first medical condition to be 
associated with a chromosome abnormality in 1959 (Lejeune et al., 1959). In the absence 
of prenatal intervention, one in 750 live births in a typical population is affected by this 
chromosomal disorder (Gardner & Sutherland, 2004; Roper and Reeves, 2006). According 
to  the  Scottish  Perinatal  and  Infant  Mortality  and  Morbidity  Report  2007,  the  rate  of 
Down’s syndrome in Scotland was 1.02 in 1000 births (1 in 980), during the period of 
2002  to  2006  (Information  Services  Division  NHS  Scotland,  2008)  and  this  lower 
incidence  reflects  the  impact  of  screening  and  prenatal  diagnosis.  A  large  number  of 
Down’s syndrome pregnancies are sufficiently viable to survive to term (Cuckle, 2005). At 
conception, the frequency of Down’s syndrome is much higher. Nearly 75% of the Down’s 
syndrome fetuses identified during the first trimester, and about 50% of those identified 
during the second trimester are lost before the completion of the pregnancy term (Roper 
and Reeves, 2006). Advanced maternal age is the strongest risk factor linked to the cause 
of Down’s syndrome pregnancies. The birth prevalence increases from 0.6 to 4.1 per 1,000 
between the age of 15 and 45. This risk increases even more with a previous history of a 
Down’s syndrome pregnancy (Cuckle, 2005).     Chapter 1 : Introduction 
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1.2.2 PHENOTYPE OF DOWN’S SYNDROME 
Down’s syndrome is associated with variable phenotypes. However, mental retardation, 
neonatal hypotonia, small and hypocellular brain and minor facial dysmorphic features 
such as small nose, up-slanting palpebral fissures, speckling of iris (Brushfield spots), flat 
facial profile, low set ears, single palm crease, wide gap between the first and second toes 
and shortened fifth finger can be seen in almost all individuals with Down’s syndrome 
(Korenberg et al., 1994). 
Those with Down’s syndrome also suffer from other congenital abnormalities such as heart 
defects and gastrointestinal abnormalities. A study conducted by Hayes et al (1997) in 
Dublin showed that heart defect is the most common abnormality among children (found 
in 45.8%) with Down’s syndrome followed by gastrointestinal disorders. This finding was 
consistent  with  another  study  conducted  in  Strasbourg  by  Stoll  et  al  (1998).  Other 
abnormalities such as urinary tract malformation, limb defects and congenital cataract have 
also been reported along with Alzheimer disease in those surviving beyond the age of 40 
(Hayes et al., 1997; Stoll et al., 1998; Noble, 1998; Baliff and Mooney, 2003). Chapter 1 : Introduction 
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Non-disjunction 
at maternal 
meiosis I 
Chromosome 21 
Normal meiosis I 
Trisomy 21  Monosomy 21 
1.2.3 CYTOGENETICS OF DOWN SYNDROME 
Over 95% of Down’s syndrome cases are caused by trisomy 21, where the cells in the 
body have three copies of chromosome 21 instead of the normal two. Studies have shown 
that non-disjunction at maternal meiosis 1 is the primary cause of most trisomy 21 cases 
(Robinson,  1977;  Sherman  et  al.,  1994;  Noble,  1998).  Non-disjunction  occurs  when 
homologous chromosomes fail to segregate symmetrically at cell division. This causes one 
daughter cell to have two copies of chromosome 21 and the other have none (Gardner & 
Sutherland,  2004).  Figure  1.1  illustrates  the  classic  view  of  the  mechanism  of  non-
disjunction.  The  other  causes  of  Down’s  syndrome  are  Mosaicism  and  Robertsonian 
chromosomal translocation. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: The mechanism of non-disjunction in Trisomy 21 
(Reproduced from http://www.perinatal.nhs.uk/car/anomaly/chromosome/downs.htm) Chapter 1 : Introduction 
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1.3 PRENATAL DIAGNOSIS   
Prenatal diagnosis allows the option of termination of pregnancy or better obstetric care 
and planned delivery for the pregnancy. Prenatal diagnosis may be offered to women who 
are identified as high risk through a screening test, who are in advanced childbearing age, 
or who have had a previous child with a chromosome abnormality.   
1.3.1 AMNIOCENTESIS 
Prenatal  diagnosis  of  chromosomal  disorders  using  amniocentesis  has  been  well 
established since the early 1970s. In second trimester amniocentesis, which is performed 
around 16  weeks  of  gestation, a needle is inserted through the  abdominal wall ideally 
under ultrasound guidance into the amniotic cavity and a sample of amniotic fluid (20mls) 
is collected. The fetal cells from the amniotic fluid can then be cultured and karyotyping 
performed. The disadvantage of this diagnostic procedure is that the results are available 
only after 16 weeks of gestation as cell culture and karyotyping may take 2 to 3 weeks. The 
long  waiting  period  for  the  diagnostic  results  can  cause  anxiety  among  the  pregnant 
women  and  termination  of  pregnancy  is  more  difficult  and  traumatic  at  late  stages  of 
pregnancy (Alfirevic et al., 2003; Gardner & Sutherland, 2004).   
Early amniocentesis, which is performed at 9 to 14 weeks of gestation, was first introduced 
in  the  late  1980s.  This  diagnostic  procedure  is  the  same  as  the  second  trimester 
amniocentesis. Ultrasound was considered essential to guide the needle into the amniotic 
cavity due to the small target area (Alfirevic et al., 2003; Gardner & Sutherland, 2004). 
Studies however have found that fetal loss rate in early amniocentesis (2.2%) was greater 
than in second trimester amniocentesis (0.6%)  (Nicolaides et al., 1994b; Daniel et al., 
1998;  Collins  et  al.,  1998)  and  this  method  has  generally  been  abandoned.  Early Chapter 1 : Introduction 
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amniocentesis also has an adverse effect on perinatal lung function. Yuksel et al (1997) 
reported that infants whose mothers had had early amniocentesis during pregnancies had 
higher  thoracic  gas  volume  (TGV)  and  lower  functional  residual  capacity  (FRC)  than 
infants whose mother had undergone no invasive diagnosis procedure.    
1.3.2 CHORIONIC VILLUS SAMPLING  
Chorionic villus sampling (CVS) is a first trimester diagnostic procedure performed at 10 
to 11 weeks of gestation. This procedure was first developed in China in the mid 1970s and 
then expanded to the Western countries in 1980s (Alfirevic et al., 2003).  In CVS, the 
sampling of placental tissue is done using percutaneous transabdominal or transvaginal / 
transcervical method with ultrasound guidance. The transabdominal technique is the most 
commonly used method now. The early diagnosis of chromosomal abnormalities permits 
pregnant women to access early pregnancy termination (Alfirevic et al., 2003; Gardner & 
Sutherland, 2004). However, this diagnostic procedure has a risk of fetal loss of 1.5-2% 
(Brun et al., 2003).   
1.3.3  RAPID  DIAGNOSTIC  TECHNIQUES  APPLIED  TO 
AMNIOCENTESIS & CVS 
The standard karyotype analysis involves cell culture, harvesting of dividing cells, staining 
and the analysis of chromosome banding. In the UK, the average reporting time using this 
analytical method is 13 to 14 days (NEQAS, 2000).  It was the need for a quick and rapid 
method for the detection of chromosomal abnormalities that led to the development of 
fluorescence in situ hybridisation (FISH) and quantitative fluorescence polymerase chain 
reaction (QF-PCR) techniques. FISH uses chromosome-specific probes with fluorescent 
labels attached for detection of fetal chromosomal abnormalities. QF-PCR is based on the Chapter 1 : Introduction 
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amplification of repeat sequences at the polymorphic loci. The application of FISH and 
QF-PCR  enables  diagnosis  and  reporting  of  chromosomal  abnormalities  within  24-48 
hours of sample receipt (Pertl et al., 1999; Mann et al., 2001; Grimshaw et al., 2003; 
Nicolini et al., 2004).  
1.4 PRENATAL SCREENING 
The development of screening for fetal abnormalities has greatly improved the prenatal 
care in many developed countries. According to Wald (1994), screening  is defined as ‘The 
systematic application of a test or inquiry, to identify individuals at sufficient risk of a 
specific disorder to benefit from further investigation or direct preventative action, among 
persons who have not sought medical attention on account of symptoms of the disorder’. 
Women who are screened positive are generally offered counselling and a diagnostic test.  
In the 1970s, screening for Down’s syndrome was performed based on advanced maternal 
age. The women, who were pregnant at the age of 35 or above, were offered diagnostic 
testing through amniocentesis (Benn, 2002; Powell and Grudzinskas, 1995). Due to the 
small but distinct risk of pregnancy loss following amniocentesis and the inability to detect 
Down’s syndrome pregnancies in women who were aged less than 35 years, efforts were 
made to develop a screening test which could be offered to all women and identify those 
who are at high risk of fetal aneuploidy (Powell and Grudzinskas, 1995). The estimated 
rate of Down’s syndrome rises from about 0.6 per 1000 (1 in 1667) at age 20 to about 1.1 
per 1000 (1 in 909) at age 30, 3.2 per 1000 (1 in 313) at age 35, 11.1 per 1000 (1 in 90) at 
age 40 and 40.5 per 1000 (1 in 25) at age 45 (Hook, 1981). 
All  pregnant  women  are  therefore  at  risk  of  having  a  pregnancy  with  a  chromosomal 
abnormality. When a pregnant woman opts into a screening programme, her individual risk Chapter 1 : Introduction 
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is calculated based on the ‘a priori risk’, which depends on maternal age, gestational age, 
and  the  screening  test  results.  The  ‘a  priori  risk’  is  multiplied  by  the  likelihood  ratio 
derived from the screening test, to determine the patient-specific risk. The ‘a priori risk’ 
generally  increases  with  maternal  age  and  decreases  with  advancing  gestation.  This  is 
because fetuses with chromosome abnormalities are more likely to die in utero compared 
to normal fetuses (Hook, 1981; Ferguson-Smith and Yates, 1984; Snijders et al., 1994; 
Snijders et al., 1999; Nicolaides, 2004). 
1.4.1 MATERNAL AGE RISK  
With the development of prenatal screening, a need for maternal age-specific prevalence 
rates arose. A maternal age-specific rate schedule developed by Cuckle et al (1987) is 
widely employed for the purpose. The maternal age-specific risk schedule was developed 
by plotting a regression curve using the combined results of eight large, published surveys 
of  Down’s  syndrome  in  live  births.  It  was  widely  used  in  risk  calculation  and  was 
embedded in many computer programmes used in routine screening.  The widespread use 
of  this  rate  schedule  and  the  need  for  accurate  maternal  age-specific  rates  of  Down’s 
syndrome,  led  to  further  critical  re-evaluations  of  this  data  (Hecht  and  Hook,  1994). 
Subsequently, Hecht and Hook (1996) reported that the schedule in their study predicted 
higher rates than those predicted by Cuckle et al (1987), particularly in older women and 
proposed an alternate rate schedule. This finding was confirmed by Bray et al (1998) using 
meta-analysis of nine data sets to estimate maternal age-specific risk.  In 1998, Cuckle 
investigated  the  effect  of  using  different  maternal  age-specific  prevalence  curves  on 
detection rate, for three second trimester screening protocols. Cuckle (1998) concluded that 
the inaccuracy caused by the use of different maternal age curves is unlikely to markedly 
influence the Down’s syndrome screening result. Chapter 1 : Introduction 
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Pregnancies with Down’s syndrome are likely to end in spontaneous fetal loss. Therefore, 
the  risk  of  having  pregnancy  with  Down’s  syndrome  changes  with  gestational  age.  In 
1999, Morris et al investigated the fetal loss rates in Down’s syndrome pregnancies using 
data from National Down’s syndrome Cytogenetics Register. Based on this study together 
with two other previous studies (Macintosh et al., 1995; Halliday et al., 1995), Morris et al 
(1999)  reported  that  nearly  43%  of  pregnancies  ended  in  a  miscarriage  or  still  birth 
between the time of CVS and term, and about 23% of miscarriages or still births occurred 
between the time of amniocentesis and term and 12% of births were stillborn or resulted in 
a neonatal death. A later study by Savva et al (2006) on the relationship between maternal 
age and the risk of spontaneous fetal loss in Down’s syndrome pregnancies confirmed that 
the fetal loss rate in Down’s syndrome pregnancies increases with maternal age.             
1.4.2 SCREENING MARKERS 
Nuchal translucency (NT), alpha fetoprotein (AFP), human chorionic gonadotropin (hCG), 
free β  human chorionic gonadotropin (fβhCG), pregnancy associated plasma protein A 
(PAPP-A), unconjugated estriol (uE3) and inhibin A (InhA) are commonly used markers in 
Down’s syndrome screening. The concentrations of these biochemical markers changes 
with gestation. Therefore, in order to remove the fluctuation caused by gestation in the 
marker levels, the concentrations of the markers are normally expressed as ‘multiple of the 
median’ (MoM) where the observed concentration is expressed as a ratio of the median 
value observed in a normal pregnancy of the same gestation. When the MoM values are 
transformed to log, the distributions in both normal and Down’s syndrome pregnancies are 
Gaussian.  However,  there  is  no  complete  separation  between  the  normal  and  Down’s 
syndrome pregnancies (Spencer, 2007; Aitken et al., 2007). Cuckle et al (1987) proposed 
the use of Gaussian distribution to derive the likelihood that a particular marker level is Chapter 1 : Introduction 
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associated with Down’s syndrome pregnancy. Likelihood ratio is the proportion of affected 
pregnancies with a given marker level divided by the proportion of unaffected pregnancies 
with the same marker level. Using the Gaussian distribution, the likelihood ratio can be 
derived from the ratio of the heights of the two log Gaussian frequency distributions at the 
given marker level (Cuckle et al., 1987).  
1.4.3 MARKER PREDICTIVE VALUE 
The efficiency of a marker in screening depends on two factors;1) the shift of the mean or 
median level in affected cases and 2) the spread of the values (the standard deviation (SD)) 
in  affected  and  unaffected  cases.  The  marker  with  greater  median  shift  in  affected 
pregnancies and/or with smaller spread of values will have better predictive value and be 
more effective. Mahalanobis distance is normally used to evaluate the effectiveness of a 
marker in screening for Down’s syndrome. Mahalanobis distance is calculated using the 
following equation:  
(Mean [unaffected] – Mean [affected]) / SD [unaffected]
2 
Table  1.1  shows  the  estimated  Mahalanobis  distance  for  Down’s  syndrome  screening 
markers in first and second trimesters. Using this calculation, PAPP-A, fβhCG and NT 
measurement are the best markers for first trimester screening and hCG, InhA and fβhCG  
are the best markers for second trimester screening (Aitken et al., 2007). 
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Table 1.1: Mahalanobis Distance of Down’s syndrome screening markers (Aitken et  
al., 2007) 
 
1.4.4 SECOND TRIMESTER SCREENING 
1.4.4.1 ALPHA-FETOPROTEIN (AFP) 
Second trimester screening is performed between 15 and 20 weeks of gestation. In 1984, 
alpha-fetoprotein (AFP) was discovered to be a potential biochemical marker to identify 
pregnancies with increased risk of Down’s syndrome and other trisomies (Merkatz et al., 
1984). AFP is a 69kD protein that belongs to the albuminoid family. AFP is synthesized by 
the yolk sac and the fetal liver (Powell et al., 1995, Seppala, 1975, Mizejewski, 2001). 
During pregnancy, fetal AFP enters the maternal circulation via two possible pathways; 
transplacental diffusion and transamniotic membrane diffusion (Mizejewski, 2001). AFP 
concentration  in  the  maternal  circulation  increases  progressively  to  peak  at  32  weeks 
(Macintosh and Chard, 1993). 
Markers 
Mahalanobis Distance 
First trimester  Second trimester 
AFP  0.23  0.69 
hCG  0.38  1.86 
InhA  0.35  1.65 
uE3  0.68  1.20 
PAPP-A  2.08  - 
FβhCG  1.45  2.04 
NT  6.46  - Chapter 1 : Introduction 
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According  to  several  studies,  a  reduction  in  the  maternal  serum  AFP  level  occurs  in 
Down’s syndrome pregnancies, in the second trimester (Merkatz et al., 1984; Cuckle et al., 
1984; Fuhrmann et al.,  1984; Tabor et al., 1984). A study by Newby  et al (1997) on 
biochemical markers and pathophysiology of Down’s syndrome pregnancies indicated that 
the unchanged level of AFP in fetal liver homogenates and the significant elevation of AFP 
in placental tissue from Down’s syndrome pregnancies suggest a possible transport defect 
specific to AFP which reduces the amount of AFP reaching the maternal circulation to 
about 75% of the level in unaffected pregnancies. 
In 2002, Spencer et al studied the trend of marker median levels in Down’s syndrome 
pregnancies  between  6  and  20  weeks  of  gestation.  Figure  1.2  illustrates  the  trend  of 
multiple of the median (MoM) of AFP in Down’s syndrome pregnancies between 6 and 20 
weeks of gestation. The AFP measurement does not separate unaffected pregnancies from 
Down’s  syndrome  pregnancies  for  gestational  ages  below  10  weeks.  The  optimum 
gestational age for AFP measurement for Down’s syndrome screening is at approximately 
16 weeks as there is the maximum separation at that gestational age (Spencer et al., 2002).   
In the 1970s, screening for Down’s syndrome was performed based on advanced maternal 
age  alone.  In  1987,  Cuckle  and  co-workers  estimated  the  risk  of  having  a  Down’s 
syndrome pregnancy by combining maternal age and maternal serum AFP level. Cuckle et 
al  (1987)  reported  that  screening  for  Down’s  syndrome  using  both  maternal  age  and 
maternal  serum  AFP  level  was  more  efficient  than  using  maternal  age  alone.  For  an 
example, using maternal age and AFP level, a detection rate of 28% with a false positive 
rate of 2.8% would be achieved for a risk cut-off of 1:200. Using maternal age alone, the 
same  detection  rate  (28%)  could  be  achieved  with  a  higher  false  positive  rate  (4.3%) 
(Cuckle et al., 1987).      Chapter 1 : Introduction 
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1.4.4.2 HUMAN CHORIONIC GONADOTROPIN (hCG) 
In 1987, Bogart et al discovered an association between elevated second trimester human 
chorionic gonadotropin (hCG) levels and Down’s syndrome pregnancies. Human chorionic 
gonadotropin  is  a  glycoprotein  hormone  with  a  molecular  weight  of  36,000  to  46,000 
daltons. Human chorionic gonadotropin is synthesized in the syncytiotrophoblast cells and 
composed of two subunits (alpha and beta). The alpha subunit has a structure similar to 
that of luteinizing hormone, follicle stimulating hormone and thyroid stimulating hormone. 
Whereas, the beta subunit is a unique glycoprotein specific to hCG. In the circulation, hCG 
is  mostly  in  the  intact  form  and  0.3%  to  4%  exists  as  free  beta  human  chorionic 
gonadotrophin (fβhCG) (Powell and Grudzinskas, 1995; Albertini et al., 1982; Macintosh 
and Chard, 1993).  
Figure 1.2: Mean log10 (AFPMoM) for each gestational age 
(reproduced from Spencer et al., 2002) 
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Spencer (1991) investigated the analytical and clinical performance of the measurement of 
second  trimester  fβhCG  in  pregnancies  affected  by  Down’s  syndrome.  The  study 
demonstrated  that  fβhCG  is  elevated  (0.99  MoM  in  unaffected,  2.06  MoM  in  Down’s 
syndrome) in pregnancies affected by Down’s syndrome. Studies by Newby et al (1997) 
also showed that hCG and fβhCG levels in second trimester placental tissue from Down’s 
syndrome  pregnancies  were  higher  than  those  in  placental  tissues  from  unaffected 
pregnancies. The similar changes of these markers both in the maternal serum and the 
placental tissue from Down’s syndrome pregnancies suggest that the transport of these 
markers from their site of synthesis to the maternal circulation is not affected in Down’s 
syndrome pregnancies.      
Later studies of Spencer et al (2002) showed that optimum efficiency of screening using 
hCG can be achieved at 16 weeks of gestation. hCG level was found to be similar in both 
affected  and  unaffected  pregnancies  between  10  to  12  weeks  of  gestation  (Figure  1.3) 
(Spencer et al., 2002). 
 
 
Figure 1.3: Mean log10 (hCGMoM) for each gestational age 
 (reproduced from Spencer et al., 2002) 
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FβhCG  level  was  found  to  be  a  viable  marker  between  10  to  20  weeks  of  gestation. 
However  the  optimum  efficiency  can  be  achieved  when  screening  is  performed  at  15 
weeks of gestation (Figure 1.4) (Spencer et al., 2002). 
 
 
1.4.4.3 UNCONJUGATED ESTRIOL (uE3) 
The reduction in secretion of AFP by the fetal liver in Down’s syndrome led Canick and 
co-workers (1988) to investigate other fetal liver products which might also be associated 
with Down’s syndrome. Unconjugated estriol (uE3), a steroid product of the fetoplacental 
unit, requires the participation of the fetal liver for its synthesis. It is synthesized in the 
syncytiotrophoblast from fetal precursors. Dehydroepiandrosterone (DHEA) is produced 
by the fetal adrenal and is converted to 16OH-DHEA by the fetal liver. These compounds 
circulate in the fetus as sulphate conjungates. The newly formed 16OH-DHEA sulphate is 
deconjugated  by  the  placenta  and  converted  to  estriol  by  an  aromatase.  Estriol  can  be 
measured as unconjugated steroid in maternal circulation (Wald et al., 1988; Macintosh 
and Chard, 1993). 
Figure 1.4: Mean log10 (FβhCGMoM) for each gestational age 
(reproduced from Spencer et al., 2002) Chapter 1 : Introduction 
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The studies by Canick et al (1988) indicated that maternal serum uE3 was decreased in 
Down’s  syndrome  pregnancies  with  a  median  MoM  of  0.79.    This  finding  was  later 
confirmed by other studies on uE3 (Wald et al., 1988; Wald et al., 1991; Crossley et al., 
1993). Although uE3 was found to be a useful marker for Down’s syndrome screening, 
there was concern regarding the high correlation between AFP and uE3 (Crossley et al., 
1993;  Powell  and  Grudzinskas,  1995)  and  imprecision  of  uE3  assay  (Powell  and 
Grudzinskas, 1995). 
1.4.4.4. INHIBIN A (InhA) 
In 1992, Van Lith et al published a report showing that inhibin may be a useful marker for 
Down’s  syndrome  screening.  Inhibin  ,  a  heterodimeric  glycoprotein  with  a  molecular 
weight of 32 000D, composed of an α-subunit and one of the two β subunits (βA or βB). 
When the β subunit combined with the α subunit, it gives rise to either dimeric inhibin-A 
or  inhibin-B.In  early  pregnancy,  the  feto-placental  unit  is  the  major  source  of  inhibin 
(InhA) (Florio et al., 2001). InhA levels have a profile similar to hCG and are lowest in the 
maternal  serum  from  unaffected  pregnancies  at  17  weeks  of  gestation  (Aitken  and 
Crossley, 2005).  
Maternal serum inhibin level was reported to be elevated in Down’s syndrome pregnancies 
in the second trimester (Van Lith et al., 1992; Spencer et al., 1993; Cuckle et al., 1994a). 
However the degree of elevation of inhibin levels in Down’s syndrome pregnancies varied 
from study to study. Inhibin was initially studied using non-specific assays that utilizes 
antibodies  directed  towards  the  α  subunit  of  inhibin.  Such  an  assay  measured  total 
immunoreactive  inhibin  and  failed  to  specifically  detect  intact  dimeric  InhA.  The 
development of new assay enabled to detect intact dimeric InhA rather than non-specific 
immunoreactive inhibin.  Chapter 1 : Introduction 
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In 1996, Aitken et al investigated the level of InhA in pregnancies using a new assay 
specific  for  dimeric  InhA.  Their  studies  showed  that  InhA  levels  were  significantly 
elevated in Down’s syndrome pregnancies in the second trimester and measuring the levels 
of InhA together with AFP and fβhCG significantly improved the detection rate.  This 
finding was confirmed by subsequent studies on InhA (Wallace et al., 1996; Haddow et al., 
1998; Renier et al., 1998). 
However, the value of InhA as the fourth marker in the second trimester screening had 
remained debatable, until recently. Although there have been previous reports showing that 
the  second  trimester  maternal  serum  InhA  level  is  elevated  in  Down’s  syndrome 
pregnancies (Aitken et al., 1996; Renier et al., 1998), InhA was not widely used as part of 
screening programs due to issues relating to assays and standardization. The assay is now 
on  a  new  platform  (Access  –  Beckman  Coulter)  with  reduced  inter-  and  intra-kit  lot 
variation.      
In  2001,  Spencer  et  al  reported  that  although  InhA  level  was  increased  in  Down’s 
syndrome  pregnancies  in  the  first  trimester,  it  does  not  improve  the  detection  rate  of 
screening by a combination of pregnancy associated plasma protein A (PAPP-A), fβhCG 
and nuchal translucency (NT) measurement at 10 to 14 weeks of gestation. Christiansen 
and Norgaard-Pedersen (2005) suggested that combination of InhA in early first trimester 
(prior to 11 weeks) screening can be as good as integrated and second trimester screening.   
1.4.4.5 ADAM12   
In 2003, Laigaard et al reported ADAM12 as a promising marker for Down’s syndrome 
screening. The ADAMs belongs to a family of membrane-anchored cell-surface proteins. 
Earlier report by Gilpin et al  (1998) shows that human ADAM12 exist in two forms; Chapter 1 : Introduction 
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ADAM12-S (short) and ADAM12-L (long). The study also revealed that both forms of 
ADAM12 are found in abundance in the human term placenta. 
In the studies by Laigaard et al (2003), it was found that ADAM12 level in the maternal 
serum was 60-fold increase from early to late pregnancy whereas it  is seen to decrease 
significantly  in  Down’s  syndrome  pregnancies,  in  the  first  trimester.    Laigaard  et  al 
(2006a) later reported that ADAM12 was not reduced in Down’s syndrome pregnancies in 
the late first trimester. A further large scale study conducted by  Laigaard and co-workers 
(2006b), for assessing the performance of ADAM12 as first trimester Down’s syndrome 
marker,  confirmed  the  findings  from  the  two  previous  studies  (Laigaard  et  al.,  2003; 
Laigaard  et  al.,  2006a).  ADAM12  was  concluded  to  have  the  best  discriminatory 
efficiency early in the first trimester and the discriminatory power was found to decrease 
from week 10-11 to week 12-13 (Laigaard et al., 2006b). 
Recent studies have showed that ADAM12 levels are reduced in pregnancies prior to 10 
weeks but not to the extent observed by Laigaard et al (2003) (Spencer et al., 2008a; 
Spencer  et  al.,  2008b;  Spencer  et  al.,  2008c).  These  studies  indicate  that  ADAM12  is 
unlikely to be of much value when screening for Down’s syndrome is performed between 
11  to  13  weeks  of  gestation  (Spencer  et  al.,  2008a;  Spencer  et  al.,  2008b).  However, 
certain reports have been made by Christiansen et al (2007) that maternal serum ADAM12 
level is significantly elevated in Down’s syndrome pregnancies in the second trimester. 
Though this finding was confirmed by Donalson et al (2008), the magnitude of increase 
was smaller. More prospective studies are required to establish whether ADAM12 is in fact 
a useful marker for Down’s syndrome screening.    
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The meta-analysis and distributions of maternal serum biochemical markers in Down’s 
syndrome cases in the second trimester are shown in Table 1.2 and Figure 1.5. The largest 
shift in median MoM in Down’s syndrome pregnancies is found for fβhCG, following 
intact hCG and InhA.   
 
Table 1.2: Meta-analysis of maternal serum biochemical markers in Down’s syndrome 
cases in the second trimester (From Aitken et al., 2007) 
 
 
 
 
 
 
Biochemical marker  Down’s syndrome cases  Median MoM 
AFP  1559  0.75 
fβhCG  649  2.26 
hCG  1138  2.07 
uE3  963  0.72 
InhA  930  1.99 Chapter 1 : Introduction 
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Figure 1.5: The distributions of second trimester markers in unaffected and Down’s syndrome 
pregnancies.  Chapter 1 : Introduction 
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The  risk  of  a  pregnancy  being  affected  by  Down’s  syndrome  is  calculated  from  the 
maternal age risk in combination with the AFP, hCG, uE3 and/or other marker levels. 
Table  1.3  shows  the  predicted  screening  performance  using  statistical  modelling  for 
various marker combinations (Cuckle, 2001).  
Table 1.3: Predicted detection rate for a fixed false positive rate of 5% of various second 
trimester marker combinations using statistical modelling (Cuckle, 2001). 
 
In Scotland, maternal serum AFP was first used for Down’s syndrome screening in 1987. 
Maternal serum hCG measurements was included in the screening protocol in 1991. A risk 
cut-off of 1:250 at term is currently used to identify high and low risk pregnancies. The 
results of those women with ‘high risk’ is either faxed or telephoned to the referring source 
as soon as it is available so that patients can be called in for a counselling session. All 
results, including the ‘low risk’ and ‘high risk’ ones, are sent by post to the antenatal clinic, 
in order to inform the patients about the results and to file in the patient record (personal 
communication with Dr. Jenny Crossley). 
1.4.5 FIRST TRIMESTER SCREENING  
Second trimester screening has the disadvantage of a relatively low detection rate with a 
high false positive rate and it is carried out relatively late in pregnancy. This, combined 
Marker combinations  Detection rate (%) 
AFP & hCG  59.3 
AFP, hCG & uE3  62.7 
AFP, hCG, uE3 & InhA  69.0 
AFP & fβhCG  63.2 
AFP,  fβhCG, uE3  66.8 
AFP,  fβhCG, uE3, InhA  72.1 Chapter 1 : Introduction 
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with the fact that CVS can be carried out  as a diagnostic test in the first trimester of 
pregnancy,  led  to  research  interest  in  first  trimester  screening.  As  a  result  of  research 
efforts  around  the  world,  the  two  most  effective  first  trimester  serum  markers  were 
identified; PAPP-A and fβhCG. 
1.4.5.1 PREGNANCY ASSOCIATED PLASMA PROTEIN A (PAPP-A) 
PAPP-A is a pregnancy specific glycoprotein of 750 000 to 820 000 molecular weight 
which exists in pregnancy serum as a heterotetrameric 2:2 complex with the proform of 
eosinophil major basic protein (proMBP). This complex is called PAPP-A/proMBP and 
weights approximately 500kDa. PAPP-A is synthesized in the trophoblast and is detected 
in the maternal circulation about 28 days after implantation (Bischof, 1979; Fialova and 
Malbohan , 2002; Macintosh and Chard, 1993; Powell and Grudzinskas, 1995).  
Earlier studies have shown that first trimester PAPP-A levels are significantly decreased in 
Down’s  syndrome  pregnancies  (Brambati  et  al.,  1993;    Brambati  et  al.,  1991).  Later 
studies by Newby et al (1997) show that PAPP-A levels in both placental tissues and 
maternal circulation are not significantly altered in the second trimester. However, recent 
reports by Spencer et al (2002) indicate that optimum efficiency can be achieved when 
screening is performed in the earlier stages of pregnancy, at about 8 weeks (Figure 1.6).   
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1.4.5.2 FREE β HUMAN CHORIONIC GONADOTROPIN (FβhCG) 
FβhCG level is a viable marker between 10 to 20 weeks of gestation and the optimum 
efficiency using this marker can be achieved when screening is performed at 15 weeks of 
gestation  (Figure  1.4)  (Spencer  et  al.,  2002).  Previous  studies  have  reported  that  first 
trimester  FβhCG  levels  are  significantly  increased  in  Down’s  syndrome  pregnancies 
(Macri et al., 1993; Spencer et al., 1992) and FβhCG is a better marker than intact hCG in 
the first trimester (Hallahan et al., 2000). 
 
 
 
 
Figure 1.6: Mean log10 (PAPP-AMoM) for each gestational age 
(reproduced from Spencer et al., 2002) Chapter 1 : Introduction 
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 The meta-analysis and distributions of maternal serum biochemical markers in Down’s 
syndrome cases in the first trimester are shown in Table 1.4 and Figure 1.7. In the first 
trimester, the largest shift in median MoM in Down’s syndrome pregnancies is found for 
PAPP-A, following fβhCG and InhA.   
 
Table 1.4: Meta-analysis of maternal serum biochemical markers in Down’s syndrome 
cases in the first trimester (From Aitken et al., 2007) 
 
 
Biochemical marker  Down’s syndrome cases  Median MoM 
AFP  637  0.8 
hCG  772  1.35 
uE3  294  0.74 
PAPP-A  1057  0.45 
FβhCG  1190  1.96 
InhA  317  1.47 Chapter 1 : Introduction 
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Figure 1.7: The distributions of first trimester markers in unaffected and Down’s 
syndrome pregnancies.  Chapter 1 : Introduction 
 
27 
 
1.4.5.3 NUCHAL TRANSLUCENCY (NT) 
Another effective marker for Down’s syndrome screening is ultrasound measurement of 
fetal nuchal translucency (NT) (Nicolaides et al., 1994a). ‘Nuchal translucency’ is a term 
used by Nicolaides et al (1992) to describe accumulation of fluid between the fetal skin 
and  soft  tissues  overlying  the  cervical  spine.  In  normal  fetuses,  the  average  maximum 
thickness  of  NT  is  about  1.4  to  1.5mm  at  13 weeks  of  gestation.  Figures  1.8  and  1.9 
illustrate NT in normal and Down’s syndrome fetuses at 12 weeks of gestation. Collection 
of fluid in this ultrasound-translucent area may be caused by various mechanisms including 
cardiac failure and venous congestion. The fetus with increased NT is at high risk of an 
adverse outcome like choromosomal abnormalities (Nicolaides, 2004).  Previous studies 
have shown that increased NT (≥2.5mm) is associated with Down’s syndrome pregnancy 
(Nicolaides et al., 1992; Pandya et al., 1995; Taipale et al., 1997).    
 
    
 
 
Reproduced from:  
http://www.fetalmedicine.com/fmf/training-certification/certificates-of-competence/11-13-week-scan/ 
nuchal/ 
 
Figure 1.8: Ultrasound picture of fetus 
with normal NT thickness. 
Figure 1.9: Ultrasound picture of 
fetus affected with Down’s syndrome 
with increased NT thickness. Chapter 1 : Introduction 
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The optimum gestational age for NT measurement is between 11 weeks and 13 weeks and 
6 days. Nicolaides et al (2002) stated some of the essential criteria in order to achieve 
accurate and uniform NT measurement among different ultrasound operators: 
1.  Providing appropriate training to all sonographers and auditing of their results. 
2.  Good quality ultrasound equipment with video-loop function and callipers which 
will be able to provide measurement to one decimal point (0.1mm).  
3.  Transabdominal  ultrasound  examination  can  successfully  measure  NT  in  about 
95% of cases and transvaginal sonography examination in other cases. 
4.  The fetal crown rump length (CRL) should be between 45mm and 84mm. 
5.  It is essential to take into account the gestational age when determining whether the 
NT measurement is increased because fetal NT increases with CRL. 
6.  A good sagittal section of the fetus is required for the measurement of the CRL. NT 
should be measured when the fetus is in the neutral position. 
7.  It is important to distinguish between fetal skin and amnion because both structures 
appear as thin membranes at this gestation. 
Therefore, in order to achieve a reliable measurement of NT the above criteria should be 
adhered to. The studies by Evans et al (2007) show that inaccuracies in NT measurement 
of 25% or 0.5mm can reduce the detection rate by 18%. 
Two methods are commonly used for standardizing NT measurements in the first trimester 
for Down’s syndrome screening. The first method is the parametric method of multiples of 
the median (MoM). This method involves dividing the measured value by the median of 
the normal population. The second method is the non-parametric method of the delta-NT 
differential. This method involves subtracting the median from the measured value (Wald 
and Hackshaw, 1997; Spencer et al., 2003c).  Chapter 1 : Introduction 
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In 2003, Spencer et al reported that the use of the NT MoM approach in the Down’s 
syndrome risk calculation was inaccurate and inappropriate. This was because the three 
underlying assumptions for the Gaussian MoM approach to be valid were not valid. The 
three basic assumptions were: 
1.  Either NT MoM or some transformation of NT MoM has a Gaussian distribution; 
2.  The standard deviation (SD) of the MoM in the transformed domain is constant;  
3.  The median MoM in trisomy 21 pregnancies is a constant proportion of the median 
for unaffected pregnancies.  
Spencer et al (2003c) found that the distributions of NT MoM (Figure 1.10) and log10(NT 
MoM) were not Gaussian, the SDs did not remain constant with gestation, and the median 
MoM  in  the  trisomy  21  pregnancies  was  not  a  constant  proportion  of  the  median  for 
unaffected  pregnancies.  Therefore,  Spencer  et  al  (2003c)  proposed  that  the  delta-NT 
approach is the best approach to calculate accurate patient-specific risks. Delta-NT takes 
into account the gestational variation in NT by expressing the measured fetal NT as the 
difference from the normal median NT at the measured CRL.  
0.1 0.5 1.0 2.0 5.0 10.0 20.0
Down's syndrome
Unaffected
NT(MOM)  
 
Figure 1.10: The distribution of NTMoM in unaffected and 
Down’s syndrome pregnancies Chapter 1 : Introduction 
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In 1998, Nicolaides and co-workers derived parameters for NT screening based on 95,476 
singleton unaffected pregnancies and 326 Down’s syndrome pregnancies. The median NT 
in  Down’s  syndrome  pregnancies  was  2.02  MoM.  The  log10  standard  deviation  of  the 
distribution was 0.120 in the unaffected pregnancies and 0.235 in the Down’s syndrome. 
This  large  difference  in  standard  deviation  between  unaffected  and  Down’s  syndrome 
pregnancies creates an anomaly in the calculated risk at smaller NT measurements. The 
likelihood ratio decreases as NT MoM reduces to about 0.8 MoM but thereafter begin to 
increase again at lower NT levels. Therefore, a lower truncation limit of 0.8 MoM should 
be  applied  in  the  risk  calculation  to  avoid  giving  incorrect  risks  for  small  NT 
measurements (Crossley and Aitken, 1999).       
When calculating patient-specific risk for Down’s syndrome, NT measurements can be 
incorporated  into  maternal  age-related  risk  and  biochemical  markers.  This  is  done  by 
multiplying the likelihood ratios for NT and for the biochemical markers with maternal 
age-related risk at the time of screening. 
1.4.5.4 OTHER ULTRASOUND MARKERS  
Recently new ultrasound markers have been shown to improve the performance of Down’s 
syndrome screening. Three markers; assessment of nasal bone, tricuspid regurgitation and 
abnormal flow velocity patterns in the ductus venosus appear to be promising (Spencer, 
2007). Cicero et al (2006) reported that the nasal bone was absent in 62.1% of fetuses with 
Down’s syndrome and 0.6% of normal fetus (Figures 1.11 & 1.12). Cicero et al (2005) 
reported that there is no association between an absent fetal nasal bone and PAPP-A or 
fβhCG.  A  detection  rate  of  90%  at  a  false  positive  rate  of  2.5%  can  be  achieved  by 
incorporating  nasal  bone  assessment  to  combined  ultrasound  and  biochemical  (CUB) 
screening (Cicero et al., 2006). Chapter 1 : Introduction 
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Tricuspid regurgitation is another potential marker determined by pulsed wave Doppler 
ultrasonography. Previous studies have shown that tricuspid regurgitation is found in more 
than 65% of Down’s syndrome fetuses and less than 8.0% of normal fetuses (Faiola et al., 
2005; Falcon et al., 2006a; Falcon et al., 2006b). Falcon et al (2006b) reported that there is 
no association between tricuspid regurgitation and biochemical markers and incorporating 
tricuspid regurgitation to CUB screening would be expected to achieve a detection rate of 
95% at a false positive rate of 5%. 
 
 
 
 
Many Down’s syndrome fetuses have abnormal blood flow through the ductus venosus due 
to congenital heart diseases. Studies conducted by Borrell et al (2005) show that there is no 
correlation between the pulsatility index for veins (PIV) and serum markers. Thus, addition 
of PIV to NT alone would be expected to increase the detection rate from 76% to 85% and 
 
 
 
 
 
 
 
 
 
 
 
Reproduced from Nicolaides, 2004 
Figure 1.11: Ultrasound picture of 
fetus with normal NT thickness and a 
present nasal bone. 
Figure 1.12: Ultrasound picture of 
fetus affected with Down’s syndrome 
with increased NT thickness and an 
absent nasal bone. Chapter 1 : Introduction 
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combined with serum markers, the modelled detection rate increased to 92% at a 5% false 
positive rate (Borrell et al., 2005) 
Although  the  new  ultrasound  markers  improve  the  performance  of  Down’s  syndrome 
screening,  the  usage  of  these  markers  is  time  consuming  and  requires  highly  skilled 
operators with much experience. Therefore, it is unlikely these ultrasound markers will be 
incorporated in the routine first trimester screening programme (Spencer, 2007). 
1.4.6 METHODS OF SCREENING 
Screening identifies those women who are at high risk of carrying a Down’s syndrome 
fetus. Each pregnant woman who is screened for Down’s syndrome is given a patient-
specific risk based on her age, family history and screening marker levels. A variety of 
methods  of  combining  biochemical  and  ultrasound  markers  to  give  risks  of  Down’s 
syndrome is in use or has been proposed. The performance of a screening test is normally 
evaluated  in  terms  of  ‘detection  rate’,  the  proportion  of  affected  pregnancies  that  are 
screened-positive  using  the  screening  test,  the  ‘false  positive  rate’,  the  proportion  of 
unaffected pregnancies that are screened-positive using the screening test, and the ‘screen 
positive rate’, the proportion of pregnancies that are screened positive using the screening 
test. For the best screening test the marker combination should give the highest detection 
rate for the lowest false positive rate and be acceptable to women (Cuckle, 2002).  
1.4.6.1 COMBINED ULTRASOUND AND BIOCHEMICAL MARKERS (CUB) 
SCREENING 
Combined ultrasound and biochemical (CUB) screening for Down’s syndrome using NT 
measurements, maternal serum PAPP-A and fβhCG is offered routinely in many centres. 
Due to the low or no correlation between the three markers in both normal pregnancies and Chapter 1 : Introduction 
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Down’s  syndrome  pregnancies,  CUB  screening  appears  to  be  an  effective  screening 
procedure. The effectiveness of CUB screening in clinical practice is well documented 
with detection rates of 85-91% at a 4-5% screen positive rate being typically reported 
(Spencer et al., 2000a; Stenhouse et al., 2004, Perni et al., 2006). 
In Scotland, CUB screening for Down’s syndrome started in 2000. Maternal blood samples 
are collected from 9 weeks of gestation and NT measurement are normally obtained from 
11 weeks to 13 weeks and 6 days of gestation. A fetal scan is carried out to measure CRL 
or bi-parietal diameter (BPD) measurement to determine the gestational age. A risk cut-off 
of 1 in 250 at term is used to identify high and low risk pregnancies. The combined risk 
will be reported to the antenatal clinic after a couple of days and women with risk ≥ 1 in 
250 will be re-called for counselling and offered a diagnostic test (Stenhouse et al., 2004). 
One-stop clinic for assessment of risk (OSCAR) is one way of implementing first trimester 
screening for Down’s syndrome. In the one-stop clinic, the ultrasound examination of the 
fetus  and  biochemical  testing  on  maternal  serum  are  carried  out  simultaneously  and 
patients  will  receive  their  combined  risk  at  their  antenatal  clinic  visit  (Spencer  et  al., 
2000a; Bindra et al., 2002; Spencer et al., 2003a; Avgidou et al., 2005). The advantage of 
this type of approach is that the patients can be counselled regarding their combined risk 
and the diagnostic options available, if required at the same visit. 
1.4.6.2 INTEGRATED TESTING 
In the integrated testing protocol, women are offered NT measurement and maternal serum 
PAPP-A test in the first trimester and maternal serum AFP, hCG or fβhCG, uE3 and InhA 
test  in  the  second  trimester.  The  first  trimester  test  results  will  not  be  interpreted  or 
disclosed to the patients until the second trimester test is performed. A study by Wald et al Chapter 1 : Introduction 
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(1999a) has showed that integrated testing (PAPP-A and NT in the first trimester and AFP, 
hCG, uE3 and InhA in the second trimester) could potentially achieve a detection rate of 
94%  at  a  false  positive  rate  of  5%.  This  finding  was  consistent  with  a  recent  study 
conducted in Australia where integrated screening was reported to have a detection rate of 
91% at a false positive rate of 2.5% (Cocciolone et al., 2008). In serum integrated testing, 
NT measurement is excluded from the screening protocol. The detection rate reduces from 
94% to 85% at a false positive rate of 5% when NT measurement is omitted from the 
screening protocol (Wald et al., 1999a). 
In 2003, Wald and co-workers reported the results of the Serum Urine and Ultrasound 
Screening Study (SURUSS), funded by the UK National Health Technology Assessment 
Program. The objective of SURUSS trial was to identify the most effective, safe and cost-
effective method of antenatal screening for Down’s syndrome using NT, maternal serum 
and urine markers in the first and second trimesters of pregnancy, and maternal age in 
various  combinations.  Twenty-five  maternity  units  offering  second  trimester  screening 
participated  in  this  study  and  the  results  were  based  on  47,053  singleton  pregnancies, 
including 101 Down’s syndrome pregnancies. Wald et al (2003) reported that integrated 
testing is the most effective screening method for Down’s syndrome with detection rates of 
93% at a 5% false positive rate.  
Although  integrated  testing  has  been  reported  to  have  a  high  detection  rate,  the  non-
disclosure of the first trimester screening results is a major disadvantage of this screening 
protocol. As the results from the first trimester test will not be interpreted or given to the 
patients  until  the  second  trimester  test  is  performed,  many  pregnant  women  could  be 
deprived of the chance of getting early diagnostic tests. Moreover, it also increases the 
anxiety due to the long wait for the test results till the second trimester. It is particularly Chapter 1 : Introduction 
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problematic when a larger NT measurement has been seen, as it can be difficult not to 
disclose this to the patient. A study conducted by Spencer and Aitken in 2004 on women’s 
preferences for prenatal screening testing reported that only 24% of women preferred the 
integrated test compared to 75% of women favouring first trimester screening (Spencer and 
Aitken, 2004). Apart from these issues, integrated test has also been reported to be more 
expensive that other types of screening protocols (Gilbert et al., 2001). 
1.4.6.3 CONTINGENT SCREENING 
The concept of contingent screening is illustrated in figure 1.13. All pregnant women are 
offered the first stage of screening. A risk is calculated and women are divided into three 
groups; high, intermediate and low risk, depending on the level of risk. Those falling in the 
‘high risk’ group are offered a diagnostic test while those under ‘low risk’ do not have to 
undergo any further testing. Those who fall in the ‘intermediate risk’ category are also 
advised to take a second stage of screening. A likelihood ratio is then derived from the 
second stage of screening. This ratio is then combined with the risk at the first stage of 
screening and the composite risk is assessed against a final cut-off risk. Those women with 
a final risk greater than the final risk cut-off are classified as ‘screen positive’ and added to 
the initial high risk group. Whereas, the women with final risks lower that the final risk 
cut-off are categorised as ‘screen negative’ and are listed among the initial low risk group. Chapter 1 : Introduction 
 
36 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.13: Contingent screening protocol. 
Risks derived from first stage of screening are estimated for all women and used to 
triage the population into high, low and intermediate risk groups. Women with high 
risk would be offered a diagnostic test and those women with low risk would not be 
offered  any  further  testing.  Women  with  an  intermediate  risk  would  be  offered 
second stage of screening  and those with composite risk greater than  the cut-off 
would be offered diagnostic testing. 
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Chorionic villus sampling 
(CVS) or Amniocentesis 
No invasive diagnostic procedure 
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Within First Trimester Contingent Screening 
One of the critical factors in maintaining the performance of CUB screening is consistent 
and accurate NT measurement. This requires ultrasonographers with specific training and a 
system of on-going monitoring within a quality assured programme. This has hampered the 
adoption of CUB screening in some centers which lack the ultrasound resources to provide 
high quality NT measurements to the entire booking population.  
A possible solution to this problem was proposed by Christiansen and Larsen (2002) who 
suggested  a  within-trimester  contingent  testing  approach  in  the  first  trimester.  In  this 
protocol, the women initially undergo a biochemical testing (PAPP-A and fβhCG) and then 
go on to have NT measurement only if the risk calculated from maternal age and serum 
markers falls within an intermediate risk range. Women who fall within the high risk group 
are offered diagnostic testing, whilst those in the low risk group do not have to undergo 
any further tests. Based on mathematical modelling and with initial high and low cut-off 
risks of 1 in 65 and 1 in 1000 respectively and a final risk cut-off of 1 in 400, Christiansen 
and Larsen (2002) estimated that only 19.4% of women would require an NT scan to yield 
a detection rate of 78.9% for a 4% false positive rate. This small reduction in detection rate 
compared  to  full  CUB  screening  in  all  women  is  offset  by  an  increase  in  the  cost-
effectiveness  of  CUB  screening  due  to  a  significant  decrease  in  the  number  of  NT 
measurements required. 
In 2006, Laigaard et al conducted a study on within trimester contingent screening where 
women were selected for NT and fβhCG measurement at 11 to 12 weeks of gestation based 
on PAPP-A and ADAM 12 (A Disintegrin And Metalloprotease 12) measurements at 8 to 
9 weeks of gestation. This study based on mathematical modelling has estimated that this Chapter 1 : Introduction 
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screening protocol can achieve a detection rate of 92% for a false positive rate of 1% with 
only 5.6% of women requiring NT and fβhCG measurement (Laigaard et al., 2006b).    
Contingent Screening Across The First and Second Trimesters 
In this model (Figure 1.14), women were selected for second trimester screening based on 
NT and PAPP-A measurement in the first trimester. Wright et al (2004) using data from 
SURUSS  suggested  that  at  the  cost  of  a  small  reduction  in  overall  performance,  this 
screening model offers considerable psychological and clinical advantages over integrated 
screening with early diagnosis of a proportion of the affected cases. Wright et al (2004) 
also showed that by changing the initial and final cut-off risks, the early detection and 
completion rates can be varied. For example, increasing the early completion rate from 
75%  to  80%,  with  a  30%  early  detection  rate  and  85%  overall  detection  rate  means 
lowering second trimester cut-off from 1 in 126 to 1 in 155 for a small increase in the false 
positive rate by an estimated 0.1% (Wright et al., 2004). As reported by Maymon et al 
(2004) this model obviates the ethnical and clinical implication of non-disclosure of first 
trimester results and also the financial implication of unnecessary second trimester testing 
for the whole population.  
In 2005, Benn et al (2005) had estimated the performance of contingent screening in the 
UK and USA, using statistical modelling. The contingent screening policy was based on 
the commonly used markers, cut-offs and gestational age at testing in both countries. For 
the UK, women were selected for second trimester screening based on PAPP-A and fβhCG 
measurements at 10 weeks of gestation and NT measurement at 11 weeks of gestation. In 
the second trimester screening, AFP, fβhCG, uE3 and InhA levels were measured at 14 to 
20 weeks of gestation. While for the US, the first stage of screening was based on PAPP-
A, hCG and NT measurements at 12 weeks of gestation and the second stage of screening Chapter 1 : Introduction 
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was based on AFP, hCG, uE3 and InhA measurements at 14 to 20 weeks of gestation 
(Benn et al., 2005). The studies showed that, in the UK and US, this screening protocol 
could achieve a detection rate of 91.4% and 89.1% at a false positive rate of 2.1% and 
3.1% respectively but with only 19% of women requiring second trimester screening.  
 
 
 
 
 
 
 
 
 
 
Low risk  High risk 
No invasive diagnostic procedure 
High risk   Low risk  
First trimester: PAPP-A/ NT/ maternal age 
Intermediate risk 
Second trimester:  AFP/FβhCG/uE3/InhA 
Chorionic villus sampling 
(CVS) or Amniocentesis 
Figure 1.14: Contingent screening across trimester protocol.  
Risks derived from first trimester screening are estimated for all women and used to 
triage the population into high, low and intermediate risk groups. Women with high 
risk would be offered a diagnostic test and those women with low risk would not be 
offered  any  further  testing.  Women  with  an  intermediate  risk  would  be  offered 
second trimester screening and those with composite risk greater than the cut-off 
would be offered diagnostic testing. Chapter 1 : Introduction 
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Later in 2008, Cuckle  et al conducted  a  comparison of the performance of  contingent 
screening with integrated testing using  First- and Second-Trimester Evaluation of Risk 
(FASTER) trial data. The conclusion was that the contingent screening detection rate for a 
fixed false positive rate is comparable with integrated testing, and this can be achieved 
with a significant reduction in second trimester screening requirement. However, Wald et 
al  (2006)  had  a  different  viewpoint,  reporting  integrated  testing  as  the  simplest,  most 
efficient and the safest screening policy and contingent screening as the most complex and 
least efficient screening policy.   
Three Stage Contingent Screening 
In this model (Figure 1.15), the first stage of screening is based on PAPP-A and fβhCG 
measurement  at 10 weeks of  gestational  age.  Those with a  risk above  the cut-off will 
proceed to the second stage to have NT measurement. And, a risk will be calculated based 
on maternal age, NT and first trimester biochemical markers (in the first stage). Women 
who fall within the high risk group are offered diagnostic testing whilst those in the low 
risk group will not have to undergo any further testing. Those with intermediate risk will 
be offered the second trimester screening. In the second trimester screening, AFP, fβhCG, 
uE3 and InhA levels would be measured. The combined risk will be assessed against a 
final risk cut-off and the pregnancies are classified as screen negative or positive (Wright 
et al., 2006).   
The study by Wright et al (2006) based on statistical modelling showed that if 40% of 
women proceed to the second stage of screening and 20% of these women continue to 
stage three of screening, this screening policy can achieve a detection rate of 85% for a 
false positive rate of 0.7%. In this screening strategy, 60% of women complete screening 
after the first stage and 80% of women complete screening in the first trimester.  Chapter 1 : Introduction 
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Stage 3: 
Second trimester screening 
Low risk  High risk 
Low risk  High risk 
Chorionic villus sampling 
(CVS) or Amniocentesis 
Stage 1: 
Maternal age/ PAPP-A/ FβhCG 
Stage 2: 
Nuchal translucency 
No invasive diagnostic procedure 
Low risk 
Figure 1.15: Three-stage contingent screening protocol.  
Risks derived from first trimester serum screening are estimated for all women. 
Those women with low risk would not be offered any further testing and NT would 
be measured on the remainder and the risk would be reassessed. Those with very 
low risk would be screened negative and would not be offered any further testing. 
Those with very high risk would be offered early diagnostic test. Women with an 
intermediate  risk  would  be  offered  second  trimester  screening  and  those  with 
composite risk greater than the cut-off would be offered diagnostic testing. 
(reproduced from Wright et al., 2006). Chapter 1 : Introduction 
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Contingent Screening With Advanced Ultrasound Examination In The Second Stage 
In 2005 Nicolaides et al proposed another variant of contingent screening where complex 
first trimester ultrasound examination is offered at the second stage of screening. As per 
this screening protocol, all women were offered CUB screening (NT, PAPP-A and fβhCG) 
at 11+0 to 13+6 weeks’ gestation. Those with intermediate risk are further assessed for risk 
using  first-trimester  ultrasound  examinations  for  detecting  the  presence/absence  of  the 
nasal bone, the presence/absence of tricuspid regurgitation or normal/abnormal Doppler 
velocity  waveform  in  the  ductus  venosus.  The  detection  rate  and  false  positive  rate 
achieved varies with the method used in the second stage of screening. The detection rate 
using this protocol has been found to range from 92% at false positive rate of 2.1% for 
presence/absence of nasal bone, 94.2% at 2.7% for increased impedance in the ductus 
venosus and 91.7% at 2.7% for tricuspid regurgitation (Nicolaides et al., 2005). A similar 
study conducted by Gyselaers et al (2006) concluded that contingent screening reduces the 
number of pregnancies requiring ultrasound scan.  
1.4.6.4 REPEAT MEASUREMENT  
Wright and Bradbury (2005) demonstrated the potential value of using highly correlated 
repeated measures of serum markers taken in the first and second trimester of pregnancy. 
This contradicts the conventional thinking where the choice of markers in multimarker 
screening test has been influenced by the extent to which the markers provide independent 
information  as  characterized  by  low  correlations  between  markers  and  the  univariate 
properties of markers (Wright and Bradbury, 2005).  
Using mathematical modelling and the marker parameters published by Wald et al (2003) 
(SURUSS study), they estimated the false positive rate required to give a detection rate of Chapter 1 : Introduction 
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85% for various combinations of repeat marker measurements. For example, measuring 
PAPP-A, uE3 and InhA at 10 weeks of gestation and again in a second blood sample at 15 
weeks  was  estimated  to  give  85%  detection  at  a  0.3%  false  positive  rate.  The  same 
performance was also estimated for a PAPP-A, uE3 and NT measurement at 10 weeks 
followed by repeat PAPP-A and uE3 measurements at 15 weeks (Wright and Bradbury, 
2005). The corresponding figures for the integrated test using the same marker parameters 
are 85% detection at a 1.2% false positive rate (Wald et al., 2003). This shows repeat 
measure screening using serum markers (without NT measurements) is able to achieve 
similar screening performance as integrated screening (with NT measurement). Wright and 
Bradbury (2005) has demonstrated that certain combination of highly correlated markers, 
some of which individually have poor discriminatory power, do have substantial benefits 
over the established combinations of markers used in the integrated test.  
The underlying mechanism of this approach is illustrated using PAPP-A. Even though the 
discriminatory power of an individual PAPP-A measurement is good in the first trimester 
and poor in the second trimester, the joint distribution of PAPP-A measurements in the 
first  and  second  trimesters  effectively  separates  the  Down  syndrome  and  unaffected 
populations. This separation is maximized when the measurement of the marker in the two 
trimester are highly correlated. 
The reports published by Palomaki et al in 2006, confirm that measuring PAPP-A in first 
and second trimester improves Down’s syndrome screening. Using paired first and second 
trimester  serum  samples  from  34  Down’s  syndrome  pregnancies  and  514  unaffected 
pregnancies,  Palomaki et al (2006) reported that, for a fixed false positive rate of 1%, 
repeat measures of PAPP-A in addition to the serum integrated test had a detection rate of 
86% compared with 82% using integrated testing.  Chapter 1 : Introduction 
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1.4.7 FACTORS INFLUENCING MATERNAL SERUM MARKERS 
Studies have shown that there are a number of factors affecting the level of biochemical 
markers used in Down’s syndrome screening. Some of these factors are used to correct 
results or MoMs in order to derive a more precise risk estimate.   
1.4.7.1 GESTATIONAL AGE 
Risk estimations for Down’s syndrome is critically dependent on accurate gestational age 
due to the variation of maternal serum concentrations with gestational age. AFP, uE3 and 
pregnancy-specific-beta-1-glycoprotein (SP-1) levels increase with advancing gestational 
age  in  the  second  trimester.  Meanwhile,  hCG,  fβhCG  and  InhA  levels  decreases  with 
advancing gestational age. In order to correct for this variation, the marker concentrations 
are converted to MoM which will be used to derive likelihood ratios (Aitken et al., 2007).  
Gestational  age  can  be  estimated  either  from  last  menstrual  period  (LMP)  date  or 
ultrasound scans (BPD, CRL or head circumference). Wald et al (1992a) reported that the 
detection rate for Down’s syndrome increases from 58% to 67% at a fix false positive rate 
of 5% when ultrasound scan was used to estimate gestational age. The use of ultrasound 
scan to determine gestational age reduces the variation of MoM values for AFP, hCG and 
uE3 in unaffected and Down’s syndrome pregnancies. This decreases the extend of overlap 
in these distribution and improves the Down’s syndrome screening performance (Wald et 
al., 1992a).  
In the second trimester the performance of uE3 improved the most with ultrasound based 
estimation of gestational age because uE3 concentration changes the most with gestational 
age  (Wald  et  al.,  1992a).  PAPP-A  concentration  increases  exponentially  in  the  first 
trimester and continues to increase throughout pregnancy right up to term (Fialova and Chapter 1 : Introduction 
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Malbohan, 2002). FβhCG concentration increases to a peak at approximately 64 days in 
the first trimester and then the marker concentration starts decreasing (Berry et al., 1995). 
Similar concentration profiles are found for intact hCG and InhA. When gestational age is 
overestimated, hCG, fβhCG and InhA MoM values will be higher than expected and AFP 
and uE3 MoM values will be lower. This will have the effect of increasing the derived 
risks. An underestimation of gestational age will have the reverse effect (Aitken et al., 
2007). 
1.4.7.2 MATERNAL WEIGHT 
Previous  studies  have  reported  that  heavier  women  tend  to  have  lower  serum  marker 
concentration and lighter women tend to have higher serum marker concentration (Haddow 
et al., 1981; Wald et al., 1981; Bartels et al., 1993). This occurs because of dilution effect 
in  heavy  women  who  tend  to  have  greater  blood  volume  compared  to  lighter  women.  
Correction for maternal weight is performed by dividing the MoM value by the expected 
MoM value calculated from the adjustment equation for her weight (Neveux et al., 1996). 
According to Neveux et al (1996) the reciprocal-linear equation fits second trimester AFP 
and hCG data better than the classic log-linear equation, for weight correction. In contrast, 
the reports by Reynolds et al (2006) suggest that the log-linear equation gives a better fit 
compared to the reciprocal-linear equation. Therefore, it is important for screening centres 
to construct their own weight correction equation based on data from their own population 
and these should be reviewed to take into account the changing weight profile of the pregnant 
population. For the first trimester markers, both log-linear and reciprocal-linear equation fit 
the data well (Spencer et al., 2003b). Log-linear equations were found to give a marginally 
better fit than reciprocal-linear equation for fβhCG and reciprocal-linear equation were 
found to be marginally better than reciprocal-linear for PAPP-A. Chapter 1 : Introduction 
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1.4.7.3 MATERNAL SMOKING HABITS 
A study by Thomsen et al, in 1983, showed that maternal serum AFP level was 20% higher 
in smokers compared to non-smokers and suggested that this might be due to the increase 
permeability of the placental barrier caused from smoking. This was followed by Bernstein 
et al (1989), who reported that maternal serum oestradiol level was 17.6% lower and hCG 
level was 21.5% lower in smoking women in early pregnancy. Many studies since have 
been conducted on the effect of maternal smoking habit on serum markers and the impact 
on screening for Down’s syndrome.  
Cuckle et al (1990) reported that there were significant difference in AFP and hCG levels 
between smokers and non-smokers, in the second trimester. This finding was confirmed by 
Bartels et al (1993) who reported a 21% decrease in hCG level and 3% decrease in uE3 
level in smokers compared to non-smokers. Bartels et al (1993) also reported that AFP 
level is significantly increased in smokers compared to non-smokers and that there is a 
dose-response association. The studies by Ferriman et al (1999) also indicate that InhA 
level is significantly increased in smokers compared to non-smokers. Reports by Rudnicka 
et al (2002) show that smokers had 5% higher of AFP level, 4% lower of uE3 level, 20% 
lower of fβhCG level and 62% higher of InhA level compared to non-smokers.  
The  studies  by  Spencer  (1999a)  show  that  PAPP-A  level  in  the  first  trimester  is 
significantly reduced in smokers compared to  non-smokers, and there  is no significant 
change in fβhCG level. This finding was consistent with a study by Niemimaa et al (2003) 
who reported a 20% decrease in PAPP-A level among smokers and no significant changes 
in fβhCG level. Kagan et al (2007) found a reduction of 20% in PAPP-A level and 3% in 
fβhCG level among smokers. These findings are similar to other first trimester studies on 
smoking (Spencer et al., 2004; de Graaf et al., 2000). The report by Miron et al in 2008 Chapter 1 : Introduction 
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shows  that  smoking  has  similar  effects  on  PAPP-A  and  fβhCG  levels  in  dried  blood 
samples.  
Niemimaa et al (2003) also reported a small increase in NT measurement in smokers, but 
suggested that this finding probably has no clinical relevance to the performance of NT 
screening due to the small difference between the groups. In contrast, the study by Spencer 
et al (2004) shows that there is no significant difference in NT measurements between 
smokers and non-smokers.  
In 1998, Spencer reported that the second trimester Down’s syndrome screening detection 
rate and false positive rate in smokers were 10% and 2% lower respectively than those in 
non-smokers. Correcting for smoking will result in overall 2% increase in detection rate for 
a 0.4% increase in false positive rate. Later studies by Crossley et al (2002b) showed that 
correction for smoking in the second trimester had little effect on the overall detection rate 
of  Down’s  syndrome  but  it  reduced  the  false  positive  rate  by  20%.  It  is  found  that 
correcting for smoking gives more accurate risks for individual women. In 2004, Spencer 
et al reported a similar finding on first trimester screening where the false positive rate was 
reduced from 4.48% to 3.46% after correction in the smoking group.  
 1.4.7.4 ETHNICITY 
Studies have shown that ethnic origin has an impact on the biochemical marker levels, 
which cannot be explained by differences in maternal weight. Previous studies on first 
trimester  Down’s  syndrome  marker  has  shown  that  PAPP-A  and  fβhCG  levels  were 
increased in Afro-Caribbean and Oriental women (Spencer et al., 2005b; Spencer et al., 
2000e; Leung et al., 2006). The studies by Spencer et al in 2005 show that the PAPP-A 
levels are higher and the fβhCG lower in South Asian women. Similar studies by Krantz et Chapter 1 : Introduction 
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al  (2005)  indicate  that  fβhCG  was  16%  higher  for  African  Americans,  6%  higher  for 
Asians and 9% lower for Hispanics as compared to Caucasians. PAPP-A was 35% higher 
in African-American women but no significant difference was found in other ethnic groups 
(Krantz et al., 2005). Delta NT was reported to be significantly lower in Afro-Caribbean 
and South Asian women (Spencer et al., 2005b).  
The various studies by Canick et al., 1990; Bogart et al., 1991; Burton and Nieb, 1991; 
O’Brien et al., 1997; Benn et al., 1997 confirm that ethnic origin has an impact on second 
trimester Down’s syndrome markers. In 1996, Watt et al published a report that black 
women had 22% higher AFP levels, 19% higher total hCG levels and 12% higher fβhCG 
levels compared to the Caucasian women. Higher hCG levels were also reported in black 
women by Kulch et al (1993). No significant changes were found in uE3 levels. Muller et 
al, reported in 1994 that Asian women had higher hCG levels compared to the Caucasian 
women. According to Hseih et al. (1995) and Onda et al. (1996), Oriental women have 
higher levels of AFP and hCG compared to Caucasian women.  
Correcting  biochemical  markers  for  ethnicity  would  have  a  significant  impact  on 
individual patient-specific risks which could affect a patient’s decision on whether or not 
to have a diagnostic test (Spencer et al., 2000e; Spencer et al., 2005b). However for NT, 
although  there  is  significant  difference  among  ethnic  groups  (Chen  et  al.,  2002; 
Thilaganathan et al., 1998; Spencer et al., 2005b), correcting NT for ethnicity appears 
unnecessary (Krantz et al., 2005).   
1.4.7.5 ASSISTED REPRODUCTIVE TECHNOLOGY 
One of the factors known to affect marker levels in Down’s syndrome screening is assisted 
reproductive techniques (ART). In 1996, Barkai et al reported a significant increase in Chapter 1 : Introduction 
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maternal serum hCG level and reduction in uE3 level among pregnancies with ovulation 
induction compared to pregnancies which are conceived unassisted. Pregnancies with in 
vitro fertilization (IVF) were found to have decreased levels of AFP, hCG and uE3 but 
only uE3 levels were significantly decreased. Pregnancies with egg donation were reported 
to have elevated AFP, hCG and uE3 levels (Barkai et al., 1996b).  
The  changes  in  marker  levels  in  assisted  reproductive  pregnancies  vary  from  study  to 
study. The studies conducted by Lambert-Messerlian et al (2006), show that pregnancies 
with IVF had elevated levels of hCG and InhA and decreased levels of uE3 in the second 
trimester. In assisted reproductive pregnancies with egg donation, AFP and InhA levels 
were elevated but there were no changes in uE3 and hCG levels. IVF pregnancies with egg 
donation had higher levels of AFP and InhA compared to IVF pregnancies without egg 
donation. The studies by Maymon and Shulman (2001) and Shulman and Maymon (2003) 
show  that  AFP  is  elevated  in  assisted-conception  pregnancies  with  oocyte  donation. 
Therefore, the changes in the markers in ART pregnancies will cause an increase in the 
false positive rate in Down’s syndrome screening in the second trimester (Maymon et al., 
1999; Maymon and Shulman, 2001; Raty et al., 2002; Shulman and Maymon, 2003). In 
contrast to these findings, Muller et al (2003) and Rice et al (2005) reported that there 
were  no  significant  differences  in  the  second  trimester  markers  in  ART  pregnancies 
compared with naturally conceived pregnancies and therefore, there were no changes in the 
false positive rate. However the report by Maymon et al (2006) showed that InhA levels 
are elevated in singleton pregnancies but not twin pregnancies conceived by ART. 
In the first trimester, PAPP-A levels were decreased in IVF (Liao et al., 2001; Orlandi et 
al., 2002; Maymon and Shulman, 2004; Hui et al., 2005; Tul et al., 2006; Amor et al., 
2009; Gjerris et al., 2009) and intracytoplasmic sperm injection (ICSI) pregnancies (Hui et Chapter 1 : Introduction 
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al.,  2005;  Tul  et  al.,  2006;  Amor  et  al.,  2009;  Gjerris  et  al.,  2009).  No  significant 
differences in fβhCG level in ART pregnancies were reported by Orlandi et al., 2002; Tul 
et al., 2006; Amor et al., 2009; Gjerris et al., 2009. In contrast, Liao et al (2001) reported 
an increase in fβhCG level in IVF pregnancies and Hui et al (2005) reported a decrease in 
fβhCG level in IVF pregnancies with fresh embryos. Later studies by Tul et al (2006) 
showed  no  significant  changes  in  the  first  trimester  markers  in  assisted-conception 
pregnancies without ovarian stimulation (transfer of frozen-thawed embryo or spontaneous 
cycle).  In  2009  Gjerris  et  al  reported  that  there  are  no  significant  changes  in  the  first 
trimester markers in the group treated by  frozen embryo replacement.  But Amor  et al 
(2009) contradicted these findings, by reporting that PAPP-A level is decreased in frozen 
embryo transfer and frozen-thawed embryo transfer groups.  
According to Hui et al (2005), NT measurement is significantly increased in pregnancies 
with fresh embryos from IVF, frozen-thawed embryos from IVF and fresh embryos from 
ICSI.  However  the  studies  by  Liao  et  al  (2001),  Orlandi  et  al  (2002),  Maymon  and 
Shulman (2002) and Tul et al (2006) show no significant differences in NT measurement 
in ART pregnancies. 
1.4.7.6 OTHER FACTORS 
Multiple  pregnancy,  fetal  sex,  gravidity  and  parity,  insulin-dependent  diabetes  mellitus 
(IDDM) and vaginal bleeding are some of the other factors known to affect the level of 
markers in Down’s syndrome screening. All serum markers levels in the first and second 
trimester are increased in multifetal pregnancies (Wald et al., 1991; Berry et al., 1995; 
Bersinger et al., 2003; Aitken et al., 2007). As per the reports by Spencer (2000c), the AFP 
level was significantly lowered whereas fβhCG was significantly elevated in the presence 
of a female fetus, compared to that of a male fetus in the second trimester. De Graaf et al Chapter 1 : Introduction 
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(2000) also reported similar findings for AFP and fβhCG. No differences in PAPP-A levels 
according to gender were found in the first trimester. However, the study by Spencer et al 
(2000d)  showed  that  maternal  serum  fβhCG  and  PAPP-A  were  15%  and  10%  higher 
respectively and fetal NT was 3% lower in the presence of a female fetus.  
According  to  a  report  by  Barkai  et  al  (1996a),  there  is  no  difference  in  AFP  level  in 
primigravid and multigravid women. Maternal serum hCG and uE3 levels were 5.9% and 
3.9% lower respectively in multigravid women than in those tested in their first pregnancy. 
Barkai et al (1996a) reported that these factors do not affect the detection and false positive 
rates in Down’s syndrome screening. Later studies by Spencer et al (2000b) show that 
gravidity and parity is associated with a small but progressive decrease in NT measurement 
and a small but progressive increase in fβhCG and PAPP-A levels. However, none of these 
changes was statistically significant.  
Second trimester Down’s syndrome marker levels are decreased in women with IDDM but 
variations exist in studies partly due to the fact that correction on maternal weight has not 
been performed. According to Crossley et al (1996), the AFP and hCG levels in IDDM 
patients were 0.98 and 0.92 MoM respectively after correction for maternal weight was 
performed. This finding was later confirmed by Sancken and Bartels (2001) who reported 
no significant differences in AFP, hCG and uE3 levels in the second trimester in women 
with IDDM compared with women without IDDM. However, the reports by Huttly et al 
(2004) indicate that AFP and uE3 are significantly reduced in women with IDDM but no 
significant differences were found in hCG, fβhCG and InhA levels. The previous studies 
on the effect of IDDM on InhA level appear conflicting. Wallace et al (1997) reported that 
InhA was increased in women with IDDM, whereas Wald et al (1996) reported a decrease 
in the levels of InhA.  Chapter 1 : Introduction 
 
52 
 
An InhA study by Aitken and Crossley (2005) for the UK NSC shows that there is no 
significant  change  in  InhA  level  in  women  affected  by  IDDM.  Pedersen  et  al  (1998) 
reported that PAPP-A level were significantly reduced in the first trimester in women with 
IDDM.  Spencer  et  al  (2005a)  reported  that  there  are  no  significant  differences  in  NT 
thickness, PAPP-A and fβhCG levels in women with IDDM. 
A report by Cuckle et al in 1994b showed that the AFP level was significantly increased in 
women  with  vaginal  bleeding  but  hCG  and  uE3  levels  were  not  significantly  altered. 
However Berry et al (1995) reported an increase in the AFP levels and a decrease in the 
fβhCG level in pregnancies with threatened abortion in the first trimester. The studies by 
De Biasio et al (2003) and Heinig et al (2007) indicate an increase in fβhCG level in the 
first trimester after early vaginal bleeding.  
Table 1.5 shows a summary of the impact of various factors on first and second trimester 
screening marker. This summary is based on the findings from majority of the published 
papers. However, the impact of these factors varies from study to study. 
Table  1.5:  Summary  of  the  impact  of  various  factors  on  first  and  second  trimester 
screening markers. 
Factors  First trimester  Second trimester 
PAPP-A  FβhCG  AFP  hCG 
Smoking   ↓  ↓  ↑  ↓ 
Ethnic origin:         
            Black   ↑  ↑  ↑  ↑ 
            Oriental   ↑  ↑  ↑  ↑ 
            South Asians   ↑  ↓     
            Asians     ↑    ↑ 
ART   ↓       Chapter 1 : Introduction 
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1.4.8  UK  NATIONAL  SCREENING  COMMITTEE  (NSC)  POLICY 
RECOMMENDATIONS FOR DOWN’S SYNDROME SCREENING 
In  2008,  a  report  was  published  by  the  NHS  Fetal  Anomaly  Screening  Programme 
Committee, on the UK NSC policy recommendations for Down’s syndrome screening for 
the period between 2007 and 2010. According to the recommendations put forward by the 
committee, the screening for Down’s syndrome should be carried out between 10 to 20 
weeks of gestation. However, it is ideal to complete the screening before the 14
th week of 
conception (NHS Fetal Anomaly Screening Programme, 2008).  
As per the stipulations of the committee, a Down’s syndrome detection rate of greater than 
75% with a screen positive rate of less than 3% should be achieved between April 2007 
and April 2010. By April 2010, a detection rate of greater than 90% with a screen positive 
rate of less than 2% is to be achieved. The recommended screening strategies from 2007 
are the first trimester combined ultrasound and biochemical (CUB) screening, integrated 
testing  and  serum  integrated  testing.  The  Health  Technology  Assessment  is  currently 
reviewing two new strategies for screening, namely, repeated measure and cross trimester 
testing. These tests are expected to further improve the performance of Down’s syndrome 
screening  programmes  in  the  period  after  2010  (NHS  Fetal  Anomaly  Screening 
Programme, 2008). Chapter 1 : Introduction 
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1.5 AIMS 
To devise new, and refine existing approaches to the estimation of Down’s syndrome risks 
using combinations of maternal serum marker measurements and ultrasound measurements 
of  the  fetus  with  the  objective  of  maximising  detection  rates  of  Down’s  syndrome 
pregnancies and minimising false positive rates 
Specific objectives: 
1. To design and test, within the first trimester, a screening protocol where all women have 
serum  marker  measurements  but  only  a  proportion  subsequently  have  ultrasound  NT 
measurements contingent upon the results of their biochemical tests. 
2.  To  design  and  test  using  statistical  modelling  tools  a  contingent  screening  protocol 
which incorporates repeat measures of serum markers across the first and second trimesters 
with and without ultrasound NT measurements. 
3.  To  establish,  through  retrospective  analysis  of  routine  screening  data,  the  effect  of 
smoking and ethnicity on serum marker concentrations in paired first and second trimester 
serum samples. 
4. To investigate, through retrospective analysis of routine screening data, the effects of 
assisted reproductive technology on serum marker concentrations and the implications for 
the estimation of Down’s syndrome risks. 
5. To investigate, through retrospective analysis of routinely collected screening data, the 
accuracy  of  self-reported  maternal  smoking  and  its  effect  on  birth  weight,  duration  of 
pregnancy  and  second  trimester  maternal  serum  marker  concentrations,  and  the 
implications for the estimation of Down’s syndrome risks. Chapter 2 :Materials 
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2.1 PATIENT SAMPLES 
The  Biochemical  Genetics  department  located  within  the  Duncan  Guthrie  Institute  of 
Medical Genetics, Yorkhill provides prenatal screening services for Down’s syndrome and 
neural tube defect for the 60% of the Scottish pregnant population resident in West of 
Scotland. Over 20,000 women (around 70% uptake) opt for the prenatal screening test each 
year in the West of Scotland. Screening for Down’s syndrome started in 1987 with second 
trimester  AFP  measurement  and  in  1991,  hCG  was  incorporated  into  the  screening 
programme.  Two  types  of  screening  program  are  currently  offered  to  the  pregnant 
population;  1)  first  trimester  CUB  screening  and  2)  second  trimester  double  marker 
screening. 
 
First trimester CUB screening is normally performed at 9-13 weeks of gestation. At the 
antenatal clinic, patient’s information such as age, date of last menstrual period, date of 
birth, weight, height, smoking status and ethnicity are collected. Maternal blood samples 
are collected by venepuncture in plain tubes and ultrasound scan is carried out for fetal 
viability, multiple pregnancy, gross abnormality and CRL or BPD measurement. Blood 
samples are collected from 9 weeks and 0 days of gestation to 14 weeks and 0 days of 
gestation and NT measurements are carried out on those women who have a fetal CRL 
between 40 to 84mm which equates to 10 weeks and 6 days to 14 weeks and 0 days of 
gestation. A portion of the serum not used for routine testing is stored at -20
oC.  
 
All  the  ultrasound  operators  have  receive  training  in  the  NT  measurement  protocol 
(Stenhouse et al., 2004) and are subjected to on-going quality  assurance through a bi-
monthly review of images and analyses of the distribution of NT measurements (Stenhouse Chapter 2 :Materials 
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et al.,2002). The protocols for NT measurement used in CUB screening (Crossley et al., 
2002,  Stenhouse  et  al.,  2004)  are  similar  to  those  described  by  the  Fetal  Medicine 
Foundation (FMF).  
The protocol for NT measurement used by Stenhouse et al (2004) is summarized: 
a.  NT measurements are carried out on a fetus lying in the sagittal plane. 
b.  The ultrasound image is magnified to fill at least three-quarters of the screen. 
c.  The fetal skin and amnion are visualised separately by waiting for spontaneous fetal 
movement away from the amnion or by asking the mother to cough or by tapping 
the abdomen. 
d.  Care is taken not to include the nuchal cord in the NT measurement. 
e.  The  maximum  NT  thickness  is  measured  to  the  nearest  0.1mm  by  placing  the 
callipers  on  the  inner  edge  of  the  fetal  skin  and  outer  edge  of  the  soft  tissue 
overlying the cervical spine. 
f.  Measurements are made on three separately captured images and recorded.  
Three  measurements  of  NT  are  obtained  and  the  mean  of  the  three  measurements  are 
calculated. The information on NT measurement obtained, the ultrasound machine used 
and initials of the ultrasound operator are recorded in the CUB screening request form. A 
return appointment is given to those women whose gestation is less than 9 weeks to take 
blood  samples  and  perform  NT  scan  within  the  appropriate  gestational  window.  The 
second trimester screening test is offered to those women who are too late for the first 
trimester screening test with CRL>84mm or BPD>28mm. These data are stored in the 
prenatal screening database.  
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Second trimester screening is offered at 15-20 weeks of pregnancy. Approximately 5 to 10 
mls of maternal venous blood samples are collected in the second trimester to measure 
AFP  and  hCG  levels.  All  the  blood  samples  together  with  a  standard  request  form 
providing  patient’s  information  are  sent  to  Biochemical  genetics  department.  At  the 
laboratory, the clotted blood samples are given a laboratory number and centrifuged at 
2000rpm for 10 minutes. An aliquot of serum is used for the assay and the remainder of the 
serum  is  stored  at  -20
oC.  Patient’s  information  and  sample  details  are  entered  into  a 
database using Lifecycle software. The results from the biochemical assay are merged with 
the patient’s information and the risk of having a Down’s syndrome or neural tube defect 
fetus  is  calculated.  The  first  trimester  database  contains  information  on  our  15,000 
pregnancies. For second trimester screening, data from the current Laboratory Information 
Management System (Lifecycle) was used as in this new system information on ethnicity 
and  ART  were  systematically  recorded.  This    database  contains  information  on  over 
50,000  pregnancies.  These  data  and  their  matching  serum  samples  were  the  resource 
accessed for the studies described in this thesis. 
 
2.2  RETROSPECTIVE  STUDY  OF  WITHIN-TRIMESTER 
CONTINGENT SCREENING 
Using data from routine CUB screening, a re-analysis of the marker results using a within-
trimester contingent testing model was carried out to assess the likely performance of this 
approach and gauge the potential for reducing the ultrasound resources required for first 
trimester population screening. A cohort of 10,189 pregnancies where CUB screening was 
performed between July 2000 and October 2005 was identified. These pregnancies had full 
ascertainment of Down’s syndrome cases. After exclusion of twin pregnancies, there were Chapter 2 :Materials 
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44 Down's syndrome and 10,145 unaffected pregnancies within this group. The median 
maternal age at the expected date of delivery was 33.1 years, and 36.9% of women were 
aged 35 years and over. The number of blood samples taken at each week of gestation is 
shown in Table 2.1.  
 
Table 2.1: Number of blood samples taken at each gestational week 
 
 
 
In the majority of pregnancies, blood samples and NT measurements were taken during the 
course of the same antenatal clinical appointment. In a proportion of women (28%), blood 
samples were not taken at the same visit as the NT measurement either because of logistic 
reasons  or  too  early  a  presentation  for  NT  (outside  the  CRL  range  of  40–84  mm),  or 
inability to obtain an NT measurement at the first attempt, necessitating a return visit. 
Information on PAPP-A level, fβhCG level, NT measurement, gestational age based on 
ultrasound, maternal age risk, risk based on biochemical markers and final risk of having a 
Down’s syndrome fetus for these pregnancies was available in the database.  
 
 
Gestational Week  Number of blood samples 
9  197 
10  649 
11  2234 
12  3987 
13  2891 
14  231 Chapter 2 :Materials 
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2.2.1 RETROSPECTIVE CONTINGENT TESTING BASED ON LMP 
ESTIMATE OF GESTATION 
A requirement of the above study is the need for an accurate estimation of gestation based 
on ultrasound measurement of CRL. Without this, interpretation of the serum markers 
results is not possible. As an addition to this study the performance of the model was re-
evaluated using gestational information based on LMP. This is relevant when ultrasound 
measurements are not available at venepuncture. Using the same data set information on 
last menstrual period was only available in 6895 pregnancies; 6865 unaffected and 30 
Down’s syndrome pregnancies. Of these pregnancies 5979 were certain with the LMP 
dates. All gestations were established based on LMP using the information obtained at the 
time of sampling. In this dataset, the median maternal age at the expected date of delivery 
was 33.7 years, and 39.8% of women were aged 35 years and over. 
2.3  MODELLING  CROSS-TRIMESTER  CONTINGENT 
SCREENING  
Statistical modelling is a reliable tool used to predict the efficacy of screening policies. In 
this study, S-PLUS program was used to model cross-trimester contingent screening using 
various  combinations  of  markers.  The  medians,  SD  and  correlation  coefficients  were 
obtained from 8 sources; Wald et al (2003), Glasgow dataset (as described above), Spencer 
et al (2002), Spencer et al (2003), Cuckle et al (2005), Cuckle et al (1995), Aitken and 
Crossley (2005) and Aitken et al., 2007. The SDs for the unaffected and Down’s syndrome 
pregnancies  was  assumed  to  be  equal  for  the  serum  markers  but  not  for  the  NT 
measurement. The population covariance matrices for unaffected and Down’s syndrome 
pregnancies were also assumed to be equal. This is called ‘pooled covariance matrices’ 
(personal communication from Prof. Dave Wright).  Chapter 2 :Materials 
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The performances of few screening policies were re-evaluated using 10% larger SDs for 
affected cases than for unaffected cases. Analysis using previous studies (Spencer et al., 
2002; Aitken and Crossley, 2005) have shown that the SDs for first trimester PAPP-A, 
hCG and fβhCG and second trimester AFP, hCG, fβhCG, uE3 and InhA in affected cases 
were approximately 10% larger compared to unaffected cases.  
   
The first trimester PAPP-A, fβhCG and hCG medians for Down’s syndrome pregnancies 
and SDs for unaffected pregnancies were obtained from Spencer et al (2002) which had a 
large number of unaffected and Down’s syndrome cases. The medians for first trimester 
NT were obtained from Cuckle et al (2005) where the median was derived from meta-
analysis of nine studies including one study using the Scottish population (Crossley et al., 
2002). The NT SDs were obtained from Spencer et al (2003c) which were derived from 
four large prospective studies combined. The first trimester AFP, uE3 and InhA medians 
were obtained from the Wald et al (2003). Although the program required this information, 
first trimester AFP, uE3 and InhA were not used in the analysis in this study. All medians 
of second trimester markers were obtained from Aitken et al (2007) which were derived 
from meta-analysis of various studies. The SDs of second trimester AFP, hCG, uE3 and 
InhA  were  obtained  from  Aitken  and  Crossley  (2005)  from  data  obtained  in  a  large 
retrospective  study  of  InhA  for  the  National  Screening  Committee  (personal 
communication with Dr. Jenny Crossley).   
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Most  of  the  correlation  –  coefficients  were  obtained  from  Scottish  data  (Aitken  and 
Crossley, 2005; Glasgow dataset). Correlation – coefficients from Wald et al (2003) were 
only used when the information was not available from other sources. The correlation-
coefficients  for  NT  measurement  were  assumed  to  be  0  because  NT  has  a  very  low 
correlation with other serum markers. The maternal age distribution was taken to be that 
of Scotland for the year 2007 (General Register Office for Scotland). The mean and SD 
for maternal age were obtained from Glasgow dataset. The detection and false positive 
rates were estimated using Monte-Carlo methods. Samples of 500 000 observations were 
drawn. Tables 2.2, 2.3 and 2.4 show the medians, SDs and correlation coefficient used in 
modeling of screening programme.   
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Table 2.2: Median marker levels (log10 MoM) for Down’s syndrome pregnancies 
Trimester  Markers 
Week 
Source 
10  11  12  13 
First 
NT  -  0.363612  0.32222  0.281033  Cuckle et al (2005) 
AFP  -0.0655  -0.0655  -0.0655  -0.0655  Wald et al (2003) 
uE3  -0.0044  -0.0605  -0.1024  -0.1427  Wald et al (2003) 
hCG  0.0316  0.061  0.1484  0.2267  Spencer et al (2002) 
fβhCG  0.2549  0.2586  0.3054  0.3203  Spencer et al (2002) 
Inhibin A  -0.0269  0.1303  0.2380  0.3384  Wald et al (2003) 
PAPP-A  -0.336  -0.3269  -0.2785  -0.1883  Spencer et al (2002) 
Second 
AFP  -0.1249  -0.1249  -0.1249  -0.1249  Aitken et al (2007) 
uE3  -0.1427  -0.1427  -0.1427  -0.1427  Aitken et al (2007) 
hCG  0.316  0.316  0.316  0.316  Aitken et al (2007) 
fβhCG  0.3541  0.3541  0.3541  0.3541  Aitken et al (2007) 
Inhibin A  0.2989  0.2989  0.2989  0.2989  Aitken et al (2007) 
PAPP-A  0.00432  0.00432  0.00432  0.00432  Aitken et al (2007)  
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Table 2.3: Standard deviation for the screening markers in each trimester of pregnancy 
Trimester  Markers 
Unaffected 
Affected (from 
papers) 
Affected (used 
in the analysis)  Source  Week 
10  11  12  13 
First 
NT  -  0.132  0.116  0.112  0.229  0.229  Spencer et al (2003c) 
AFP  0.1818  0.1818  0.1818  0.1818  0.1672  0.1818  Wald et al (2003) 
uE3  0.1204  0.1204  0.1204  0.1204  0.1720  0.1204  Wald et al (2003) 
hCG  0.2174  0.2174  0.2174  0.2174  0.2238  0.2174  Spencer et al (2002) 
fβhCG  0.2613  0.2613  0.2613  0.2613  0.2787  0.2613  Spencer et al (2002) 
Inhibin A  0.2191  0.2191  0.2191  0.2191  -  0.2191  Wald et al (2003) 
PAPP-A  0.2361  0.2361  0.2361  0.2361  0.2822  0.2361  Spencer et al (2002) 
Second 
AFP  0.1407  0.1407  0.1407  0.1407  0.1423  0.1407  Aitken and Crossley (2005) 
uE3  0.1187  0.1187  0.1187  0.1187  0.1385  0.1187  Aitken and Crossley (2005) 
hCG  0.2308  0.2308  0.2308  0.2308  0.2445  0.2308  Aitken and Crossley (2005) 
fβhCG  0.2613  0.2613  0.2613  0.2613  0.2787  0.2613  Spencer et al (2002) 
Inhibin A  0.2255  0.2255  0.2255  0.2255  0.2436  0.2255  Aitken and Crossley (2005) 
PAPP-A  0.2170  0.2170  0.2170  0.2170  -  0.2170  Glasgow dataset  
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Table 2.4: Correlation coefficient for serum marker 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Wald et al 
(2003) 
Glasgow 
dataset 
Spencer  et 
al (2002) 
Aitken and 
Crossley (2005) 
Cuckle  et al 
(1995)  Parameters used  Source used 
h1 - f1  0.72  0.725        0.725  Glasgow dataset 
h1 - p1  0.22  0.314  0.2382      0.2382  Spencer et al (2002) 
h1 - a2  0.07  0.067  0.135      0.067  Glasgow dataset 
h1 - u2  0.03      -0.078    -0.078  Aitken and Crossley (2005) 
h1 - h2  0.72  0.667        0.667  Glasgow dataset 
h1 - f2  0.72  0.632        0.632  Glasgow dataset 
h1 - i2  0.32      0.329    0.329  Aitken and Crossley (2005) 
h1 - p2  0.39  0.382  0.2382      0.382  Glasgow dataset 
f1 - p1  0.14  0.283  0.2178      0.2178  Spencer et al (2002) 
f1 - a2  0.02  -0.014  0.0428      0.0428  Spencer et al (2002) 
f1 - u2  -0.03        -0.136  -0.136  Cuckle et al (1995) 
f1 - h2  0.56  0.547        0.547  Glasgow dataset 
 
h1: hCG in 1
st trimester, f1: fβhCG in 1
st trimester, p1: PAPP-A in 1
st trimester, a2: AFP in 2
nd trimester, u2: uE3 in 2
nd trimester, h2: hCG in 2
nd trimester, f2: fβhCG in 
2
nd trimester, i2: InhA in 2
nd trimester, p2: PAPP-A in 2
nd trimester  
66 
 
Table 2.4: Correlation coefficient for serum marker (cont) 
  Wald et al 
(2003) 
Glasgow 
dataset 
Spencer  et 
al (2002) 
Aitken and 
Crossley (2005) 
Cuckle  et al 
(1995) 
Parameters 
used  Source used 
f1 - f2  0.76  0.753        0.753  Glasgow dataset 
f1 - i2  0.29          0.29  Wald et al (2003) 
f1 - p2  0.27  0.319  0.2178      0.319  Glasgow dataset 
p1 - a2  0.12  0.124        0.124  Glasgow dataset 
p1 - u2  0.12          0.12  Wald et al (2003) 
p1 - h2  0.06  0.158  0.2382      0.2382  Spencer et al (2002) 
p1 - f2  0.06  0.194  0.2178      0.2178  Spencer et al (2002) 
p1 - i2  0.02          0.02  Wald et al (2003) 
p1 - p2  0.7  0.777        0.777  Glasgow dataset 
a2 - u2  0.2      0.182  0.21  0.182  Aitken and Crossley (2005) 
a2 - h2  0.15  0.171  0.135  0.136  0.122  0.136  Aitken and Crossley (2005) 
a2 - f2  0.1  0.065  0.0428    0.058  0.0428  Spencer et al (2002) 
h1: hCG in 1
st trimester, f1: fβhCG in 1
st trimester, p1: PAPP-A in 1
st trimester, a2: AFP in 2
nd trimester, u2: uE3 in 2
nd trimester, h2: hCG in 2
nd trimester, f2: fβhCG in 
2
nd trimester, i2: InhA in 2
nd trimester, p2: PAPP-A in 2
nd trimester 
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Table 2.4: Correlation coefficient for serum marker (cont) 
 
  Wald et al 
(2003) 
Glasgow 
dataset 
Spencer  et 
al (2002) 
Aitken and Crossley 
(2005) 
Cuckle  et al 
(1995) 
Parameters 
used  Source used 
a2 - i2  0.2      0.191    0.191  Aitken and Crossley (2005) 
a2 - p2  0.2  0.175        0.175  Glasgow dataset 
u2 - h2  -0.04      -0.078  -0.092  -0.078  Aitken and Crossley (2005) 
u2 - f2  -0.06        -0.136  -0.136  Cuckle et al (1995) 
u2 - i2  -0.09      -0.05    -0.05  Aitken and Crossley (2005) 
u2 - p2  0.1          0.1  Wald et al (2003) 
h2 - f2  0.87  0.86        0.86  Glasgow dataset 
h2 - i2  0.43      0.329    0.329  Aitken and Crossley (2005) 
h2 - p2  0.28  0.287  0.2382      0.287  Glasgow dataset 
f2 - i2  0.41            Wald et al (2003) 
f2 - p2  0.28  0.285  0.2178      0.285  Glasgow dataset 
i2 - p2  0.25            Wald et al (2003) 
h1: hCG in 1
st trimester, f1: fβhCG in 1
st trimester, p1: PAPP-A in 1
st trimester, a2: AFP in 2
nd trimester, u2: uE3 in 2
nd trimester, h2: hCG in 2
nd trimester, f2: fβhCG in 
2
nd trimester, i2: InhA in 2
nd trimester, p2: PAPP-A in 2
nd trimester  
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2.4  RETROSPECTIVE  STUDY  ON  EFFECT  OF  SMOKING  & 
ETHNICITY  ON  SERUM  MARKER  CONCENTRATION  IN 
PAIRED FIRST AND SECOND TRIMESTER SAMPLES 
The effect of smoking and ethnicity on AFP, hCG, PAPP-A and fβhCG concentrations 
were  studied  using  paired  first  and  second  trimester  serum  samples.  All  normal 
pregnancies which were not affected by chromosomal abnormalities and which had CUB 
screening performed at the Queen Mother’s Maternity Hospital in Glasgow were identified 
between August 2000 and October 2006. After exclusion of twin pregnancies, samples 
with insufficient serum and missing samples, 939 first trimester serum samples could be 
paired with a second trimester sample taken for AFP measurement at 15 to 20 weeks of 
gestation  as  a  screen  for  neural  tube  defects.  Information  about  the  ethnic  origin  and 
maternal smoking habits of these women was obtained from the screening database. A 
recheck against the original request form and reclassification of the ethnic origin of the 
patients  was  performed  to  confirm  the  accuracy  of  the  information.  The  study  group 
consisted of 501 Caucasian, 268 South Asian, 66 Oriental, 42 Middle Eastern, 35 Black 
and 27 Asian women.  The Caucasians were used as controls. The Caucasians were a 
random selection of cases matched to the non-Caucasian group. Maternal serum PAPP-A 
and fβhCG levels were available for all the first trimester samples and AFP and hCG levels 
were available for all the second trimester samples. To study the effect of smoking, paired 
first and second trimester serum samples from 459 Caucasian women (366 non-smokers 
and 93 smokers) were analysed.  
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2.5  RETROSPECTIVE  STUDY  ON  EFFECT  OF  ASSISTED 
REPRODUCTIVE  TECHNOLOGY  ON  SERUM  MARKER 
CONCENTRATION 
The level of first and second trimester biochemical markers in women conceived after 
various form of ART was assessed in this study. Pregnant women who had CUB screening 
or second trimester screening for Down’s syndrome between October 2005 and January 
2009  were  identified  from  the  screening  database.  Due  to  patients’  confidentiality, 
information on ART was not requested in the screening request forms. Therefore, ART 
information was only available in cases where this information was volunteered.  
There  were  127  first  trimester  ART  pregnancies  and  129  second  trimester  ART 
pregnancies identified. A recheck against the original request form and classification of the 
type  of  ART  procedure  was  performed.  The  pregnancies  were  classified  into  four 
categories; 1. normal pregnancy, 2. IVF or ICSI with fresh eggs; 3. IVF or ICSI with 
frozen embryo and 4. IVF with donor egg. Table 2.5 shows the number of pregnancies in 
each category of ART procedure. 
 
Table 2.5: Number of pregnancies in each ART procedure category 
ART  1
st trimester  2
nd trimester 
1. Normal  10891  61448 
2. IVF or ICSI with fresh eggs  91  105 
3. IVF or ICSI with frozen embryo   29  15 
4. IVF with donor’s egg  7  9                                                                                                                                              Chapter 2: Materials 
 
70 
 
2.6  RETROSPECTIVE  STUDY  ON  BIRTH  WEIGHT, 
DURATION  OF  PREGNANCY  AND  SECOND  TRIMESTER 
MATERNAL  SERUM  SCREENING  MARKERS  IN  NON-
SMOKERS AND SMOKERS 
The maternal serum AFP and hCG levels, birth weight and gestation at delivery in a large 
cohort of self-reported non-smokers and smokers were studied to establish the modifying 
effect of smoking on these pregnancy and birth parameters. A cohort of 21,029 pregnant 
women who had second trimester screening for Down’s syndrome and neural tube defects 
in the West of Scotland between May 2003 and July 2004 were identified. The records of 
those  women  who  had  second  trimester  prenatal  screening  were  matched  with  their 
obstetric  records  (Scottish  Morbidity  Records  (SMR02),  NHS  Information  Services 
Division).  The  SMR02  dataset  contains  self-reported  smoking  information  at  booking 
appointment, baby’s date-of-birth, mother’s date-of-birth, maternal deprivation category of 
residence, date of booking, birth weight and gestation at delivery. The second trimester 
screening records contain self-reported smoking information at screening appointment and 
gestation at sampling. After data linkage, the final dataset contained maternal weight, AFP 
MoM,  hCG  MoM,  self-reported  smoking  information  at  both  booking  and  screening 
appointment, birth weight and gestation at delivery. The screening request form was used 
to record information on smoking status at screening appointment. Smoking information at 
booking appointment was recorded as one of three options: current smoker, former smoker 
and never smoker. At screening, four options were offered: non-smoker, smoker, stopped 
smoking during pregnancy and stopped smoking prior to pregnancy. The smoking status 
was recorded as ‘not available’ for those women who did not respond to the question or 
where smoking information was not recorded on the form.                                                                                                                                               Chapter 2: Materials 
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2.6.1 ACCURACY OF SELF-REPORTED SMOKING INFORMATION 
AT BOOKING AND SCREENING APPOINTMENTS 
In this study, the reliability of self-reported smoking information at booking and screening 
appointments  were  validated  using  cotinine  analysis.  From  the  database  3550  serum 
samples  were  randomly  selected  for  cotinine  analysis.  After  excluding  samples  with 
insufficient serum, cotinine testing was carried out on 3475 thawed serum samples using 
the Cozart STD Micro-Plate Cotinine EIA (Cozart UK Ltd). Selection of study sample for 
cotinine analysis is illustrated in Figure 2.1. 
2.6.2  EVALUATION  ON  THE  EFFECTIVENESS  OF  TWO 
SCREENING  FORMS  USED  TO  COLLECT  SELF-REPORTED 
SCREENING INFORMATION AT ANTENATAL CLINICS  
A small study was performed to compare two different screening forms used for collecting 
self-reported smoking information. Two datasets (March 2006 and March 2008) were used 
in this study. The self-reported smoking information in March 2006 dataset was collected 
using the screening form where women were given four options; non-smoker, smoker, 
stopped smoking during pregnancy and stopped smoking prior to pregnancy. The self-
reported smoking information in March 2008 dataset was collected using the screening 
form where women were given only two options; non-smoker or smoker. Those women 
who stopped smoking during pregnancy and stopped smoking prior to pregnancy were 
classified  as  ‘non-smoker’.  The  smoking  status  information  was  also  included  in  the 
screening report allowing antenatal clinic staff to contact the West of Scotland Regional 
Genetics Service department if there was any mistake in the smoking information as this 
could affect the interpretation of results. From each dataset maternal serum samples from 
100 self-reported non-smokers and 100 self-reported smokers were randomly selected for 
cotinine testing. The accuracy of self-reported smoking information was calculated.                                                                                                                                              Chapter 2: Materials 
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2.6.3 BIRTH WEIGHT AND GESTATION AT DELIVERY 
The associations between birth weight, gestation at delivery and second trimester markers 
in self-reported smokers and non-smokers were investigated using data from the routine 
second trimester prenatal screening programme in Scotland. Of 21,029 second trimester 
records 15,973 singleton pregnancies which had full information on birth weight, gestation 
at delivery, AFP level, hCG level and self-report as smoker or non-smoker were selected 
for this analysis. Those who responded with stopped during or prior to pregnancy were 
excluded from further analysis. The pregnancy was classified as ‘low birth weight’ if the 
infant was under 2500g (Wilcox and Johnson, 1992). 
 
  Women in West of Scotland with a 2004 birth (n = 29 975) 
Opted for prenatal screening (n = 21 029) 
Screening records that could be linked to Scottish Morbidity 
Records (SMR02) maternity data (n = 20 283) 
Records randomly selected for analysis (n = 3550) 
Serum samples located and analysed (n = 3475) 
Figure 2.1: Selection of study sample for cotinine analysis (Shipton et al., 2009)                                                                                                                                              Chapter 3: Methods 
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3.1  RETROSPECTIVE  STUDY  OF  WITHIN  -  TRIMESTER 
CONTINGENT SCREENING 
Retrospectively, the performance of the full CUB screening test was compared with that of 
the two-stage contingent protocol of Christiansen and Larsen (2002) but using the same 
final cut-off risk as the CUB screening programme. In this screening protocol, women 
would be offered NT measurement based on their first trimester biochemical test (Figure 
3.1). Initially, a risk at term was calculated from the PAPP-A and fβhCG results combined 
with the maternal age risk for all women. A high risk cut-off of 1:42 and a low-risk cut-off 
of 1:1000 were defined using the statistical approach described by Christiansen and Larsen 
(2002). The high-risk cut-off is dependent on the final risk and the low-risk cut-off is 
chosen empirically to adjust the proportion of women requiring NT measurement.  
Women were divided into three groups according to their initial biochemistry and maternal 
age risk. For those with intermediate risks between 1:42 and 1:1000, the likelihood ratio 
derived from the NT measurement in MoM was then combined with the biochemistry and 
maternal age risk and the composite risk assessed against a final cut-off risk of 1:250 at 
term. Those women with a final risk ≥1:250 were classified as screen positive and added to 
the  initial  high-risk  group.  Those  with  final  risks  of  <1:250  were  classified  as  screen 
negative and added to the initial low-risk group. The final risk cut-off of 1:250 was chosen 
based on the current first trimester CUB screening cut-off. From the distribution of risks in 
Down syndrome and unaffected pregnancies the detection rate and false positive rate of the 
contingent screening model was calculated.  
The performance of contingent screening using LMP based gestational age at the first stage 
of screening was also evaluated. Multiple of the appropriate gestation medians (MoM)                                                                                                                                              Chapter 3: Methods 
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(with  maternal  weight  correction  for  PAPP-A  and  fβhCG  and  smoking  correction  for 
PAPP-A) were calculated for the biochemical markers using LMP based gestational age. 
The correlation co-efficient between markers, medians and standard deviation values of all 
the markers for the unaffected and Down’s syndrome pregnancies were taken from the 
literature (Spencer et al., 1999b). Maternal age risk was calculated using the equation as 
described by Cuckle et al (1987). The likelihood ratio was calculated based on the double 
test (PAPP-A and fβhCG) and maternal age risk at the first stage of screening. Of those 
who were offered NT measurement, the MoM values of the biochemical markers were re-
calculated using CRL/BPD based gestational age. The likelihood ratio derived from NT 
measurement, PAPP-A and fβhCG in MoMs was then combined with maternal age risk. 
The detection rate and false positive rate of the contingent screening model was calculated.                                                                                                                                              Chapter 3: Methods 
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Figure  3.1  -  Within-trimester  contingent  screening  protocol.  Risks  derived  from  serum 
markers and maternal age were estimated for all women and used to triage the population 
into high, low and intermediate risk groups. Women whose risk is equal or greater than 
1:42 would be offered a diagnostic test and those women whose risk is equal or lower than 
1:1000 would not be offered any further testing. Women with an intermediate risk would 
be offered NT measurement and those with a composite risk equal or greater than the cut-
off of 1:250 would be offered diagnostic testing. 
 
 
 
 
 
High risk (risk ≥1:42)  Low risk (risk ≤1:1000) 
Double Test (PAPP-A/FβhCG/ age) 
Intermediate risk 
 Nuchal translucency (NT) 
Total risk (risk < 1:250)  Total risk (risk ≥ 1:250) 
Chorionic villus sampling 
(CVS) or Amniocentesis 
No invasive diagnostic procedure                                                                                                                                              Chapter 3: Methods 
 
77 
 
3.1.1  STATISTICAL  CALCULATION  TO  DETERMINE  THE  CUT-
OFFS 
The method used in this study was based on the statistical calculations used in a study by 
Christiansen and Larsen (2002). The final risk for a particular pregnancy is based on the 
serological test, a, and NT measurement, r.  Therefore, the final risk is, a x r. If the final 
risk is >1:250 it follows that: 
ar > 1:250 
r> 0.004/a 
The  likelihood  ratio  of  NT  measurement  was  established  using  the  published  NT 
distribution (Cuckle and van Lith, 1999) and the formulae for the distribution of NT log 
MoM in normal and DS pregnancies. 
Log10 MoM NT = -0.1076 + 0.2995 x √(0.7863 + log10 r). 
Log10 r ≥ -0.7863 ( log10 r can not be < -0.7863) 
r ≥ 0.164 
 
Therefore, if the serologically defined risk, a, is > 0.024, then no NT measurement can 
reduce the final risk to a value <1:250. Such calculations were performed to determine the 
initial high risk cut-offs for different final risk cut offs (Christiansen and Larsen, 2002)  
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3.2  MODELLING  CROSS-TRIMESTER  CONTINGENT 
SCREENING  
Using  the  S-PLUS  statistical  programme,  the  performances  of  various  types  of  cross-
trimester contingent screening policies were evaluated. Protocols were designed in which 
all women would receive a first trimester screening test and those with intermediate risks 
would receive a follow up second trimester screening test (Figure 3.2).  
 
 
 
 
   
 
 
 
Figure 3.2: Cross- trimester contingent screening protocol.  
Risks derived from first trimester screening were estimated for all women and used to 
triage the population into high, low and intermediate risk groups. Women with high risk 
would be offered a diagnostic test and those women with low risk would not be offered any 
further  testing.  Women  with  an  intermediate  risk  would  be  offered  second  trimester 
screening  and  those  with  composite  risk  greater  than  the  cut-off  would  be  offered 
diagnostic testing. 
Low risk 
Low risk   Intermediate risk  High risk  
Second trimester screening 
High risk 
Chorionic villus sampling 
(CVS) or Amniocentesis 
No invasive diagnostic procedure 
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3.2.1 MODELLING 
The performance of cross-trimester contingent screening using various combinations of 
markers was evaluated using S-PLUS statistical software. The log10 transformed marker 
values were assumed to follow multivariate Gaussian distributions for both unaffected and 
Down’s syndrome pregnancies. Truncation limits from Wald et al (2003) (SURUSS) were 
applied in the risk calculation. These were: first trimester: NT (0.5–2.5), AFP (0.4–3.0), 
uE3 (0.4–2.0), total hCG (0.3–3.0), fβhCG (0.3–5.0), InhA (0.3–5.0), PAPP-A (0.2–3.0); 
second  trimester:  AFP  (0.4–3.0),  uE3  (0.4–2.0),  total  hCG  (0.4–5.0),  fβhCG  (0.3–5.0), 
InhA (0.3–5.0), PAPP-A (0.2–3.0).  
Before  analysis  was  performed,  the  SDs,  medians  and  correlation-coefficients  for  each 
week of gestation for unaffected and Down’s syndrome pregnancies were entered into the 
database  in  the  S-PLUS  software  programme  (Figures  3.3  and  3.4).  The  maternal  age 
distributions (12 to 50 years), the mean and SD of maternal age were also entered into the 
database in the software (Figure 3.5).  
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Figure 3.3: Screen shot of the database where the standard deviations for all the markers 
are recorded                                                                                                                                              Chapter 3: Methods 
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Figure 3.4: Screen-shot of the database where the correlation coefficients between markers 
are recorded 
Figure 3.5: Screen-shot of the database where the maternal age distributions are recorded                                                                                                                                              Chapter 3: Methods 
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Two functions; gen2.lr and rep2f, written by Prof. Dave Wright (Plymouth) were used in 
the statistical modelling. The markers used in the analysis, the number of observation and 
the gestational week when the screening was performed were entered in the first function, 
gen2.lr (Figure 3.6). In this study, samples of 1, 000,000 observations were drawn (500, 
000 were taken as Down’s syndrome pregnancies and 500, 000 as unaffected pregnancies).  
 
 
 
When the gen2.lr function was executed, for each observation, the likelihood ratio was 
computed for each set of markers at each stage of screening (Figure 3.7).  
 
Gestation week 
Number of 
observations 
Number of marker 
used in the 2
nd stage 
of screening 
Number of marker 
used in the 1
st stage of 
screening 
Markers used in the 
analysis 
Figure 3.6: Screen-shot of the gen2.lr function                                                                                                                                              Chapter 3: Methods 
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Once all the likelihood ratios were computed, the rep2f function was executed. Before the 
function was executed, the high, low and final cut-off risks were entered into the function. 
In this study, a high risk cut-off of 1:42 and a low-risk cut-off of 1:1000 were used, similar 
to the one used in the within-trimester contingent screening policy (see Figure 3.1). A final 
cut-off risk at term of 1:150 was chosen based on the current UK NSC policy. Apart from 
the above information, the gestation week when screening was performed, the range of 
maternal  age  and  the  name  of  the  database  where  the  maternal  age  distributions  were 
recorded were also entered in the function (Figure 3.8).  
 
 
 
Figure 3.7: Screen-shot of S-PLUS programme                                                                                                                                               Chapter 3: Methods 
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When  the  rep2f  function  was  executed,  the  maternal  age  specific  detection  and  false 
positive rates were derived from the likelihood ratios computed earlier and the maternal 
age distribution of Down’s syndrome and unaffected pregnancies. The early completion 
rates were computed based on those women who were offered diagnostic test after the first 
stage of screening and those who were not offered any further screening after the first stage 
of screening. Figure 3.9 shows an example of the output once the analysis was completed.   
 
Gestation 
week 
Maternal 
age range 
Database of 
the maternal 
age distribution 
Low cut-
off risk 
 High cut-
off risk 
Final cut-
off risk 
Figure 3.8: Screen-shot of the rep2f function                                                                                                                                              Chapter 3: Methods 
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Figure 3.9: Screen-shot of the example of output once analysis was completed                                                                                                                                              Chapter 3: Methods 
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In summary, SDs, medians of markers, correlation-coefficients, maternal age distributions, 
gestation when the screening was performed, number of observations, markers used and 
cut-off risks are the variables which can be configured based on local circumstances when 
using S-PLUS statistical software. 
3.2.2 CROSS-TRIMESTER CONTINGENT SCREENING PROTOCOL 
WITH AND WITHOUT REPEAT MEASURES 
The  effectiveness  of  cross  trimester  contingent  screening  policies  with  various 
combinations of markers was evaluated. An initial risk at term was calculated from the first 
trimester screening results combined with the maternal age risk for all women. A high risk 
cut-off of 1:42 and a low-risk cut-off of 1:1000 were used in this screening policy. Women 
were divided into three groups according to their initial first trimester screening test results 
and maternal age risk. For those with intermediate risks between 1:42 and 1:1000, the 
likelihood ratio derived from the second trimester screening test was then combined with 
the first trimester screening test and maternal age risk and the composite risk assessed 
against a final cut-off risk of 1:150. Those women with a final risk ≥1:150 were classified 
as screen positive and added to the initial high-risk group. Those with final risks of <1:150 
were classified as screen negative and added to the initial low-risk group (Figure 3.10). 
From the distribution of risks in Down syndrome and unaffected pregnancies the detection 
rate  and  false  positive  rate  of  the  cross-trimester  contingent  screening  model  was 
calculated. The combinations of markers examined in this study are shown in Table 3.1.                                                                                                                                              Chapter 3: Methods 
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Table 3.1: Cross-trimester contingent screening protocols evaluated in this study 
Screening protocol 
1.  Cross-trimester contingent screening with second trimester double, triple or quadruple test 
(with and without NT measurement) 
2.  Cross-trimester contingent screening with repeat measure of FβhCG (with and without NT 
measurement) 
3.  Cross-trimester contingent screening with repeat measure of PAPP-A (with and without 
NT measurement) 
4.  Cross-trimester contingent screening with repeat measure of hCG and PAPP-A (with and 
without NT measurement) 
5.  Cross-trimester contingent screening with repeat measure of FβhCG and PAPP-A (with 
and without NT measurement) 
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Figure  3.10  -  Cross-trimester  contingent  screening  protocol.  Risks  derived  from  first 
trimester screening test and maternal age were estimated for all women and used to triage 
the population into high, low and intermediate risk groups. Women whose risk is equal or 
greater than 1 in 42 would be offered a diagnostic test and those women whose risk is equal 
or  lower  than  1  in  1000  would  not  be  offered  any  further  testing.  Women  with  an 
intermediate  risk  would  be  offered  second  trimester  screening  test  and  those  with  a 
composite risk equal or greater than the cut-off of 1 in 150 would be offered diagnostic 
testing. 
 
Total risk (risk < 1:150)  Total risk (risk ≥ 1:150) 
No invasive diagnostic procedure 
 Second trimester screening 
test 
Low risk  
(risk ≤1:1000) 
First trimester screening test 
Intermediate risk 
Chorionic villus sampling (CVS) or 
Amniocentesis 
High risk 
(risk ≥1:42)                                                                                                                                              Chapter 3: Methods 
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3.3  RETROSPECTIVE  STUDY  ON  EFFECT  OF  SMOKING  & 
ETHNICITY  ON  SERUM  MARKER  CONCENTRATION  IN 
PAIRED FIRST AND SECOND TRIMESTER SAMPLES 
Maternal serum PAPP-A and fβhCG levels were available for all the first trimester samples 
and AFP and hCG levels were available for all the second trimester samples. The first 
trimester  AFP  and  hCG  levels  and  second  trimester  PAPP-A  and  fβhCG  levels  were 
measured  in  939  paired  first  and  second  trimester  serum  samples  using  the  DELFIA 
fluoroimmunoassay  system  (Perkin  Elmer  LAS,  UK)  according  to  the  manufacturer’s 
instructions. All samples were coded before analysis such that their origin was unknown to 
the assay operator.   
3.3.1 FLUOROIMMUNOASSAY - AutoDELFIA 
AutoDELFIA  is  an  automatic  immunoassay  system  used  in  diagnostic  or  screening 
laboratories. In the DELFIA assay, the labels employed are chelates of europium or other 
lanthanide metals. The AutoDELFIA uses time resolved fluorometry (TRF) to measure the 
signal. Extreme sensitivity combined with a wide dynamic measuring range is obtained 
due to the large Stokes’ shift and long decay times of europium. Furthermore, several 
different  lanthanides  have  unique  fluorescence  emission  profiles.  This  allows  multiple 
assays  to  be  performed  using  AutoDELFIA  system  where  dual  label  kits  utilizing 
europium and samarium allow simultaneous measurement of analytes that are commonly 
required at the same time. 
The system consists of a sample processor where automatic dilution and pipetting of serum 
samples are performed and a plate processor where reagent handling and all assay stages                                                                                                                                              Chapter 3: Methods 
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including measurement are performed. AutoDELFIA is controlled by the Windows- based 
AutoDELFIA workstation software.     
3.3.1.1 PREGNANCY ASSOCIATED PLASMA PROTEIN A (PAPP-A) 
PAPP-A, a glycoprotein, is produced by trophoblastic tissues in the placenta of pregnant 
women. PAPP-A is secreted into maternal circulation as a heterotetrameric complex of two 
PAPP-A subunits disulfide-bonded to two molecules of proMBP. Maternal serum PAPP-A 
level  is  found  to  be  significantly  decreased  in  the  first  trimester  in  Down’s  syndrome 
pregnancies.   
The PAPP-A concentration in maternal serum was measured using a solid phase two-site 
fluorometric assay based on the indirect sandwich technique (DELFIA). Biotin labeled 
capture antibodies, added in the first incubation period, reacts with the microtitration strips 
coated with streptavidin. The strips are washed before adding the standards, controls and 
samples in the second incubation. PAPP-A molecules in the serum samples react with the 
tracer  antibodies  labeled  with  chelates  of  europium.  The  strips  are  washed  and 
enhancement solution is added to dissociate europium ion from the labeled antibody. The 
europium  ion  and  components  of  the  enhancement  solution  forms  highly  fluorescent 
chelates, and the fluorescent counts are measured by the AutoDelfia machine. 
3.3.1.2 FREE β HUMAN CHORIONIC GONADOTROPIN (FβhCG) 
FβhCG, a glycoprotein, is one of the two subunits of hCG. FβhCG is expressed in the 
placenta and found to be significantly elevated in maternal serum of Down’s syndrome 
pregnancies.  The  fβhCG  concentration  in  maternal  serum  was  measured  using  a  solid 
phase two-site fluorometric assay based on the direct sandwich technique (DELFIA). The 
fβhCG  molecules  in  maternal  serum  are  reacted  with  immobilized  fβhCG  specific                                                                                                                                              Chapter 3: Methods 
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monoclonal antibodies and samarium-labeled monoclonal antibodies at different antigen 
sites.  The  enhancement  solution  is  added  to  dissociate  samarium  ion  from  the  labeled 
antibody. The samarium ion and components of the enhancement solution forms highly 
fluorescent chelates, and the fluorescent counts are measured by the AutoDelfia machine. 
3.3.1.3 ALPHA FETOPROTEIN (AFP) 
AFP, a glycoprotein of fetal origin, is produced by the embryonic yolk sac in the early 
stage  of  pregnancy  and  later  by  the  fetal  liver.  AFP  diffuses  into  the  maternal  blood 
circulation  through  the  amniotic  membrane.  AFP  level  is  found  to  be  decreased 
significantly  in  the  second  trimester  in  Down’s  syndrome  pregnancies.  The  AFP 
concentration  in  maternal  serum  was  measured  using  a  solid  phase  two-site 
fluoroimmunometric assay based on the direct sandwich technique (DELFIA). In the one 
incubation  period  protocol,  the  AFP  molecules  in  maternal  serum  are  reacted 
simultaneously  with  immobilized  AFP  specific  monoclonal  antibodies  and  europium-
labeled monoclonal antibodies at different antigen sites on the same AFP molecules. The 
enhancement solution is added to dissociate europium ion from the labeled antibody. The 
europium  ion  and  components  of  the  enhancement  solution  forms  highly  fluorescent 
chelates, and the fluorescent counts are measured by the AutoDelfia machine. 
3.3.1.4 HUMAN CHORIONIC GONADOTROPIN (hCG) 
Human chorionic gonadotropin, a glycoprotein hormone, is produced by the trophoblastic 
cells of the fertilized ovum in the early stage of pregnancy and later by the placental tissue. 
hCG diffuses into the maternal blood circulation through the placenta. hCG level is found 
to be elevated significantly in the second trimester in Down’s syndrome pregnancies. The 
hCG  concentration  in  maternal  serum  was  measured  using  a  solid  phase  two-site                                                                                                                                              Chapter 3: Methods 
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fluoroimmunometric assay based on the direct sandwich technique (DELFIA). The hCG 
molecules in maternal serum are firstly reacted with immobilized monoclonal antibodies 
directed against a specific antigen site on the β subunit of hCG and then with europium-
labeled  antibodies  directed  against  a  specific  antigen  site  on  the  α  subunit.  The 
enhancement solution is added to dissociate europium ion from the labeled antibody. The 
europium  ion  and  components  of  the  enhancement  solution  forms  highly  fluorescent 
chelates, and the fluorescent counts are measured by the AutoDelfia machine. 
3.3.2 PROTOCOL OF THE ASSAY 
All the samples retrieved from the freezer were left to thaw slowly at 4
oC. The samples 
were then vortexed and given barcodes. The quality controls for the first trimester (PAPP-
A and fβhCG) and second trimester (AFP and hCG) assays were commercially produced 
by  Brahms  Kryptor  and  Biorad  respectively.  The  quality  control  samples  have  three 
different levels and are composed of pooled, lyophilised human serum. Information about 
the samples and controls were entered in the AutoDelfia software. Samples, controls and 
standard were placed in the vials according to the information given in the software and 
then loaded into the machine. The reagents; wash solution, buffer, enhancement solution 
were placed into the reagent cassette. The plates were loaded into the machine and then the 
assays were started. After the assays were completed, all the samples, controls, standards 
and  plates  were  discarded.  The  results  were  automatically  calculated  by  WIACALC 
programme on Multicalc 2000. Dilution (1 in 10) was performed on those samples which 
had biochemical marker concentrations above the assay top standard and the samples were 
reanalysed. All the results were entered into SPSS software.        
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3.3.3 ASSAY PARAMETERS 
All the results were converted to multiple of median (MoM) of the appropriate gestation. 
Three quality control samples were assayed twice in each batch of samples. Table 3.2 
shows the mean and intra- and inter- assay coefficient of variations (CVs) of the quality 
control samples. 
 
Table 3.2: The mean and intra- and inter-assay CVs of the quality control samples 
Biochemical 
Markers 
Parameters 
Quality Control 
1 
Quality Control 
2 
Quality Control 
3 
AFP  Mean  8.5 U/ml  26.1 U/ml  72.1 U/ml 
  Intra-assay CV  1.7%  2.2%  1.5% 
  Inter-assay CV  1.7%  2.8%  2.4% 
hCG  Mean  13.2 U/ml  38.3 U/ml  77.2 U/ml 
  Intra-assay CV  2.6%  2.8%  3.2% 
  Inter-assay CV  3.0%  3.5%  3.6% 
PAPP-A  Mean  265.1 mU/L  1489.5 mU/L  4386.7 mU/L 
  Intra-assay CV  4.6%  4.0%  3.1% 
  Inter-assay CV  4.8%  5.0%  3.7% 
fβhCG  Mean  69.4 ng/ml  17.2 ng/ml  6.9 ng/ml 
  Intra-assay CV  2.2%  2.0%  3.9% 
  Inter-assay CV  3.1%  3.1%  4.2% 
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3.3.4. STATISTICAL ANALYSIS 
AFP,  hCG,  fβhCG  and  PAPP-A  levels  were  measured  and  regressed  medians  were 
calculated  for  each  gestational  week  (from  week  9  to  week  20)  using  the  data  from 
Caucasian women with normal singleton pregnancies. The gestational ages were calculated 
either from CRL or the time since the first day of the LMP. The MoM for each marker at 
each gestation was calculated using the regression equation from the best fitted model for 
each marker. This was done by using the curve estimation routine in SPSS. To check 
whether  the  simple  regression  chosen  was  appropriate,  the  regression  curves  were 
compared  with  the  regression  curve  normally  used  in  routine  screening  at  Institute  of 
Medical  Genetics,  Glasgow.  All  MoM  values  were  corrected  for  maternal  weight  and 
smoking status by dividing the observed MoM value by the expected MoM value. These 
formulas were derived solely from Caucasian women. The Mann Whitney test was used to 
compare the median values of the serum markers in the smoking group with the non-
smoking group among the Caucasians and the median values of the serum markers in each 
ethnic group with the Caucasian group. Results were classified as significant when p<0.05. 
 
3.4 RETROSPECTIVE STUDY ON THE EFFECT OF ASSISTED 
REPRODUCTIVE  TECHNOLOGY  ON  SERUM  MARKER 
CONCENTRATION 
The  Down’s  syndrome  screening  marker  levels  in  127  first  trimester  and  129  second 
trimester  pregnancies  conceived  after  ART  were  compared  with  the  marker  levels  in 
naturally conceived pregnancies. The pregnancies were classified into four categories; 1. 
normal pregnancy, 2. IVF or ICSI with fresh eggs, 3. IVF or ICSI with frozen embryo and 
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AFP and hCG between the controls and ART groups in the second trimester and fβhCG 
and PAPP-A in the first trimester. Marker measurements were carried out using DELFIA 
assays as described in Section 3.3. Results were classified as significant when p<0.05. 
 
3.5  RETROSPECTIVE  STUDY  ON  BIRTH  WEIGHT, 
DURATION  OF  PREGNANCY  AND  SECOND  TRIMESTER 
MATERNAL  SERUM  SCREENING  MARKERS  IN  NON-
SMOKERS AND SMOKERS 
3.5.1 COTININE ANALYSIS 
The  accuracy  of  the  self-reported  smoking  information  on  the  screening  form  was 
established using cotinine analysis. Cotinine is the major metabolite of nicotine and can be 
detected  in  the  biological  fluids  of  both  active  and  passive  smokers.  Due  to  its  high 
specificity for tobacco smoke, long half-life of 15 to 19 hours in different body fluids and 
easy detection with sensitive analytical techniques, cotinine has become the biochemical 
marker of choice to detect smokers.  
From  the  database  of  21,029  pregnant  women,  3550  serum  samples  were  randomly 
selected for cotinine analysis. After excluding samples with insufficient serum, cotinine 
testing was carried out on 3475 thawed serum samples using the Cozart STD Micro-Plate 
Cotinine EIA (Cozart UK Ltd). All samples were assayed without knowledge of smoking 
status  and  in  singleton.  Those  women  who  had  cotinine  levels  above  13.7ng/ml  were 
classified as smokers (Jarvis et al., 1987). Those samples with cotinine levels between 10 
and 30ng/ml (close to the chosen cut off of 13.7 ng/ml) were re-assayed and the final 
cotinine concentration was taken from the mean of the two values. 
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3.5.1.1 PRINCIPLE OF THE COTININE ASSAY 
Cotinine in maternal serum was detected using  a semi quantitative assay; Cozart STD 
Micro-Plate Cotinine EIA (Cozart UK Ltd). Aliquots of maternal serum are added to the 
wells of the microtitre strips which are coated with anti-cotinine antibody. Horseradish 
peroxide (HRP)-labelled cotinine competes with the free cotinine in the serum samples for 
the anti-cotinine antibody binding sites on the microtitre strips during the first incubation. 
Tetramethylbenzidine substrate solution is added after the wells are washed to remove any 
excess enzyme material. Stop solution terminates the reaction and the absorbance is read 
spectrophotometrically at 450nm using the Wallac Victor multilabel counter.  
3.5.1.2 PROTOCOL OF THE COTININE ASSAY 
All the samples retrieved from the freezer were left to thaw slowly at 4
oC and were then 
vortexed. Two quality control samples; positive and negative (smokers and non-smokers), 
were used and they were composed of pooled human serum from the routine screening 
programme. Forty-two serum samples from self-reported smokers and forty-three samples 
from self-reported non-smokers were pooled together for the positive and negative controls 
respectively. The positive controls had values above the top positive standard (50ng/mL) 
and the negative controls had values below the bottom positive standard (5ng/mL). Each 
Cozart Cotinine EIA Serum kit contained each of the following components and reagents. 
1.  Anti-Cotinine Coated Plate – 12 x 8 well strips in break-apart format. Anti-cotinine 
polyclonal antibody immobilised on a polystyrene plate supplied in dry form. 
2.  Enzyme Conjugate – Cotinine derivative labelled with horseradish peroxidase and 
diluted in a protein matrix with stabilisers. 
3.  Wash buffer – Each vial is diluted to 1500mL with distilled water. 
4.  Substrate solution – Each bottle containing <0.05% 3,3’,5,5’-tetramethylbenzidine.                                                                                                                                              Chapter 3: Methods 
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5.  Stop solution – Each bottle containing 1mol/L sulphuric acid. 
6.  Negative calibrator – Protein matrix negative for cotinine. 
7.  Positive calibrator – Protein matrix containing 10ng/mL, 25ng/mL and 50ng/mL 
cotinine.  
An additional positive calibrator was required in order to improve the fit of the standard 
curve. A 5ng/mL calibrator solution was prepared by a 1/10 dilution of 50ng/mL calibrator 
solution.  All  samples  were  assayed  anonymously  and  in  singleton.  10µL  of  controls, 
samples  or  calibrator  was  added  to  each  well  within  25  minutes.  100µL  of  enzyme 
conjugate was then added to each well and the plate was incubated for 30 minutes. After 
the incubation, the plate was washed four times with wash buffer (which was diluted by 
1:30 dilution with distilled water) using the DELFIA
® Platewasher. 100µL of substrate 
solution was added to the well and the plate was incubated for 30 minutes. 100µL of stop 
solution was added after the incubation and the absorbance was measured at 450nm using 
Wallac Victor 1420 Multilabel Counter.  
3.5.1.3 WALLAC VICTOR 1420 MULTILABEL COUNTER 
Wallac  1420  is  a  multi-task,  multi-label  plate  counter  which  is  used  for  quantitative 
detection of light emitting or light absorption markers. The Victor measures all commonly 
used florescent labels and time-resolved florescence labels. After measurement of a plate, 
the results were automatically calculated by MultiCalc.  
3.5.1.4 DATA ANALYSIS 
All  the  results  were  entered  into  SPSS  software.  Those  samples  with  cotinine  levels 
between 10 and 30ng/ml (close to the chosen cut off of 13.7 ng/ml) were re-assayed and 
the final cotinine concentration was taken from the mean of the two values. Those women                                                                                                                                              Chapter 3: Methods 
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who had cotinine levels above 13.7ng/ml were classified as smokers (Shipton et al., 2009, 
Jarvis et al., 1987). The accuracy of self-reported smoking information at booking and 
screening were calculated. 
3.5.2 BIRTH WEIGHT AND GESTATION AT DELIVERY  
The mean birth weight in self-reported non-smokers and smokers was stratified according 
to maternal serum AFP and hCG levels (in MoM) in the second trimester. The pregnancy 
was classified as ‘low birth weight’ if the infant was under 2500g (Wilcox and Johnson, 
1992). The Mann Whitney test was used to compare the mean birth weight for the smoking 
group with the non-smoking group. Results were classified as significant when p<0.05. 
Regression was performed to test the trend in birth weight with AFP and hCG levels in 
smokers and non-smokers. The median gestation at delivery for non-smokers and smokers 
was  calculated  according  to  maternal  serum  AFP  and  hCG  levels  (in  MoM).  The 
percentage of pregnancies delivered at 38 weeks and earlier were calculated for each AFP 
and hCG group. 
 
3.6 STATISTICAL METHODS 
3.6.1 MEDIANS 
The median is the middle value when the data are sorted in ascending order. The median 
measures the central tendency and is not sensitive to extreme values. It is usually used 
when the distribution is skewed. Medians were calculated using the SPSS 12.0.1 program. 
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3.6.2 MEANS 
The mean is a measure of central tendency but greatly influenced by outliers. The mean 
value is calculated by dividing the sum of all the data by the number of data. Means were 
calculated using the SPSS 12.0.1 program. 
3.6.3 PERCENTILES  
Percentile is the value below which a certain percentage of observations fall.  For example 
the  90
th  percentile  is  the  value  below  which  90%  of  the  cases  fall.  Percentiles  were 
calculated using the SPSS 12.0.1 program. 
3.6.4 STANDARD DEVIATION 
The standard deviation (SD) measures the amount of variation or spread of the data. A low 
standard deviation indicates that all the values in the dataset are close to the mean while a 
high standard deviation indicates that the values in the dataset are spread out over a large 
range of values. Standard deviation was calculated using the following equations: 
 
( )
1 -
-
= ∑
n
x x
SD  or 
56 . 2
) 10 ( log ) 90 ( log 10 10 centile centile
th th -
 
 
where  x  is the mean and n is the number of cases. Standard deviations were calculated 
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99 
 
 
3.6.5 STANDARD ERROR OF MEAN (SEM) 
The standard error of mean indicates the variability of the mean among many samples 
taken from the same distribution. SEM is calculated using the following equation: 
n
SD
SEM =  
where n is the number of cases.  
3.6.6 CONFIDENCE INTERVALS (CI) 
A confidence interval is a range of values derived from a sample, which represents where 
the true population value is likely to fall. In this study, 95% CI were used and this is 
interpreted  as  a  range  of  which  contains  the  true  population  mean  with  probability  of 
0.95%.  
3.6.7 COEFFICIENT OF VARIANCE (CV) 
Assay reproducibility is measured using coefficient of variance (CV). CV indicates the 
ratio of standard deviation (SD) to the mean (x ) expressed as percentage. The inter- and 
intra-assay CV was calculated using the following equation. 





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3.6.8 CORRELATION COEFFICIENT (r) 
Correlation coefficient indicates the level of association between two variables; X and Y. 
The r value has a range between -1 and 1. A positive value indicates positive correlation 
and a negative value indicates negative correlation. If there is no association between the 
two variables, the r value would be close to 0. The formula to calculate r value for two 
variables is: 
∑ ∑
∑
- -
- -
=
2 2 ) ( ) (
) )( (
y y x x
y y x x
r
i i
i i  
where xi and yi are the values of X and Y for the i
th individual.  A simple box-plot was used 
to check for outliers. Outliers between the ranges of ± 3SD were accepted. Correlation 
coefficients were calculated using the SPSS 12.0.1 program. 
3.6.9 COVARIANCE MATRIX 
The covariance matrix is derived from the standard deviations and correlation coefficients. 
The covariance matrix of variable x and y was calculated using the following equation. 
) , ( ) ( ) ( , y x r y SD x SD Cov y x ´ ´ =  
where r is the correlation coefficient between x and y.  
3.6.10 REGRESSION ANALYSIS 
Regression analysis is performed to estimate the relationship between two variables. In this 
study, regression was used to determine the relationship between 1) marker levels and 
gestational  week  and  2)  marker  levels  with  maternal  weight.  Various  models  such  as 
quadratic, cubic and inverse were used to estimate the relationship between two variables. 
Regression  coefficient,  r
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model. The MoM of the appropriate gestation was calculated using the regression equation 
from the best fitted model for each marker. This was done by using the curve estimation 
routine in SPSS. 
3.6.11  MULTIPLE  OF  MEDIAN  OF  THE  APPROPRIATE 
GESTATION 
All the Down’s syndrome screening marker levels were converted to a multiple of the 
control median (MoM) at the appropriate gestational week. This allows changes of marker 
levels with the gestational age to be compared. The equation used to calculate the MoM 
value is as follows. 
gestation   e appropriat at  ion  concentrat median    Regressed
ion concentrat Marker 
= MoM  
3.6.12 CORRECTION FACTORS 
The  biochemical  marker  levels  were  corrected  for  maternal  weight  and  smoking.  For 
correcting the maternal weight, an equation is derived using regression analysis. In this 
study,  Caucasian  women  who  were  non-smokers  were  used  to  derive  this  equation. 
Correcting for smoking was done by dividing the observed MoM value in smokers by the 
expected MoM value in non-smokers. The expected MoM values were derived from the 
Caucasian  women  who  were  non-smokers.  The  equations  used  to  for  correcting  these 
factors are as follows: 
 
Maternal weight: 
 weight maternal   e appropriat at  ion  concentrat median    Regressed
ion concentrat Marker 
= MoM  
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Maternal smoking 
MoM   Expected
MoM1
2 = MoM  
where MoM1 is  the multiple of median marker level of the appropriate gestation. 
3.6.13 DETECTION RATE, FALSE POSITIVE RATE AND SCREEN 
POSITIVE RATE 
Detection rate is the ratio of the number of affected cases which are correctly identified to 
the  total  number  of  affected  cases.  This  is  sometimes  referred  to  as  the  sensitivity  of 
screening. False positive rate is the ratio of the number of unaffected pregnancies with a 
screen positive test result to the total number of unaffected cases. Both detection and false 
positive  rate  are  normally  expressed  in  percentages  (%).  Screen  positive  rate  is  the 
percentage  of  pregnancies  reported  to  have  an  increased  risk  of  having  an  affected 
pregnancy. 
3.6.14 MANN-WHITNEY TEST 
Mann-Whitney test is a non-parametric test based on ranking and ordering of data. This 
test compares the medians of two independent groups by combining and ordering the data 
from the two groups from lowest to highest. Mann-Whitney test was used to compare the 
medians  values  for  biochemical  markers  in  various  ethnic  groups  with  Caucasians, 
smokers with non-smokers and ART treated pregnancies with normal pregnancies. P value 
less  than  0.05  were  considered  as  significant.  The  SPSS  12.0.1  program  was  used  to 
perform the Mann-Whitney test.   
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3.7 RISK CALCULATION FOR DOWN’S SYNDROME                                                                                                                       
The risk of having a Down’s syndrome pregnancy was calculated using the following 
equations. 
Gestational age 
For the ultrasound based gestational age, the CRL measurement was used. If there was 
only BPD measurement, BPD was converted to CRL using the following formula: 
CRL = BPD x 3 (Crossley et al., 2002) 
Gestational age =  73 . 23 ) 052 . 8 ) 037 . 1 ) 1 (( ( + ´ ´ + crl  
For the LMP based gestational age, the gestational age was calculated using the following 
equation: 
Gestational age = the date of sampling - the date of LMP 
 
Age at estimated date of delivery (EDD)  
To calculate the age at EDD, firstly the age at NT scan was calculated. 
Age at NT scan = (date of NT scan – date of birth)/365.25 
Age at EDD = Age at NT scan + ((280 – gestational age)/365) 
                                                                                                                                              Chapter 3: Methods 
 
104 
 
 
Maternal age risk 
The maternal age risk at term was calculated as described by Cuckle et al (1987), where  
p = 0.000627+ e
(-16.2395+0.286*(age at EDD-0.5)) 
and the risk of having a Down’s syndrome pregnancy was  
Term risk = 1: (1-p)/p. 
A correction factor of 0.5 is used when the maternal age is recorded in fractions of years.  
 
Screening marker levels 
Firstly, an average NT measurement was calculated if more than one measurement was 
taken.  
For example, if three measurements were taken: 
Average NT = (nt1 + nt2 + nt3)/3  
Then, NT MoM was calculated. The equation was obtained from the regression analysis 
using the curve estimation routine in SPSS. 
gestation   e appropriat at    levels median    Regressed
NT   Average
= NTMoM  
The fβhCG and PAPP-A MoMs were also calculated using the same method. 
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Correcting for maternal weight and smoking 
The MoM values of the screening markers were corrected for maternal weight and 
smoking (refer to section 3.6.12). 
 
Likelihood ratio for Down’s syndrome from NT measurement 
Truncation of the NT risk at 0.8 MoM was applied. This is done because the risks start to 
increase again below 0.8 MoM due to the shapes of the Gaussian distributions.   
Likelihood ratio: 
a = ((log10 (NT MoM) – Meanx) / SDx)
2 
b = (log10(NT MoM) / SDy)
2 
Likelihood ratio from NT = (SDy / SDx) * e 
(-0.5 x (a-b)) 
where x is Down’s syndrome pregnancies and y is unaffected pregnancies 
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Likelihood ratio for Down’s syndrome from fbhCG and PAPP-A 
The equations below were used to calculate the likelihood ratio from fβhCG and PAPP-A. 
c = log10(fβhCG MoM) / SDy
q 
d = (log10(fβhCG MoM)-Meanx
q) / SDx
q 
e = log10(PAPP-A MoM) / SDy
p 
f = (log10(PAPP-A MoM)-Meanx
p) / SDx
p 
g = (c
2 - (2 * ry * c * e) + e
2) / (1 – ry
2) 
h = (d
2 - (2 * rx * d * f) + f
2) / (1 – rx
2) 
Likelihood ratio from  fβhCG and PAPP-A = 
((SDy
q * SDy
p) / (SDx
q * SDx
p)) * √ ((1 – ry
2) / (1 – rx
2)) * e 
((g – h) / 2) 
where:  x - Down’s syndrome pregnancies, y - unaffected pregnancies, q - fβhCG, p - 
PAPP-A and r - correlation coefficient between PAPP-A and fβhCG 
Truncation  limits  for  PAPP-A  (0.1  –  5.0)  and  fβhCG  (0.2  –  5.0)  applied  in  the  risk 
calculation were based on the truncation limits used in routine screening in Glasgow.  
Combined likelihood ratio for Down’s syndrome from NT, fβhCG and PAPP-A 
Combined likelihood = likelihood ratio from NT x likelihood ratio from fβhCG and  
PAPP-A 
Risk for Down’s syndrome  
Risk for Down’s syndrome = Maternal age risk / combined likelihood ratio                                                                                                                                             Chapter 4: Results 
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4.1  RETROSPECTIVE  STUDY  ON  WITHIN-TRIMESTER 
CONTINGENT SCREENING 
The performance of a two-stage contingent screening protocol for Down’s syndrome based 
on initial serum marker analysis for all women and NT measurement only in women with 
intermediate risks was assessed. Biochemical marker and NT data in 10189 women who 
had CUB screening, were re-analysed using the contingent model (refer to section 2.2). A 
risk was calculated from the results of the PAPP-A and fβhCG measurements and maternal 
age. For risks between 1:42 and 1:1000, the likelihood ratio from the NT measurement was 
incorporated and assessed against a final cut-off risk at term of 1:250. 
Figure 4.1 illustrates the performance of the contingent screening model in this study group 
using initial high and low cut-offs of 1:42 and 1:1000 respectively and a final cut off of 
1:250. There were 313 (3.1%) unaffected and 27 (61.4%) Down’s syndrome pregnancies 
with initial risks ≥1:42 and these were classified as high risk. In this approach to screening 
these women would be offered a diagnostic test (CVS/amniocentesis) at this stage. NT 
measurement would not be offered to these women because their initial risk is so high that 
a subsequent NT measurement would be unlikely to bring the risk down below the final 
threshold risk of 1:250.  
Within the low risk group with risks ≤1:1000, there were 6887 (67.9%) unaffected and 2 
(4.5%) Down’s syndrome pregnancies. According to the protocol, these women would be 
counselled that they would not be offered any further test because the initial risk is low. 
The remaining 2960 (29%) women fell within the intermediate risk category and would be 
offered  NT  measurement.  Of  these,  when  the  risk  from  the  NT  measurement  was                                                                                                                                              Chapter 4: Results 
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Figure 4.1 – The performance of within-trimester contingent screening in this study. There were 
313 (3.1%) unaffected and 27 (61.4%) Down’s syndrome pregnancies with initial risks ≥1:42. 
These pregnancies were classified as high risk and offered a diagnostic test. Within the low risk 
group with risks ≤1:1000, there were 6887 (67.9%) unaffected and 2 (4.5%) Down’s syndrome 
pregnancies. The remaining 2960 (29%) women fell within the intermediate risk category and 
would be offered NT measurement. Of these, when the risk from the NT measurement was 
combined  with  the  initial  risk,  276  (2.7%)  unaffected  pregnancies  and  12  (27.3%)  Down’s 
syndrome pregnancies had final risk of ≥1:250 and would be offered a diagnostic test. This 
contingent screening protocol would have achieved a detection rate of 88.7% at a false positive 
rate of 5.8% but with only 29% of women requiring an NT measurement. 
 
combined with the initial risk, 276 (2.7%) unaffected pregnancies and 12 (27.3%) Down’s 
syndrome pregnancies had final risk of ≥1:250 and would be offered a diagnostic test.  
 
 
 
 
 
 
 
 
 
Nuchal Translucency 
Chorionic villus sampling (CVS) or Amniocentesis 
    5.8% of unaffected                                                        
     88.7% of Down’s syndrome   
Total risk (risk ≥ 1:250) 
2.7% of unaffected 
27.3% of Down’s syndrome 
Total risk (risk < 1:250) 
26.3% of unaffected 
6.8% of Down’s syndrome 
High risk (risk ≥1:42) 
3.1% of unaffected 
61.4% of Down’s syndrome 
Low risk (risk ≤1:1000) 
67.9% of unaffected 
4.5% of Down’s syndrome 
Double Test (PAPP-A/FβhCG/ age) 
Intermediate risk 
29% of unaffected 
34.1% of Down’s syndrome 
No invasive diagnostic procedure 
           94.2% of unaffected 
11.37% of Down’s syndrome                                                                                                                                              Chapter 4: Results 
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 Therefore in the CUB screened population in the West of Scotland, adopting the above 
contingent screening protocol would have achieved a detection rate of 88.7% at a false 
positive rate of 5.8% (compared with 90.9% detection at a 6.4% false positive rate for the 
full  CUB  screen)  but  with  only  29%  of  women  requiring  an  NT  measurement.  By 
changing the initial and final cut-off risks the detection rate, false positive rate and NT 
measurement  rate  can  be  varied  (Table  4.1).    This  would  allow  individual  centres  to 
develop protocols best suited to local circumstances. If, for example, it was desired to keep 
the false positive rate low, an initial high risk cut-off of 1:24 and final risk cut off of 1:150 
gives a false positive rate of 3.7% for only a small reduction in detection to 84.1%.  
 
Table 4.1: The frequency of nuchal translucency (NT) measurement and overall screening 
performance in contingent testing with different risk cut-off values. 
Final risk 
cut offs 
(at term) 
High risk cut 
offs 
(at term) 
Low risk cut 
offs 
(at term) 
NT 
frequency 
(%) 
Detection rate 
(%) 
False positive 
rate (%) 
1:250  1:42  1:1000  29.1  88.7  5.8 
    1:800  25.1  86.4  5.8 
    1:600  20.7  84.1  5.6 
    1:400  15.3  81.9  5.5 
1:200  1:33  1:1000  29.7  86.4  4.8 
    1:800  25.8  84.1  4.8 
    1:600  21.3  81.8  4.6 
    1:400  16.0  79.6  4.5 
1:150  1:24  1:1000  30.3  84.1  3.7 
    1:800  26.4  81.8  3.7 
    1:600  21.9  79.5  3.6 
    1:400  16.6  77.3  3.5                                                                                                                                              Chapter 4: Results 
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4.1.1 RETROSPECTIVE CONTINGENT TESTING BASED ON LMP 
ESTIMATE OF GESTATION  
As the performance of this contingent screening model is very dependent on an accurate 
interpretation of biochemical marker results, accurate assessment of gestation is essential. 
However, due to limited availability of ultrasound resources in some areas, gestational age 
is  often  determine  by  relying  on  LMP.  Using  the  same  data-set,  the  performance  of 
contingent testing model was re-evaluated by using LMP based gestational age. 
For all women, a risk was calculated from the maternal age and the results of the PAPP-A 
and  fβhCG  measurements  using  LMP  based  gestational  age.  For  women  with  risks 
between  1:42  and  1:1000,  the  biochemical  marker  measurements  in  MoM  were  re-
calculated  using  ultrasound  based  gestational  age  (this  being  available  at  the  NT 
measurement  appointment)  and  the  likelihood  ratio  from  the  NT  measurement  was 
incorporated. The composite risk was assessed against a final cut-off risk at term of 1:250. 
Information  on  LMP  was  only  available  in  6895  pregnancies;  6865  unaffected  and  30 
Down’s syndrome pregnancies. Of the 6895 pregnancies, 5979 pregnancies had certain 
LMP dates.  
Figures 4.2 and 4.3 illustrate the performance of the contingent screening model in all 
pregnancies (uncertain and certain LMP dates) and pregnancies with certain LMP dates 
using initial high and low cut-offs of 1:42 and 1:1000 respectively and a final cut off of 
1:250.  When  analysis  was  performed  on  all  the  pregnancies,  there  were  275  (4.0%) 
unaffected  and  18  (60.0%)  Down’s  syndrome  pregnancies  with  initial  risks  ≥1:42  and 
these were classified as high risk. Within the low risk group with risks ≤1:1000, there were 
4814 (70.1%) unaffected and 3 (10.0%) Down’s syndrome pregnancies. The remaining 
1785 (25.9%) women fell within the intermediate risk category and would be offered NT                                                                                                                                              Chapter 4: Results 
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measurement. Of these, when the risk from the NT measurement was combined with the 
initial  risk,  230  (3.4%)  unaffected  pregnancies  and  7  (23.3%)  Down’s  syndrome 
pregnancies had final risk of ≥1:250 and would be offered a diagnostic test.  
When analysis was performed only on pregnancies with certain LMP dates, there were 217 
(3.6%) unaffected and 17 (63.0%) Down’s syndrome pregnancies in the high risk group 
with risks initial ≥1:42. Within the low risk group with risks ≤1:1000, there were 4231 
(71.1%)  unaffected  and  2  (7.4%)  Down’s  syndrome  pregnancies.  The  remaining  1512 
(25.3%) women fell within the intermediate risk category and of these, when the risk from 
the  NT  measurement  was  combined  with  the  initial  risk,  197  (3.3%)  unaffected 
pregnancies and 7 (25.9%) Down’s syndrome pregnancies had final risk of ≥1:250.  
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Figure 4.2 – The performance of within-trimester contingent screening using LMP based 
gestation  in  pregnancies  with  certain  and  uncertain  LMP  dates.  There  were  275  (4.0%) 
unaffected and 18 (60.0%) Down’s syndrome pregnancies with initial risks ≥1:42. These 
pregnancies were classified as high risk and would be offered a diagnostic test. Within the 
low  risk  group  with  risks  ≤1:1000,  there  were  4814  (70.1%)  unaffected  and  3  (10.0%) 
Down’s  syndrome  pregnancies.  The  remaining  1785  (25.9%)  women  fell  within  the 
intermediate risk category and would be offered NT measurement. Of these, when the risk 
from  the  NT  measurement  was  combined  with  the  initial  risk,  230  (3.4%)  unaffected 
pregnancies and 7 (23.3%) Down’s syndrome pregnancies had final risk of ≥1:250 and 
would be offered  a diagnostic test. Using  LMP based  gestation, this  screening protocol 
would have achieved a detection rate of 83.3% at a false positive rate of 7.4% with 25.9% of 
women requiring an NT measurement. 
                                        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
High risk (risk ≥1:42) 
4.0% of unaffected 
60.0% of Down’s 
Low risk (risk ≤1:1000) 
70.1% of unaffected 
10.0% of Down’s syndrome 
Double Test (PAPP-A/FβhCG/ age) 
Intermediate risk 
25.9% of unaffected 
30.0% of Down’s syndrome 
Chorionic villus sampling (CVS) or 
Amniocentesis 
  7.4% of unaffected                                                        
     83.3% of Down’s syndrome   
 
No invasive diagnostic procedure 
           92.6% of unaffected 
16.7% of Down’s syndrome 
Nuchal Translucency 
Total risk (risk ≥ 1:250) 
3.4% of unaffected 
23.3% of Down’s syndrome 
 
Total risk (risk < 1:250) 
22.5% of unaffected 
6.7% of Down’s syndrome 
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Double Test (PAPP-A/Free β-hCG/ age) 
High risk (risk ≥1:42) 
3.7% of unaffected 
63.0% of Down’s syndrome 
 
Intermediate risk 
25.3% of unaffected 
29.6% of Down’s syndrome 
 
Low risk (risk ≤1:1000) 
71.1% of unaffected 
7.4% of Down’s syndrome 
Total risk (risk ≥ 1:250) 
3.3% of unaffected 
25.9% of Down’s syndrome 
 
Total risk (risk < 1:250) 
21.96% of unaffected 
3.70% of Down’s syndrome 
Chorionic villus sampling (CVS) or Amniocentesis 
 6.96 % of unaffected                                                        
     88.89% of Down’s Syndrome   
 
No invasive diagnostic procedure 
93.05% of unaffected 
11.11% of Down’s Syndrome 
 
Nuchal Translucency 
Figure 4.3 – The performance of within-trimester contingent screening using LMP based 
gestation in pregnancies with certain LMP dates. There were 217 (3.6%) unaffected and 
17 (63.0%) Down’s syndrome pregnancies in the high risk group with risks initial ≥1:42. 
Within the low risk group with risks ≤1:1000, there were 4231 (71.1%) unaffected and 2 
(7.4%) Down’s syndrome pregnancies. The remaining 1512 (25.3%) women fell within 
the intermediate risk category and of these, when the risk from the NT measurement was 
combined with the initial risk, 197 (3.3%) unaffected pregnancies and 7 (25.9%) Down’s 
syndrome pregnancies had final risk of ≥1:250. This contingent screening protocol would 
have achieved a detection rate of 88.9% at a false positive rate of 7.0% with 25.3% of 
women requiring an NT measurement.                                                                                                                                              Chapter 4: Results 
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Therefore using  LMP based  gestational  age,  contingent screening protocol would have 
achieved a detection rate of 83.3% at a false positive rate of 7.4% with 25.9% of women 
requiring an NT measurement. When analysis was performed only on pregnancies with 
certain LMP dates, contingent screening protocol would have achieved a detection rate of 
88.9%  at  a  false  positive  rate  of  7.0%  with  25.3%  of  women  requiring  an  NT 
measurement.  By  changing  the  initial  and  final  cut-off  risks  the  detection  rate,  false 
positive rate and NT measurement rate can be varied (Tables 4.2 and 4.3).   
 
Table 4.2: The frequency of nuchal translucency (NT) measurement and overall screening 
performance in contingent testing with different risk cut-off values in pregnancies with 
certain and uncertain LMP dates. 
Final risk cut 
offs 
(at term) 
High risk cut 
offs 
(at term) 
Low risk cut 
offs 
(at term) 
NT frequency 
(%) 
Detection rate 
(%) 
False positive 
rate (%) 
1:250  1:42  1:1000  25.9  83.3  7.4 
    1:800  22.5  83.3  7.3 
    1:600  18.5  80.0  7.1 
    1:400  13.3  80.0  6.9 
1:200  1:33  1:1000  26.5  80.0  6.3 
    1:800  23.1  80.0  6.2 
    1:600  19.1  76.7  6.1 
    1:400  13.9  76.7  5.9 
1:150  1:24  1:1000  27.3  80.0  5.0 
    1:800  23.9  80.0  5.0 
    1:600  19.9  76.7  4.9 
    1:400  14.6  76.7  4.7                                                                                                                                              Chapter 4: Results 
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Table 4.3: The frequency of nuchal translucency (NT) measurement and overall screening 
performance in contingent testing with different risk cut-off values in pregnancies with 
certain LMP dates. 
 
Table  4.4  shows  the  summary  of  NT  measurement  frequency  and  overall  screening 
performance of contingent screening according to type of gestational estimate. The use of 
LMP based gestation leads to increased false positive rate compared with using ultrasound 
based  gestation.  There  is  a  decrease  in  detection  rate  in  the  LMP  dating  (certain  and 
uncertain)  group  compared  with  the  ultrasound  scan  group.  Although  there  was  no 
significant difference in the detection rate between the ultrasound scan group and certain 
LMP dating group, the false positive rate was higher in the certain LMP dating group.  For 
the LMP dating groups, ultrasound scan is not required in the first stage of screening. The 
Final risk cut 
offs 
(at term) 
High risk cut 
offs 
(at term) 
Low risk cut 
offs 
(at term) 
NT 
frequency 
(%) 
Detection 
rate (%) 
False positive 
rate (%) 
1:250  1:42  1:1000  25.3  88.9  7.0 
    1:800  22.0  88.9  6.9 
    1:600  18.0  85.2  6.8 
    1:400  12.9  85.2  6.5 
1:200  1:33  1:1000  25.9  85.2  6.1 
    1:800  22.6  85.2  6.0 
    1:600  18.6  81.5  5.9 
    1:400  13.4  81.5  5.7 
1:150  1:24  1:1000  26.5  85.2  4.8 
    1:800  23.2  85.2  4.8 
    1:600  19.3  81.5  4.7 
    1:400  14.1  81.5  4.5                                                                                                                                              Chapter 4: Results 
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NT frequency in the second stage of screening was also lower in the LMP dating groups 
compared with the ultrasound scan group. Although contingent screening using LMP based 
gestational  age  significantly  reduces  the  ultrasound  workload,  the  false  positive  rate 
increases from 5.8% to 7.0%.   
 
Table 4.4: Summary of NT measurement frequency and overall screening performance of 
contingent screening according to method of gestational estimate. 
Final risk cut-off: 1:250; high risk cut-off: 1:42; low risk cut-off: 1:1000  
 
 
 
 
 
 
 
 
 
Method of gestational estimate  NT frequency 
(%) 
Detection rate 
(%) 
False positive rate 
(%) 
Ultrasound scan  29.1  88.7  5.8 
LMP dating (certain and 
uncertain LMP)  25.9  83.3  7.4 
Certain LMP dating  25.3  88.9  7.0                                                                                                                                              Chapter 4: Results 
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4.2 CROSS - TRIMESTER CONTINGENT SCREENING  
Using  S-PLUS  programme,  various  types  of  cross-trimester  contingent  screening  were 
modelled (refer to sections 2.3 and 3.2.1). Protocols were designed in which all women 
would  receive  a  first  trimester  screening  test  and  those  with  intermediate  risks  would 
receive follow up second trimester screening test (refer to Figure 3.2). 
4.2.1  CROSS-TRIMESTER  CONTINGENT  SCREENING  WITH 
SECOND TRIMESTER DOUBLE, TRIPLE OR QUADRUPLE TEST 
In this screening policy, all women would be offered first trimester screening (PAPP-A, 
fβhCG and NT measurement) and those with intermediate risk would be offered a second 
trimester  double  serum  marker  test.  To  demonstrate  the  performance  of  this  screening 
policy,  a  theoretical  population  of  500,000  pregnant  women  comprising  714  Down’s 
syndrome  pregnancies  and  499,286  unaffected  pregnancies  were  used  (refer  to  section 
3.2.1). A high risk cut-off of 1:42, a low-risk cut-off of 1:1000 and a final cut-off risk of 
1:150 were used in this study.  
Using  the  S-PLUS  statistical  software  programme  the  model  identified  542  (75.9%) 
Down’s syndrome and 3495 (0.7%) unaffected pregnancies with initial risks ≥1:42, and 
these were classified as high risk. In this approach to screening these women would be 
offered a diagnostic test (CVS/amniocentesis) at this stage. Within the low-risk group with 
risks ≤1:1000, there were 35 (4.9%) Down’s syndrome and 447,360 (89.6%) unaffected 
pregnancies. According to the protocol, these women would be counselled that they would 
not be offered any further test because the initial risk was low. The remaining 48,568 
(9.7%) women fell within the intermediate risk category and would be offered second 
trimester double test. Of these, when the risk from the second trimester double test was                                                                                                                                              Chapter 4: Results 
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combined with the initial risk, 99 (13.8%) Down’s syndrome and 5492 (1.1%) unaffected 
pregnancies had final risk of ≥1:150 and would be offered a diagnostic test. Therefore, this 
model suggests that this screening policy can achieve a detection rate of 89.7% with a false 
positive rate of 1.8% but with only 9.7% requiring second trimester screening. Figure 4.4 
illustrates the performance of this cross-trimester contingent screening policy for final risk 
cut-off of 1:150. 
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High risk (risk ≥1:42) 
542 Down’s syndrome (75.9%) 
3495 Unaffected (0.7%) 
 
Intermediate risk 
137 Down’s syndrome (19.2%) 
48431 Unaffected (9.7%) 
Low risk (risk ≤1:1000) 
35 Down’s syndrome (4.9%) 
447,360 Unaffected (89.6%) 
 
First trimester screening test  
(NT, PAPP-A, fβhCG, maternal age)  
500, 000 pregnant women 
(714 Down’s syndrome, 499,286 Unaffected) 
Chorionic villus sampling (CVS) or Amniocentesis 
641 Down’s syndrome (89.7%) 
8987 Unaffected (1.8%) 
No invasive diagnostic procedure 
73 Down’s syndrome (10.3%) 
490,299 Unaffected (98.2%) 
Second trimester screening test 
(AFP, hCG) 
 
Total risk (risk ≥ 1:150) 
99 Down’s syndrome (13.8%) 
5492 Unaffected (1.1%) 
Total risk (risk < 1:150) 
38 Down’s syndrome (5.4%) 
42,939 Unaffected (8.6%) 
Figure  4.4:  The  modelled  performance  of  cross-trimester  screening  with  a  second 
trimester test. There were 542 (75.9%) Down’s syndrome and 3495 (0.7%) unaffected 
pregnancies with initial risks ≥1:42, and these were classified as high risk. Within the 
low-risk  group  with  risks  ≤1:1000,  there  were  35  (4.9%)  Down’s  syndrome  and 
447,360 (89.6%) unaffected pregnancies. The remaining 48,568 (9.7%) women fell 
within the intermediate risk category and would be offered second trimester double 
test. Of these, when the risk from the second trimester double test was combined with 
the initial risk, 99 (13.8%) Down’s syndrome and 5492 (1.1%) unaffected pregnancies 
had final risk of ≥ 1:150 and would be offered a diagnostic test. This screening policy 
can achieve a detection rate of 89.7% with a false positive rate of 1.8% but with only 
9.7% requiring second trimester screening.                                                                                                                                              Chapter 4: Results 
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Tables  4.5  (a-f)  shows  the  performance  of  contingent  screening  with  second  trimester 
double, triple or quadruple serum marker tests using various combinations of screening 
markers. Addition of NT measurement to the serum markers in the first trimester improved 
the overall screening performances. Table 4.5a shows the performance of the screening 
policy based on first trimester NT and PAPP-A followed by selective use of a second 
trimester  screening  test.  Addition  of  fβhCG  in  the  first  trimester  further  increased  the 
detection rate and early completion rate, decreased the second trimester testing frequency 
and  gave  less  fall  off  of  screening  performance  as  gestation  increased.  There  were  no 
significant changes in the false positive rate. The detection rate and early completion rate 
decreased and second trimester frequency increased when fβhCG was replaced with hCG 
in the first trimester. For those screening policies with NT measurement, there were no 
changes in the false positive rates. For the screening policies without NT measurement, 
when fβhCG was replaced with hCG in the first trimester, the false positive rate generally 
decreased when screening was performed at 10 or 11 weeks of gestation. There were no 
changes in the false positive rates when screening was performed at 12 or 13 weeks of 
gestation.  
The screening policy with second trimester quadruple test (AFP, hCG, InhA and uE3) had 
the  highest  detection  rate  and  the  lowest  false positive  rate  compared  with  the  second 
trimester double and triple marker tests.  For the second trimester triple test, addition of 
InhA to the base test comprising AFP and hCG/fβhCG had a higher detection rate and 
lower false positive rate compared to addition of uE3 to the double test (Tables 4.5a, 4.5b 
and 4.5c). Therefore, InhA and not uE3 was used as part of the triple test in the subsequent 
analysis.  The  detection  rate  decreased  and  false  positive  rate  increased  as  gestation 
advanced  in  all  screening  policies.  The  early  completion  rate  decreased  and  second                                                                                                                                              Chapter 4: Results 
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trimester frequency increased as gestation advanced in all but one screening policy.  In the 
screening policy in which all women would be tested for PAPP-A and hCG level in the 
first trimester and those with intermediate risks would be tested in the second trimester for 
double, triple or quadruple test, the early completion rate increased and second trimester 
testing frequency decreased from week 10 to week 12. At week 13, the early completion 
rate decreased and second trimester testing frequency increased.  
When hCG in the second trimester was replaced with fβhCG, there was a decrease in the 
detection rate and an increase in the false positive rate (Table 4.6a and 4.6b). This suggests 
that fβhCG is a better marker in the first trimester compared to hCG but hCG is the better 
marker in the second trimester.    
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Table 4.5a: Performance of contingent screening in which all women would receive first trimester serum biochemical test (PAPP-A) with NT measurement 
and those with intermediate risk would be offered second trimester double, triple or quadruple test.  
Biochemical 
markers 
(First stage / 
Second stage) 
Week 
Overall  1
st trimester  2
nd trimester 
DR (%)  FPR (%)  ECR (%)  2
nd trimester 
frequency (%)  DR (%)  FPR (%)  DR (%)  FPR (%) 
NT, PAPP-A / 
AFP, hCG 
 
11  88.5  1.9  86.9  13.1  69.5  0.7  19.0  1.2 
12  86.2  2.0  84.6  15.4  66.7  0.7  19.5  1.3 
13  81.9  2.4  79.9  20.1  58.9  0.7  23.0  1.7 
NT, PAPP-A / 
AFP, hCG, uE3 
 
11  89.0  1.8  87.0  13.0  69.5  0.7  19.5  1.1 
12  86.7  1.9  84.7  15.3  66.7  0.7  20.0  1.2 
13  82.7  2.3  79.9  20.1  58.8  0.7  23.9  1.6 
NT, PAPP-A / 
AFP, hCG, InA 
 
11  89.2  1.7  87.0  13.0  69.4  0.8  19.8  0.9 
12  87.2  1.9  84.6  15.4  66.7  0.7  20.5  1.2 
13  83.3  2.2  80.0  20.0  58.6  0.7  24.7  1.5 
NT, PAPP-A / 
AFP, hCG, InA, 
uE3 
11  89.6  1.7  87.0  13.0  69.3  0.7  20.3  1.0 
12  87.6  1.8  84.7  15.3  66.7  0.7  20.9  1.1 
13  83.9  2.0  80.0  20.0  58.7  0.7  25.2  1.3 
   DR: detection rate; FPR: False positive rate; ECR: Early completion rate  
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Table 4.5b: Performance of contingent screening in which all women would receive first trimester serum biochemical test (PAPP-A and fβhCG) with NT  
measurement and those with intermediate risk would be offered second trimester double, triple or quadruple test.  
Biochemical 
markers 
(First stage / 
Second stage) 
Week 
Overall  1
st trimester  2
nd trimester 
DR (%)  FPR (%)  ECR (%)  2
nd trimester 
frequency (%)  DR (%)  FPR (%)  DR (%)  FPR (%) 
NT, PAPP-A, 
fβhCG / 
AFP, hCG 
 
11  89.7  1.8  90.3  9.7  75.9  0.7  13.8  1.1 
12  88.4  2.0  89.3  10.7  74.9  0.7  13.5  1.3 
13  84.9  2.4  85.9  14.1  68.2  0.8  16.7  1.6 
NT, PAPP-A, 
fβhCG  / 
AFP, hCG, uE3 
 
11  90.2  1.7  90.3  9.7  75.9  0.7  14.3  1.0 
12  89.0  1.9  89.4  10.6  74.9  0.7  14.1  1.2 
13  85.9  2.3  85.9  14.1  68.4  0.8  17.5  1.5 
NT, PAPP-A, 
fβhCG  / 
AFP, hCG, InA 
 
11  90.7  1.7  90.3  9.7  75.9  0.7  14.8  1.0 
12  89.5  1.8  89.3  10.7  74.8  0.7  14.7  1.1 
13  86.6  2.2  85.9  14.1  68.3  0.7  18.3  1.5 
NT, PAPP-A, 
fβhCG  / 
AFP, hCG, InA, 
uE3 
11  91.1  1.6  90.3  9.7  76.0  0.7  15.1  0.9 
12  90.0  1.7  89.3  10.7  74.8  0.7  15.2  1.0 
13  87.2  2.1  85.9  14.1  68.3  0.8  18.9  1.3 
   DR: detection rate; FPR: False positive rate; ECR: Early completion rate  
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Table 4.5c: Performance of contingent screening in which all women would receive first trimester serum biochemical test (PAPP-A and hCG) with NT 
measurement and those with intermediate risk would be offered second trimester double, triple or quadruple test.  
Biochemical 
markers 
(First stage / 
Second stage) 
Week 
Overall  1
st trimester  2
nd trimester 
DR (%)  FPR (%)  ECR (%) 
2
nd trimester 
frequency (%) 
DR (%)  FPR (%)  DR (%)  FPR (%) 
NT, PAPP-A, 
hCG / 
AFP, hCG 
 
11  88.9  1.8  87.9  12.1  70.9  0.7  18.0  1.1 
12  86.9  2.0  87.1  12.9  70.6  0.7  16.3  1.3 
13  83.6  2.5  84.8  15.2  65.9  0.7  17.7  1.8 
NT, PAPP-A, 
hCG  / 
AFP, hCG, uE3 
 
11  89.5  1.7  87.9  12.1  71.0  0.7  18.5  1.0 
12  87.6  1.9  87.1  12.9  70.5  0.7  17.1  1.2 
13  84.8  2.3  84.9  15.1  65.8  0.7  19.0  1.6 
NT, PAPP-A, 
hCG  / 
AFP, hCG, InA 
 
11  90.0  1.6  87.9  12.1  70.9  0.7  19.1  0.9 
12  88.4  1.8  87.0  13.0  70.6  0.7  17.8  1.1 
13  85.6  2.2  84.8  15.2  65.9  0.7  19.7  1.5 
NT, PAPP-A, 
hCG  / 
AFP, hCG, InA, 
uE3 
11  90.3  1.5  87.9  12.1  70.9  0.7  19.4  0.8 
12  88.8  1.8  87.0  13.0  70.6  0.7  18.2  1.1 
13  86.4  2.1  84.9  15.1  65.9  0.8  20.5  1.3 
     DR: detection rate; FPR: False positive rate; ECR: Early completion rate  
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Table  4.5d:  Performance  of  contingent  screening  in  which  all  women  would  receive  first  trimester  serum  biochemical  test  (PAPP-A)  without  NT 
measurement and those with intermediate risk would be offered second trimester double, triple or quadruple test.  
Biochemical 
markers 
(First stage / 
Second stage) 
Week 
Overall  1
st trimester  2
nd trimester 
DR (%)  FPR (%)  ECR (%)  2
nd trimester 
frequency (%)  DR (%)  FPR (%)  DR (%)  FPR (%) 
PAPP-A / 
AFP, hCG 
 
10  78.3  4.2  67.0  33.0  31.9  1.2  46.4  3.0 
11  77.8  4.2  66.1  33.9  30.6  1.2  47.2  3.0 
12  75.1  4.5  61.0  39.0  24.3  1.0  50.8  3.5 
13  69.7  4.9  51.4  48.6  14.8  0.7  54.9  4.2 
PAPP-A / 
AFP, hCG, InA 
 
10  80.4  3.8  67.0  33.0  31.9  1.2  48.5  2.6 
11  80.0  3.8  66.1  33.9  30.7  1.2  49.3  2.6 
12  77.6  4.0  61.1  38.9  24.3  1.0  53.3  3.0 
13  73.4  4.3  51.3  48.7  14.8  0.7  58.6  3.6 
PAPP-A / 
AFP, hCG, InA, 
uE3 
10  81.2  3.6  67.0  33.0  32.0  1.2  49.2  2.4 
11  80.8  3.7  66.1  33.9  30.6  1.2  50.2  2.5 
12  78.7  3.8  61.0  39.0  24.4  1.0  54.3  2.8 
13  74.9  4.0  51.3  48.7  14.8  0.7  60.1  3.3 
     DR: detection rate; FPR: False positive rate; ECR: Early completion rate  
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Table 4.5e: Performance of contingent screening in which all women would receive first trimester serum biochemical test (PAPP-A and fβhCG) without NT 
measurement and those with intermediate risk would be offered second trimester double, triple or quadruple test.  
Biochemical 
markers 
(First stage / 
Second stage) 
Week 
Overall  1
st trimester  2
nd trimester 
DR (%)  FPR (%)  ECR (%) 
2
nd trimester 
frequency (%) 
DR (%)  FPR (%)  DR (%)  FPR (%) 
PAPP-A, fβhCG / 
AFP, hCG 
 
10  80.7  4.1  77.8  22.2  49.9  1.4  30.8  2.7 
11  80.3  4.1  77.3  22.7  49.1  1.4  31.2  2.7 
12  78.9  4.4  76.6  23.4  47.7  1.4  31.2  3.0 
13  74.9  4.8  71.8  28.2  39.4  1.3  35.5  3.5 
PAPP-A, fβhCG  / 
AFP, hCG, InA 
 
10  82.8  3.7  77.8  22.2  49.8  1.4  33.0  2.3 
11  82.5  3.8  77.3  22.7  49.1  1.4  33.4  2.4 
12  81.3  4.0  76.6  23.4  47.6  1.4  33.7  2.6 
13  77.9  4.4  71.8  28.2  39.2  1.3  38.7  3.1 
PAPP-A, fβhCG  / 
AFP, hCG, InA, 
uE3 
10  83.6  3.6  77.8  22.2  50.0  1.4  33.6  2.2 
11  83.3  3.6  77.3  22.7  49.1  1.4  34.2  2.2 
12  82.1  3.8  76.7  23.3  47.6  1.3  34.5  2.5 
13  79.3  4.2  71.8  28.2  39.4  1.3  39.9  2.9 
     DR: detection rate; FPR: False positive rate; ECR: Early completion rate  
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Table 4.5f: Performance of contingent screening in which all women would receive first trimester serum biochemical test (PAPP-A and hCG) without NT 
measurement and those with intermediate risk would be offered second trimester double, triple or quadruple test.  
 
Biochemical 
markers 
(First stage / 
Second stage) 
Week 
Overall  1
st trimester  2
nd trimester 
DR (%)  FPR (%)  ECR (%)  2
nd trimester 
frequency (%)  DR (%)  FPR (%)  DR (%)  FPR (%) 
PAPP-A, hCG / 
AFP, hCG 
 
10  79.5  3.8  69.0  31.0  34.9  1.3  44.6  2.5 
11  78.8  4.0  69.2  30.8  35.3  1.3  43.5  2.7 
12  76.0  4.5  69.8  30.2  35.8  1.2  40.2  3.3 
13  72.5  5.0  68.6  31.4  33.3  1.2  39.2  3.8 
PAPP-A, hCG  / 
AFP, hCG, InA 
 
10  82.1  3.3  69.0  31.0  34.9  1.3  47.2  2.0 
11  81.6  3.5  69.3  30.7  35.3  1.3  46.3  2.2 
12  79.2  4.0  69.7  30.3  35.7  1.3  43.5  2.7 
13  76.3  4.5  68.7  31.3  33.3  1.2  43.0  3.3 
PAPP-A, hCG  / 
AFP, hCG, InA, 
uE3 
10  82.9  3.2  69.0  31.0  34.9  1.2  48.0  2.0 
11  82.3  3.3  69.2  30.8  35.3  1.3  47.0  2.0 
12  80.3  3.8  69.8  30.2  35.8  1.3  44.5  2.5 
13  77.9  4.2  68.7  31.3  33.3  1.2  44.6  3.0 
     DR: detection rate; FPR: False positive rate; ECR: Early completion rate  
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Table 4.6a: Performance of contingent screening in which all women would receive first trimester serum biochemical test (PAPP-A) with NT measurement 
and those with intermediate risk would be offered second trimester double, triple or quadruple test (with fβhCG in the second trimester).  
 
Biochemical 
markers 
(First stage / 
Second stage) 
Week 
Overall  1
st trimester  2
nd trimester 
DR (%)  FPR (%)  ECR (%)  2
nd trimester 
frequency (%)  DR (%)  FPR (%)  DR (%)  FPR (%) 
NT, PAPP-A /  
AFP, fβhCG   
11  88.1  2.0  87.0  13.0  69.4  0.7  18.7  1.3 
12  85.8  2.2  84.7  15.3  66.6  0.7  19.2  1.5 
13  81.4  2.6  79.9  20.1  58.8  0.7  22.6  1.9 
NT, PAPP-A /  
AFP, fβhCG , 
InhA 
11  88.9  1.8  87.0  13.0  69.4  0.7  19.5  1.1 
12  86.7  2.0  84.7  15.3  66.8  0.7  19.9  1.3 
13  82.7  2.3  79.9  20.1  58.7  0.7  24.0  1.6 
NT, PAPP-A /  
AFP, fβhCG , 
InhA, uE3 
11  89.1  1.8  87.0  13.0  69.3  0.7  19.8  1.1 
12  87.1  1.9  84.7  15.3  66.7  0.7  20.4  1.2 
13  83.3  2.2  80.0  20.0  58.7  0.7  24.6  1.5 
     DR: detection rate; FPR: False positive rate; ECR: Early completion rate  
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Table  4.6b:  Performance  of  contingent  screening  in  which  all  women  would  receive  first  trimester  serum  biochemical  test  (PAPP-A)  without  NT 
measurement and those with intermediate risk would be offered second trimester double, triple or quadruple test (with fβhCG in the second trimester).  
 
Biochemical 
markers 
(First stage / 
Second stage) 
Week 
Overall  1
st trimester  2
nd trimester 
DR (%)  FPR (%)  ECR (%)  2
nd trimester 
frequency (%)  DR (%)  FPR (%)  DR (%)  FPR (%) 
PAPP-A /  
AFP, fβhCG   
10  77.4  4.5  67.0  33.0  31.9  1.2  45.5  3.3 
11  77.0  4.6  66.0  34.0  30.7  1.2  46.3  3.4 
12  74.1  4.8  61.1  38.9  24.4  1.0  49.7  3.8 
13  68.7  5.2  51.4  48.6  14.8  0.7  53.9  4.5 
PAPP-A /  
AFP, fβhCG , 
InhA 
10  79.3  4.1  67.0  33.0  32.0  1.2  47.3  2.9 
11  78.9  4.1  66.2  33.8  30.6  1.2  48.3  2.9 
12  76.3  4.3  61.1  38.9  24.3  1.0  52.0  3.3 
13  72.1  4.6  51.3  48.7  14.8  0.7  57.3  3.9 
PAPP-A /  
AFP, fβhCG , 
InhA, uE3 
10  80.1  3.9  66.9  33.1  32.0  1.2  48.1  2.7 
11  79.7  3.9  66.1  33.9  30.7  1.2  49.0  2.7 
12  77.4  4.2  61.0  39.0  24.3  1.0  53.1  3.2 
13  73.6  4.3  51.4  48.6  14.7  0.7  58.9  3.6 
     DR: detection rate; FPR: False positive rate; ECR: Early completion rate                                                                                                                                                 Chapter 4: Results 
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4.2.2  CROSS-TRIMESTER  CONTINGENT  SCREENING  WITH 
REPEAT MEASURE 
The performance of the cross-trimester contingent model described in section 4.2.1 was re-
evaluated by repeating the measurement of each of the first trimester markers in the second 
trimester. Table 4.7 (4.7a and 4.7b) shows the performance of contingent screening with 
repeat  measure  of  fβhCG.  In  this  screening  policy,  a  repeat  sampling  and  testing  for 
maternal  serum  fβhCG  is  carried  out  in  those  with  intermediate  risks  in  the  second 
trimester. The performance of this screening policy was compared with the performance of 
screening  policy  in  which  women  are  selected  for  second  trimester  double,  triple  or 
quadruple test (with hCG) based on initial first trimester PAPP-A and fβhCG measurement 
(with or without NT) (Tables 4.5b and 4.5d).  This screening policy with repeat measure of 
fβhCG had lower detection rate and higher false positive rate than contingent screening 
with second trimester double, triple or quadruple test.  
The  performance  of  contingent  screening  with  repeat  measure  of  PAPP-A  was  also 
evaluated (Table 4.8 a-d). Addition of repeat measure of PAPP-A to the double, triple or 
quadruple test in the second trimester increased the detection rate and decreased the false 
positive  rate.  Repeat  measure  of  hCG  and  PAPP-A  (Table  4.9a  and  4.9b)  had  lower 
detection rate and early completion rate and higher second trimester frequency compared 
with repeat measure of PAPP-A alone. This again showed that fβhCG is a better marker in 
the first trimester compared to hCG. 
 
                                                                                                                                                  Chapter 4: Results 
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At week 11, repeat measure of PAPP-A and fβhCG (with NT measurement) achieved a 
detection rate of 90.8% with a false positive rate of 1.7% (Table 4.10a and 4.10b). This 
screening policy also had an early completion rate of 90.3% and second trimester testing 
frequency of 9.7%. The screening policies with repeat measure of PAPP-A and fβhCG had 
higher detection rates, false positive rates and early completion rates and lower second 
trimester frequencies compared to the screening policies with repeat measure of PAPP-A 
and hCG.   
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Table 4.7a: Performance of contingent screening (with NT measurement) with repeat measure of fβhCG   
Biochemical 
markers 
(First stage / 
Second stage) 
Week 
Overall  1
st trimester  2
nd trimester 
DR (%)  FPR (%)  ECR (%) 
2
nd trimester 
frequency (%) 
DR (%)  FPR (%)  DR (%)  FPR (%) 
NT, PAPP-A, 
fβhCG  /  
AFP, fβhCG   
11  89.2  2.0  90.3  9.7  76.0  0.7  13.2  1.3 
12  87.7  2.1  89.3  10.7  74.9  0.7  12.8  1.4 
13  83.9  2.6  85.9  14.1  68.3  0.8  15.6  1.8 
NT, PAPP-A, 
fβhCG  /  
AFP, fβhCG , 
InhA 
11  90.2  1.8  90.4  9.6  75.9  0.7  14.3  1.1 
12  89.0  2.0  89.4  10.6  75.0  0.7  14.0  1.3 
13  85.9  2.4  85.8  14.2  68.3  0.8  17.6  1.6 
NT, PAPP-A, 
fβhCG  /  
AFP, fβhCG , 
InhA, uE3 
11  90.6  1.8  90.3  9.7  75.9  0.7  14.7  1.1 
12  89.5  1.9  89.3  10.7  74.9  0.7  14.6  1.2 
13  86.6  2.3  85.9  14.1  68.3  0.7  18.3  1.6 
     DR: detection rate; FPR: False positive rate; ECR: Early completion rate  
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Table 4.7b: Performance of contingent screening (without NT measurement) with repeat measure of fβhCG  
 
Biochemical 
markers 
(First stage / 
Second stage) 
Week 
Overall  1
st trimester  2
nd trimester 
DR (%)  FPR (%)  ECR (%)  2
nd trimester 
frequency (%)  DR (%)  FPR (%)  DR (%)  FPR (%) 
PAPP-A, fβhCG  /  
AFP, fβhCG   
10  79.6  4.5  77.7  22.3  49.9  1.4  29.7  3.1 
11  79.1  4.5  77.3  22.7  49.1  1.4  30.0  3.1 
12  77.1  4.8  76.6  23.4  47.6  1.4  29.5  3.4 
13  72.6  5.3  71.8  28.2  39.3  1.3  33.3  4.0 
PAPP-A, fβhCG  /  
AFP, fβhCG , 
InhA 
10  81.7  4.1  77.8  22.2  49.9  1.4  31.8  2.7 
11  81.3  4.1  77.4  22.3  49.0  1.4  32.3  2.7 
12  80.0  4.4  76.6  23.4  47.7  1.4  32.3  3.0 
13  76.5  4.8  71.8  28.2  39.4  1.3  37.1  3.5 
PAPP-A, fβhCG  /  
AFP, fβhCG , 
InhA, uE3 
10  82.5  3.9  77.8  22.2  49.9  1.4  32.6  2.5 
11  82.3  4.0  77.4  22.6  49.2  1.4  33.1  2.6 
12  81.1  4.2  76.7  23.3  47.7  1.4  33.4  2.8 
13  78.0  4.6  71.7  28.3  39.3  1.3  38.7  3.3 
                DR: detection rate; FPR: False positive rate; ECR: Early completion rate  
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Table 4.8a: Performance of contingent screening (with PAPP-A and NT measurement in the first trimester) with repeat measure of PAPP-A 
 
Biochemical 
markers 
(First stage / 
Second stage) 
Week 
Overall  1
st trimester  2
nd trimester 
DR (%)  FPR (%)  ECR (%)  2
nd trimester 
frequency (%)  DR (%)  FPR (%)  DR (%)  FPR (%) 
NT, PAPP-A / 
AFP, hCG,  
PAPP-A 
11  90.1  1.5  87.0  13.0  69.3  0.7  20.8  0.8 
12  87.8  1.7  84.7  15.3  66.8  0.7  21.0  1.0 
13  82.9  2.2  79.9  20.1  58.7  0.7  24.2  1.5 
NT, PAPP-A  / 
AFP, hCG, InhA, 
PAPP-A 
11  90.2  1.5  87.1  12.9  69.2  0.7  21.0  0.8 
12  88.0  1.7  84.7  15.3  66.7  0.7  21.3  1.0 
13  83.6  2.1  79.9  20.1  58.7  0.7  24.9  1.4 
NT, PAPP-A / 
AFP, hCG, InhA, 
uE3, PAPP-A 
11  90.5  1.4  87.0  13.0  69.3  0.7  21.2  0.7 
12  88.4  1.6  84.7  15.3  66.7  0.7  21.7  0.9 
13  84.2  2.0  80.0  20.0  58.8  0.7  25.4  1.3 
  DR: detection rate; FPR: False positive rate; ECR: Early completion rate  
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Table 4.8b: Performance of contingent screening (with PAPP-A, fβhCG and NT measurement in the first trimester) with repeat measure of PAPP-A 
 
Biochemical 
markers 
(First stage / 
Second stage) 
Week 
Overall  1
st trimester  2
nd trimester 
DR (%)  FPR (%)  ECR (%)  2
nd trimester 
frequency (%)  DR (%)  FPR (%)  DR (%)  FPR (%) 
NT, PAPP-A, 
fβhCG  / 
AFP, hCG,  
PAPP-A 
11  91.7  1.5  90.3  9.7  75.8  0.7  15.9  0.8 
12  90.1  1.7  89.3  10.7  74.9  0.7  15.2  1.0 
13  86.0  2.2  85.9  14.1  68.2  0.7  17.8  1.5 
NT, PAPP-A, 
fβhCG  / 
AFP, hCG, InhA, 
PAPP-A 
11  91.9  1.5  90.3  9.7  76.0  0.7  15.9  0.8 
12  90.4  1.6  89.3  10.7  74.9  0.7  15.5  0.9 
13  86.8  2.2  85.9  14.1  68.2  0.8  18.6  1.4 
NT, PAPP-A, 
fβhCG  / 
AFP, hCG, InhA, 
uE3, PAPP-A 
11  92.2  1.4  90.3  9.7  75.8  0.7  16.4  0.7 
12  90.9  1.6  89.4  10.6  74.9  0.7  16.0  0.9 
13  87.5  2.1  85.9  14.1  68.3  0.8  19.2  1.3 
               DR: detection rate; FPR: False positive rate; ECR: Early completion rate  
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Table 4.8c: Performance of contingent screening (with PAPP-A in the first trimester) with repeat measure of PAPP-A  
 
Biochemical 
markers 
(First stage / 
Second stage) 
Week 
Overall  1
st trimester  2
nd trimester 
DR (%)  FPR (%)  ECR (%)  2
nd trimester 
frequency (%)  DR (%)  FPR (%)  DR (%)  FPR (%) 
PAPP-A / 
AFP, hCG,  
PAPP-A 
10  82.9  3.2  67.1  32.9  32.0  1.2  50.9  2.0 
11  82.4  3.2  66.1  33.9  30.6  1.2  51.8  2.0 
12  79.1  3.7  61.0  39.0  24.3  1.0  54.8  2.7 
13  72.4  4.4  51.3  48.7  14.7  0.7  57.7  3.7 
PAPP-A  / 
AFP, hCG, InhA, 
PAPP-A 
10  83.2  3.1  67.1  32.9  32.0  1.2  51.2  1.9 
11  82.7  3.2  66.1  33.9  30.6  1.2  52.1  2.0 
12  79.7  3.5  61.0  39.0  24.3  1.0  55.4  2.5 
13  74.3  4.1  51.4  48.6  14.8  0.7  59.5  3.4 
PAPP-A / 
AFP, hCG, InhA, 
uE3, PAPP-A 
10  83.9  2.9  67.0  33.0  32.0  1.2  51.9  1.7 
11  83.3  3.0  66.0  34.0  30.6  1.2  52.7  1.8 
12  80.6  3.4  61.0  39.0  24.3  1.0  56.3  2.4 
13  75.6  3.8  51.3  48.7  14.8  0.7  60.8  3.1 
               DR: detection rate; FPR: False positive rate; ECR: Early completion rate  
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Table 4.8d: Performance of contingent screening (with PAPP-A and fβhCG in the first trimester) with repeat measure of PAPP-A 
 
 
Biochemical 
markers 
(First stage / 
Second stage) 
Week 
Overall  1
st trimester  2
nd trimester 
DR (%)  FPR (%)  ECR (%)  2
nd trimester 
frequency (%)  DR (%)  FPR (%)  DR (%)  FPR (%) 
PAPP-A, fβhCG  / 
AFP, hCG,  
PAPP-A 
10  85.3  3.2  77.7  22.3  49.9  1.4  35.4  1.8 
11  84.8  3.2  77.3  22.7  49.1  1.4  35.7  1.8 
12  82.6  3.7  76.6  23.4  47.7  1.4  34.9  2.3 
13  76.8  4.5  71.8  28.2  39.3  1.3  37.5  3.2 
PAPP-A, fβhCG  / 
AFP, hCG, InhA, 
PAPP-A 
10  85.6  3.1  77.8  22.2  49.9  1.4  35.7  1.7 
11  85.3  3.2  77.3  22.7  49.2  1.4  36.1  1.8 
12  83.2  3.6  76.6  23.4  47.7  1.4  35.5  2.2 
13  78.6  4.3  71.8  28.2  39.3  1.3  39.3  3.0 
PAPP-A, fβhCG  / 
AFP, hCG, InhA, 
uE3, PAPP-A 
10  86.2  3.0  77.7  22.3  49.9  1.4  36.3  1.6 
11  85.8  3.0  77.3  22.7  49.0  1.4  36.8  1.6 
12  84.0  3.4  76.6  23.4  47.7  1.4  36.3  2.0 
13  79.8  4.1  71.9  28.1  39.4  1.3  40.4  2.8 
  DR: detection rate; FPR: False positive rate; ECR: Early completion rate  
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Table 4.9a: Performance of contingent screening (with NT measurement) with repeat measure of PAPP-A and hCG   
 
Biochemical 
markers 
(First stage / 
Second stage) 
Week 
Overall  1
st trimester  2
nd trimester 
DR (%)  FPR (%)  ECR (%)  2
nd trimester 
frequency (%)  DR (%)  FPR (%)  DR (%)  FPR (%) 
NT, PAPP-A, 
hCG  / 
AFP, hCG,  
PAPP-A 
11  91.1  1.3  87.9  12.1  70.9  0.7  20.2  0.6 
12  89.1  1.7  87.1  12.9  70.5  0.7  18.6  1.0 
13  85.0  2.3  84.8  15.2  65.9  0.7  19.1  1.6 
NT, PAPP-A, 
hCG  / 
AFP, hCG, InhA, 
PAPP-A 
11  91.3  1.3  87.8  12.2  70.8  0.7  20.5  0.6 
12  89.4  1.6  87.1  12.9  70.5  0.7  18.9  0.9 
13  86.0  2.2  84.8  15.2  65.8  0.7  20.2  1.5 
NT, PAPP-A, 
hCG  / 
AFP, hCG, InhA, 
uE3, PAPP-A 
11  91.5  1.2  87.9  12.1  70.8  0.7  20.7  0.5 
12  89.8  1.5  87.1  12.9  70.5  0.7  19.3  0.8 
13  86.7  2.1  84.8  15.2  65.9  0.7  20.8  1.4 
  DR: detection rate; FPR: False positive rate; ECR: Early completion rate  
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Table 4.9b: Performance of contingent screening (without NT measurement) with repeat measure of PAPP-A and hCG   
 
Biochemical 
markers 
(First stage / 
Second stage) 
Week 
Overall  1
st trimester  2
nd trimester 
DR (%)  FPR (%)  ECR (%)  2
nd trimester 
frequency (%)  DR (%)  FPR (%)  DR (%)  FPR (%) 
PAPP-A, hCG  / 
AFP, hCG, 
PAPP-A 
10  84.9  2.7  69.0  31.0  34.9  1.3  50.0  1.4 
11  84.3  2.8  69.3  30.7  35.4  1.3  48.9  1.5 
12  80.9  3.6  69.8  30.2  35.7  1.2  45.2  2.4 
13  75.1  4.6  68.7  31.3  33.3  1.2  41.8  3.4 
PAPP-A, hCG  / 
AFP, hCG, InhA, 
PAPP-A 
10  85.4  2.6  69.0  31.0  34.9  1.3  50.5  1.3 
11  84.7  2.8  69.3  30.7  35.3  1.3  49.4  1.5 
12  81.7  3.5  69.9  30.1  35.7  1.3  46.0  2.2 
13  77.2  4.3  68.7  31.3  33.4  1.2  43.8  3.1 
PAPP-A, hCG  / 
AFP, hCG, InhA, 
uE3, PAPP-A 
10  85.9  2.5  69.0  31.0  34.9  1.3  51.0  1.2 
11  85.4  2.6  69.3  30.7  35.4  1.3  50.0  1.3 
12  82.7  3.2  69.8  30.2  35.7  1.3  47.0  1.9 
13  78.8  4.0  68.7  31.3  33.3  1.2  45.5  2.8 
  DR: detection rate; FPR: False positive rate; ECR: Early completion rate 
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Table 4.10a: Performance of contingent screening (with NT measurement) with repeat measure of PAPP-A and fβhCG   
 
Biochemical 
markers 
(First stage / 
Second stage) 
Week 
Overall  1
st trimester  2
nd trimester 
DR (%)  FPR (%)  ECR (%)  2
nd trimester 
frequency (%)  DR (%)  FPR (%)  DR (%)  FPR (%) 
NT, PAPP-A, 
fβhCG  /  
PAPP-A, fβhCG   
11  90.8  1.7  90.3  9.7  75.8  0.7  15.0  1.0 
12  88.7  2.0  89.3  10.7  74.9  0.7  13.8  1.3 
13  83.4  2.7  85.9  14.1  68.4  0.8  15.0  1.9 
NT, PAPP-A, 
fβhCG  / 
AFP, fβhCG, 
PAPP-A   
11  91.5  1.6  90.3  9.7  75.8  0.7  15.7  0.9 
12  89.7  1.8  89.3  10.7  74.9  0.7  14.8  1.1 
13  85.3  2.5  85.9  14.1  68.3  0.8  17.0  1.7 
NT, PAPP-A, 
fβhCG  /  
AFP, PAPP-A, 
fβhCG, InhA   
11  91.6  1.5  90.3  9.7  75.9  0.7  15.7  0.8 
12  90.1  1.8  89.3  10.7  74.9  0.7  15.2  1.1 
13  86.2  2.4  85.8  14.1  68.2  0.8  18.0  1.6 
NT, PAPP-A, 
fβhCG  /  
AFP, PAPP-A, 
fβhCG, InhA, uE3   
11  91.9  1.5  90.3  9.7  75.9  0.7  16.0  0.8 
12  90.5  1.7  89.3  10.7  74.9  0.7  15.6  1.0 
13  86.9  2.2  85.9  14.1  68.2  0.8  18.7  1.4 
  DR: detection rate; FPR: False positive rate; ECR: Early completion rate  
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Table 4.10b: Performance of contingent screening (without NT measurement) with repeat measure of PAPP-A and fβhCG   
 
Biochemical 
markers 
(First stage / 
Second stage) 
Week 
Overall  1
st trimester  2
nd trimester 
DR (%)  FPR (%)  ECR (%)  2
nd trimester 
frequency (%)  DR (%)  FPR (%)  DR (%)  FPR (%) 
PAPP-A, fβhCG  /  
PAPP-A, fβhCG   
10  83.4  3.7  77.8  22.2  49.9  1.4  33.5  2.3 
11  82.8  3.8  77.4  22.6  49.1  1.4  33.7  2.4 
12  79.5  4.5  76.5  23.5  47.8  1.4  31.7  3.1 
13  71.5  5.5  71.8  28.2  39.3  1.3  32.2  4.2 
PAPP-A, fβhCG  / 
AFP, fβhCG,  
PAPP-A   
10  84.8  3.4  77.8  22.2  49.8  1.4  35.0  2.0 
11  84.3  3.5  77.4  22.6  49.1  1.4  35.2  2.1 
12  81.6  4.0  76.6  23.4  47.6  1.4  34.0  2.6 
13  75.3  5.0  71.8  28.2  39.3  1.3  36.0  3.7 
PAPP-A, fβhCG  /  
AFP, PAPP-A, 
fβhCG, InhA   
10  85.0  3.4  77.8  22.2  49.8  1.4  35.2  2.0 
11  84.7  3.4  77.3  22.7  49.1  1.4  35.6  2.0 
12  82.2  3.9  76.6  23.4  47.6  1.4  34.6  3.9 
13  77.3  4.7  71.8  28.2  39.3  1.3  38.0  3.4 
PAPP-A, fβhCG  /  
AFP, PAPP-A, 
fβhCG, InhA, uE3   
10  85.7  3.2  77.7  22.3  49.9  1.4  35.8  1.8 
11  85.3  3.3  77.3  22.7  49.1  1.4  36.2  1.9 
12  83.3  3.7  76.7  23.3  47.8  1.4  35.5  2.3 
13  78.8  4.4  71.9  28.1  39.3  1.3  39.5  3.1 
  DR: detection rate; FPR: False positive rate; ECR: Early completion rate                                                                                                                                                 Chapter 4: Results 
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Tables 4.11a and 4.11b show the summary of the performance of all the screening policies 
at week 12 with and without NT measurement. Addition of fβhCG to PAPP-A and NT 
measurement  in  the  first  trimester  screening  increased  the  detection  rate  and  early 
completion  rate  and  decreased  the  second  trimester  testing  frequency.    There  were  no 
significant changes in the screening performance when hCG was added to PAPP-A and NT 
measurement  in  the  first  trimester  screening.  When  hCG  measurement  in  the  second 
trimester  was  replaced  with  fβhCG,  there  was  a  slight  decrease  in  the  detection  rate. 
Among  all  the  cross-trimester  contingent  screening  with  repeat  measure  policies,  the 
screening policy with repeat measure of PAPP-A had the highest detection rate of 91.7% 
with a false positive rate of 1.5%. The screening policy with repeat measure of PAPP-A 
and hCG had the lowest false positive rate of 1.3% with a detection rate of 91.1%. The 
early  completion  rate  and  second  trimester  frequency  was  the  highest  and  lowest 
respectively in the screening policies with repeat measure of fβhCG, repeat measure of 
PAPP-A and repeat measure of fβhCG and PAPP-A.  
Without NT measurement in the first trimester the detection rates and early completion 
rates  were  decreased  and  false  positive  rates  and  second  trimester  frequencies  were 
increased (Table 4.11b). Therefore adopting the contingent screening protocol with repeat 
measure of PAPP-A (NT, PAPP-A, fβhCG / AFP, hCG, InhA, uE3, PAPP-A) would have 
achieved a detection rate of 92.2% at a false positive rate of 1.4% (compared with 91.8% 
detection at a 1.5% false positive rate for the complete integrated test with quadruple test in 
the second trimester) but with only 9.7% of women requiring a second trimester screening 
test (Figure 4.5). Without NT measurement, this screening policy would have achieved a 
detection rate of 86.2% at a false positive rate of 3.0% (compared with 84.7% detection at 
a  3.3%  false  positive  rate  for  the  full  serum  integrated  test  with  quadruple  test  in  the                                                                                                                                                  Chapter 4: Results 
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second trimester) but with only 22.3% of women requiring a second trimester screening 
test.  
The performances of screening policies in tables 4.11a and 4.11b were re-evaluated using 
larger SDs for affected cases (Table 4.11c and 4.11d). The SDs used for the affected cases 
were calculated by inflating the SDs for unaffected cases by 10%. Although there was 
deterioration  in  the  screening  performance  by  using  larger  SDs  for  affected  cases,  the 
differences were small. For example, screening policy using NT, fβhCG and PAPP-A in 
the first trimester and AFP, fβhCG and PAPP-A in second trimester would have achieved a 
detection  rate  of  89.7%  with  a  false  positive  rate  of  1.8%  using  the  same  SDs  for 
unaffected and Down’s syndrome cases. A detection rate of 87.6% with a false positive 
rate of 1.9% would have been achieved when larger SDs was used for the affected cases. 
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Table 4.11a: Summary of the performance of all the screening policies at week 12 with NT measurement 
 
 
   
Biochemical markers 
(First stage / Second stage) 
Overall  1
st trimester  2
nd trimester 
DR (%)  FPR (%)  ECR (%)  2
nd trimester 
frequency (%)  DR (%)  FPR (%)  DR (%)  FPR (%) 
NT, PAPP-A / AFP, hCG  86.2  2.0  84.6  15.4  66.7  0.7  19.5  1.3 
NT, PAPP-A, fβhCG / AFP, hCG 
  88.4  2.0  89.3  10.7  74.9  0.7  13.5  1.3 
NT, PAPP-A, hCG /AFP, hCG 
  86.9  2.0  87.1  12.9  70.6  0.7  16.3  1.3 
NT, PAPP-A / AFP, fβhCG  85.8  2.2  84.7  15.3  66.6  0.7  19.2  1.5 
NT, PAPP-A, fβhCG  / AFP, fβhCG  87.7  2.1  89.3  10.7  74.9  0.7  12.8  1.4 
NT, PAPP-A, fβhCG  / 
AFP, hCG, PAPP-A  90.1  1.7  89.3  10.7  74.9  0.7  15.2  1.0 
NT, PAPP-A, hCG  / 
AFP, hCG, PAPP-A  89.1  1.7  87.1  12.9  70.5  0.7  18.6  1.0 
NT, PAPP-A, fβhCG  / 
AFP, fβhCG, PAPP-A  89.7  1.8  89.3  10.7  74.9  0.7  14.8  1.1 
  DR: detection rate; FPR: False positive rate; ECR: Early completion rate 
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Table 4.11b: Summary of the performance of all the screening policies at week 12 without NT measurement 
  
Biochemical markers 
(First stage / Second stage) 
Overall  1
st trimester  2
nd trimester 
DR (%)  FPR (%)  ECR (%)  2
nd trimester 
frequency (%)  DR (%)  FPR (%)  DR (%)  FPR (%) 
PAPP-A / AFP, hCG  75.1  4.5  61.0  39.0  24.3  1.0  50.8  3.5 
PAPP-A, fβhCG / AFP, hCG 
  78.9  4.4  76.6  23.4  47.7  1.4  31.2  3.0 
PAPP-A, hCG /AFP, hCG 
  76.0  4.5  69.8  30.2  35.8  1.2  40.2  3.3 
PAPP-A / AFP, fβhCG  74.1  4.8  61.1  38.9  24.4  1.0  49.7  3.8 
PAPP-A, fβhCG  / AFP, fβhCG  77.1  4.8  76.6  23.4  47.6  1.4  29.5  3.4 
PAPP-A, fβhCG  / 
AFP, hCG, PAPP-A  82.6  3.7  76.6  23.4  47.7  1.4  34.9  2.3 
PAPP-A, hCG  / 
AFP, hCG, PAPP-A  80.9  3.6  69.8  30.2  35.7  1.2  45.2  2.4 
PAPP-A, fβhCG  / 
AFP, fβhCG, PAPP-A  81.6  4.0  76.6  23.4  47.6  1.4  34.0  2.6 
    DR: detection rate; FPR: False positive rate; ECR: Early completion rate 
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Figure 4.5: The performance of cross-trimester screening with repeat measure of PAPP-
A. There were 541 (75.8%) Down’s syndrome and 3495 (0.7%) unaffected pregnancies 
with initial risks ≥1:42, and these were  classified as high  risk. Within the low-risk 
group  with  risks  ≤1:1000,  there  were  35  (4.9%)  Down’s  syndrome  and  447,360 
(89.6%) unaffected pregnancies. The remaining 48,568 (9.7%) women fell within the 
intermediate risk category and would be offered second trimester double test. Of these, 
when the risk from the second trimester double test and PAPP-A was combined with 
the initial risk, 117 (16.4%) Down’s syndrome and 3495 (0.7%) unaffected pregnancies 
had final risk of ≥ 1:150 and would be offered a diagnostic test. This screening policy 
can achieve a detection rate of 92.2% with a false positive rate of 1.4% but with only 
9.7% requiring second trimester screening. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
High risk (risk ≥1:42) 
541 Down’s syndrome (75.8%) 
3495 Unaffected (0.7%) 
Intermediate risk 
138 Down’s syndrome (19.3%) 
48,431 Unaffected (9.7%) 
 
Low risk (risk ≤1:1000) 
35 Down’s syndrome (4.9%) 
447,360 Unaffected (89.6%) 
 
First trimester screening test  
(NT, PAPP-A, fβhCG, maternal age)  
 
500, 000 pregnant women 
(714 Down’s syndrome, 499,286 Unaffected) 
Total risk (risk < 1:150) 
21 Down’s syndrome (2.9%) 
44,936 Unaffected (9.0%) 
Total risk (risk ≥ 1:150) 
117 Down’s syndrome (16.4%) 
3495 Unaffected (0.7%) 
 
Chorionic villus sampling (CVS) or Amniocentesis 
658 Down’s syndrome (92.2%) 
6990 Unaffected (1.4%) 
No invasive diagnostic procedure 
56 Down’s syndrome (7.8%) 
491,797 Unaffected (98.6%) 
 
Second trimester screening test 
(AFP, hCG, InhA, uE3, PAPP-A)  
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Table 4.11c: Summary of the performance of all the screening policies at week 12 with NT measurement (SDs for affected cases 10% larger than for 
unaffected)  
 
 
Biochemical markers 
(First stage / Second stage) 
Overall  1
st trimester  2
nd trimester 
DR (%)  FPR (%)  ECR (%)  2
nd trimester 
frequency (%)  DR (%)  FPR (%)  DR (%)  FPR (%) 
NT, PAPP-A / AFP, hCG  83.8  2.2  82.8  17.2  62.7  0.7  21.1  1.5 
NT, PAPP-A, fβhCG / AFP, hCG 
  86.1  2.1  87.9  12.1  71.5  0.7  14.6  1.4 
NT, PAPP-A, hCG /AFP, hCG 
  84.5  2.1  85.4  14.6  66.9  0.7  17.6  1.4 
NT, PAPP-A / AFP, fβhCG  83.5  2.3  82.7  17.3  62.7  0.7  20.8  1.6 
NT, PAPP-A, fβhCG  / AFP, fβhCG  85.4  2.2  87.9  12.1  71.6  0.7  13.8  1.5 
NT, PAPP-A, fβhCG  / 
AFP, hCG, PAPP-A  88.0  1.8  87.9  12.1  71.6  0.7  16.4  1.1 
NT, PAPP-A, hCG  / 
AFP, hCG, PAPP-A  86.8  1.8  85.5  14.5  66.8  0.7  20.0  1.1 
NT, PAPP-A, fβhCG  / 
AFP, fβhCG, PAPP-A  87.6  1.9  87.9  12.1  71.5  0.7  16.1  1.2 
    DR: detection rate; FPR: False positive rate; ECR: Early completion rate 
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Table 4.11d: Summary of the performance of all the screening policies at week 12 without NT measurement (SDs for affected cases 10% larger for than 
unaffected)   
Biochemical markers 
(First stage / Second stage) 
Overall  1
st trimester  2
nd trimester 
DR (%)  FPR (%)  ECR (%)  2
nd trimester 
frequency (%)  DR (%)  FPR (%)  DR (%)  FPR (%) 
PAPP-A / AFP, hCG  72.4  4.2  60.8  39.2  24.6  1.0  47.8  3.2 
PAPP-A, fβhCG / AFP, hCG 
  76.2  4.0  75.5  24.5  46.4  1.3  29.8  2.7 
PAPP-A, hCG /AFP, hCG 
  73.0  4.2  69.1  30.9  35.2  1.2  37.8  3.0 
PAPP-A / AFP, fβhCG  71.6  4.5  60.7  39.3  24.6  1.0  47.0  3.5 
PAPP-A, fβhCG  / AFP, fβhCG  74.7  4.4  75.6  24.4  46.4  1.2  28.3  3.2 
PAPP-A, fβhCG  / 
AFP, hCG, PAPP-A  80.1  3.5  75.6  24.4  46.4  1.3  33.7  2.2 
PAPP-A, hCG  / 
AFP, hCG, PAPP-A  78.3  3.4  69.0  31.0  35.2  1.1  43.1  2.3 
PAPP-A, fβhCG  / 
AFP, fβhCG, PAPP-A  79.2  3.8  75.6  24.4  46.4  1.2  32.8  2.3 
     DR: detection rate; FPR: False positive rate; ECR: Early completion rate 
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4.3  EFFECT  OF  SMOKING  &  ETHNICITY  ON  FIRST  AND 
SECOND TRIMESTER SERUM MARKERS 
Maternal smoking habit and ethnic origin are two factors known to affect the biochemical 
marker  levels  in  Down’s  syndrome  screening.  However,  there  is  little  information  on 
whether  correction  factors  for  ethnicity  and  maternal  smoking  status  vary  between 
trimesters  for  AFP,  hCG,  fβhCG  and  PAPP-A.  Of  the  CUB  screening  cohort  between 
August 2000 and October 2006, 939 paired first and second trimester serum samples were 
identified, recovered from frozen storage and assayed for all serum markers where the 
information was not available routinely (refer to section 2.4). The description of the study 
population is shown in Table 4.12. 
 
Table 4.12: Description of the study population 
The Mann-Whitney test was used to compare the median values. The median values (shown in 
bold) are significantly different (p<0.05) when compared with the median values of Caucasian 
women.  
 
Ethnicity  Number of 
women 
Median age 
(years) 
Median 
weight (kg) 
(1
sttrimester) 
Median weight 
(kg) 
(2
ndtrimester) 
% Smokers 
Caucasian  501  31.0  65.0  65.0  18.56% 
South Asian  268  28.0 
(p=0.000) 
59.2 
(p=0.000) 
58.8 
(p=0.000)  3.36% 
Oriental  66  30.0  54.8 
(p=0.000) 
55.0 
(p=0.000)  3.03% 
Middle 
Easterners  42  29.5  62.4  63.6  2.38% 
Black 
population  35  29.0 
(p=0.023)  68.0  68.0  11.43% 
Asians  27  32.0  58.0 
(p=0.003) 
58.0 
(p=0.002)  0% Chapter 4: Results 
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The median age of South Asian and Black women at the time of screening was found to be 
significantly younger compared to Caucasian women. Although Oriental and Middle East 
women were found to be younger than Caucasian women, the differences in median age 
were not significant. The information on maternal weight in first and second trimester was 
collected  by  weighing  pregnant  women  in  each  trimester.  The  median  weights  of 
Caucasian women in their first and second trimester were 65.0kg. In all the ethnic groups, 
there was no significant difference between the first and second trimester median weight. 
The  South  Asian,  Oriental  and  Asian  women  were  found  to  be  significantly  lighter 
(p<0.05) compared to the Caucasian women. There was a higher percentage of smokers 
amongst the Caucasian (18.56%) and the Black (11.43%) women compared to the other 
ethnic groups. There were no smokers found among the Asian women.  
4.3.1 SMOKING 
To study the effect of smoking, paired 1st and 2nd trimester serum samples from 459 
Caucasian  women  who  had  provided  smoking  information  (366  non-smokers  and  93 
smokers)  were  analysed.  Apart  from  Caucasians,  the  number  of  smokers  in  individual 
ethnic groups was too small to examine the effect of smoking in these groups (Table 4.12).   
The  AFP  level  in  smokers  was  increased  significantly  in  the  first  trimester  by  16.3% 
(p=0.001) but not in the second trimester (p=0.077) when compared with the non-smokers. 
This change between trimesters was significant (p=0.024). The hCG level in smokers was 
significantly decreased by 27.6% and 30.5% in the first and second trimesters respectively 
(p<0.05), with no significant trend between trimesters (p=0.407). The fβhCG level was 
significantly decreased in smokers in the second trimester by 17.1% (p=0.007) but not in 
the first trimester (p=0.998) when compared with non-smokers. There was a significant Chapter 4: Results 
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trend  (p=0.027)  between  trimesters.  The  PAPP-A  level  was  significantly  decreased  by 
14% and 22.8% in first and second trimesters respectively (p<0.05) when compared with 
non-smokers, with no significant trend between trimesters (p=0.661) (Figure 4.6). 
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Figure 4.6: Multiple of median levels for AFP, hCG, fβhCG and PAPP-A in non-
smokers and smokers in first and second trimester  
Middle line represents median level, the box represents the 25th and 75th percentiles, the lines represent 
the 5th and 95th percentiles  Chapter 4: Results 
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4.3.2 ETHNICITY 
To study the effect of ethnicity, 939 paired first and second trimester serum samples were 
analysed  for  AFP,  hCG,  fβhCG  and  PAPP-A  levels  routinely  or  retrospectively.  The 
Caucasians  were  used  as  the  reference  population.  Median  marker  levels  for  different 
ethnic  groups  are  shown  in  Table  4.13.  Results  are  corrected  for  maternal  weight  and 
smoking. South Asian women had significantly higher hCG levels in the first trimester 
(p=0.020) but not in the second trimester (p=0.759) compared with Caucasian women, 
with a significant trend between trimesters (p<0.001). They also had significantly lower 
fβhCG  and  PAPP-A  in  the  second  trimester  (MoM=0.87,  p=0.006  and  MoM=0.93, 
p=0.018 respectively) when compared with Caucasian women, with a significant trend 
between trimesters (p<0.001). Oriental women had significantly higher first and second 
trimester  hCG  levels,  with  median  MoMs  of  1.41  (p<0.001)  and  1.19  (p=0.001) 
respectively  when  compared  with  Caucasian  women,  with  a  significant  trend  between 
trimesters (p=0.022). They also had significantly higher fβhCG and PAPP-A levels in the 
first trimester (MoM=1.08, p=0.037 and MoM=1.20, p=0.044 respectively).  
Middle East women had significantly lower first trimester AFP with a median MoM of 
0.88 (p=0.036) when compared with Caucasian women, but no other significant changes. 
There was also no significant trend between trimesters for all markers. Black women had 
significantly higher hCG in the first trimester (p=0.029) but not in the second trimester 
when  compared  with  Caucasian  women,  with  a  significant  trend  (p=0.004)  between 
trimesters. In Black women, the median PAPP-A level was also significantly elevated in 
both  trimesters  (1.43  MoM,  p<0.001  and  1.62  MoM,  p<0.001  respectively)  when 
compared with Caucasian women, with no significant trend between trimesters.   Chapter 4: Results 
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Table 4.13: Median marker levels in different ethnic groups 
The Mann-Whitney test was used to compare the median values. The median values (shown in 
bold) are significantly different (p<0.05) when compared with the median values of Caucasian 
women.  
 
4.4 RETROSPECTIVE STUDY ON THE EFFECT OF ASSISTED 
REPRODUCTIVE  TECHNOLOGY  ON  SERUM  MARKER 
CONCENTRATION 
The effect of ART on first and second trimester biochemical markers in Down’s syndrome 
screening  requires  clarification.  In  this  study,  the  level  of  first  and  second  trimester 
biochemical markers in women pregnant after various form of ART was assessed (refer to 
section 2.5). 
4.4.1 FIRST TRIMESTER 
From  the  CUB  screening  cohort  between  October  2005  and  January  2009,  127  ART 
pregnancies  were  identified.  The  control  group  consisted  of  10891  pregnancies.  The 
pregnancies were grouped into 4 categories; 1. normal pregnancy, 2. IVF or ICSI with 
fresh eggs, 3. IVF or ICSI with frozen embryo and 4. IVF with donor’s egg. Table 4.14 
Ethnic 
groups 
Median AFP(MoM)  Median hCG (MoM)  Median fβhCG (MoM)  Median PAPP-A 
(MoM) 
1
st 
trimester 
2
nd 
trimester 
1
st 
trimester 
2
nd 
trimester 
1
st 
trimester 
2
nd 
trimester 
1
st 
trimester 
2
nd 
trimester 
Caucasian  0.99  1.01  1.02  1.01  1.02  1.00  1.00  1.01 
South 
Asians  0.99  0.98  1.09 
(p=0.020)  0.98  0.91  0.87 
(p=0.006)  0.97  0.93 
(p=0.018) 
Orientals  0.98  0.98  1.41 
(p<0.001) 
1.19 
(p=0.001) 
1.08 
(p=0.034)  1.07  1.20 
(p=0.044)  1.14 
Middle 
Easterners 
0.88 
(p=0.036)  0.96  1.12  1.09  1.02  1.00  0.92  0.98 
Black 
women  1.07  1.01  1.26 
(p=0.029)  0.91  0.98  0.90  1.43 
(p<0.001) 
1.62 
(p=0.001) Chapter 4: Results 
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shows the baseline parameters of the controls and ART pregnancies. The women pregnant 
after  ART  with  a  median  maternal  age  of  38.6  years  (range,  29.8  –  47.0)  were 
significantly older (p<0.05) compared with women who had conceived spontaneously. 
The proportion of women of advanced maternal age (maternal age ≥ 35 years) was higher 
in the ART group compared with the controls, at 82.5% vs. 41.3%. When the median 
maternal  age  of  each  ART  treatment  groups  were  compared  with  the  control  group, 
women pregnant after IVF or ICSI with fresh eggs,with frozen embryos and donor’s egg 
were significantly older (p<0.05).  
 
Table 4.14: Baseline parameters of the ART pregnancies in the first trimester 
 
1. IVF or ICSI with fresh eggs, 2. IVF or ICSI with frozen embryo and 3. IVF with donor’s egg 
The Mann-Whitney test was used to compare the median values. The median values (shown in 
bold) are significantly different (p<0.05) when compared with the median values of controls.  
 
Women  pregnant  after  ART  had  their  blood  samples  taken  for  PAPP-A  and  fβhCG 
analysis significantly later (p=0.002) in pregnancy compared with the control group, at a 
median gestational age of 89 days (range, 81-97) vs. 88 days (range, 63-101). When the 
median gestational age at sampling of each ART treatment groups was compared with the 
controls, women pregnant after IVF or ICSI with fresh eggs had blood taken significantly 
Parameters 
Controls 
(n = 10891) 
ART pregnancies 
All 
(n = 127) 
1 
(n = 91) 
2 
(n = 29) 
3 
(n = 7) 
Maternal age (years)  33.5 
38.6 
(p<0.05)
 
38.7 
(p<0.05) 
36.8 
(p<0.05) 
44.7 
(p<0.05) 
GA at Blood sampling 
(days) 
88.0 
89.0 
(p=0.002)
 
89.0 
(p=0.022) 
89.0 
(p=0.075) 
91.0 
(p=0.161) 
GA at NT 
measurement (days) 
89.0 
89.0 
(p=0.545) 
89.0 
(p=0.872) 
88.5 
(p=0.908) 
93.0 
(p=0.084) Chapter 4: Results 
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later (p=0.022) in pregnancy. There was no significant difference in the gestational age at 
NT measurement between the women pregnant after ART and women who had conceived 
spontaneously.  
The median MoM levels of PAPP-A, fβhCG and NT together with the 95% CI is shown in 
Table 4.15. There were no significant differences in PAPP-A and fβhCG levels found 
when the ART group overall was compared with the controls.  The women pregnant after 
ART had significantly higher (p=0.016) NT measurement compared with women who had 
conceived  spontaneously  with  a  median  MoM  of  1.1041.  The  median  PAPP-A  was 
significantly lower (p = 0.035) in the IVF or ICSI with fresh eggs group when compared 
with the controls. Among the ART treatment groups, the NT was significantly higher (p = 
0.006) in the IVF or ICSI with fresh eggs group when compared with the controls. There 
were  no  significant  differences  in  the  fβhCG  concentrations  in  all  the  different  ART 
treatment groups when compared with the controls.  Chapter 4: Results 
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Table 4.15: Median multiples of the median (MoM) levels of PAPP-A, fβhCG and NT 
measurement in ART and control pregnancies. 
 1. IVF or ICSI with fresh eggs, 2. IVF or ICSI with frozen embryo and 3. IVF with donor egg 
The Mann-Whitney test was used to compare the median values. The median values (shown in 
bold) are significantly different (p<0.05) when compared with the median values of controls.  
 
 
4.4.2 SECOND TRIMESTER 
A  cohort  of  129  ART  pregnancies  where  second  trimester  screening  was  performed 
between  October  2005  and  January  2009  was  identified  from  the  routine  screening 
database.  The control group consisted of 61,448 pregnancies. The baseline parameters of 
the ART pregnancies and controls are shown in Table 4.16. The women pregnant after 
ART  were  significantly  older  (p<0.05)  compared  with  those  who  had  conceived 
spontaneously  with  a  median  maternal  age  of  35.5  years  (range,  20.2  –  43.5).  The 
proportion of women of advanced maternal age (maternal age ≥ 35 years) at screening was 
53.2% in the ART group and 19.8% in the control group. When the median maternal age 
of each ART treatment groups was compared with the controls, the median maternal age 
was significantly higher (p<0.05) in groups 1,  2 and 3. 
Markers  Controls 
ART pregnancies 
All  1  2  3 
PAPP-A 
1.0164 
(1.0058, 1.0271) 
0.9240 
(0.8177, 1.0441) 
(p=0.083) 
0.8901
 
(0.7856, 1.0085) 
(p=0.035) 
1.0210 
(0.7814, 1.3331) 
(p=0.734) 
1.2448 
(0.6923, 2.2382) 
(p=0.396) 
FβhCG 
0.9811 
(0.9702, 0.9922) 
1.0564 
(0.9485, 1.1764) 
(p=0.109) 
1.0821 
(0.9439, 1.2405) 
(p=0.119) 
0.9841 
(0.7906, 1.2209) 
(p=0.717) 
0.9498 
(0.5140, 1.7554) 
(p=0.631) 
NT 
1.0088 
(1.0038, 1.0139) 
1.1041
 
(1.0538, 1.1568) 
(p=0.016) 
1.1296
 
(0.9945, 1.2832) 
(p=0.006) 
1.0417 
(0.9295, 1.1674) 
(p=0.983) 
1.1041 
(0.9034, 1.3493) 
(p=0.622) Chapter 4: Results 
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Table 4.16: Baseline parameters of the ART pregnancies in the second trimester 
1.  IVF or ICSI with fresh eggs, 2. IVF or ICSI with frozen embryo and 3. IVF with donor’s egg 
The Mann-Whitney test was used to compare the median values. The median values (shown in 
bold) are significantly different (p<0.05) when compared with the median values of controls.  
GA: Gestational age 
 
Women  pregnant  after  ART  had  blood  taken  for  AFP  and  hCG  analysis  significantly 
earlier (p=0.003) in pregnancy compared to those who had conceived spontaneously at the 
median gestational age of 112 days (range, 105-144) vs. 113 days (range, 105-146). When 
the median gestational age at sampling of each ART treatment groups was compared with 
the  controls,  women  pregnant  after  IVF  or  ICSI  with  fresh  eggs  had  blood  taken 
significantly earlier (p=0.001) in pregnancy.  
The median MoM levels of AFP and hCG together with the 95% CI are shown in Table 
4.17. There was no significant difference found in the AFP levels when the ART group 
overall was compared with the controls. The AFP level was significantly higher (p=0.011) 
in  the  IVF  with  donor’s  egg  group  when  compared  with  the  controls.  There  were  no 
significant differences in the AFP levels between the other ART treatment groups and 
controls. The hCG level was significantly higher (p<0.05) in the ART group overall when 
compared with the controls. When the median hCG MoM level of each ART treatment 
Parameters  Controls 
(n=61448) 
ART pregnancies 
All  
(n = 129) 
1 
(n = 105) 
2 
(n = 15) 
3 
(n = 9) 
Maternal age (years)  29.5  35.5 
(p<0.05)
 
35.7 
(p<0.05) 
35.2 
(p=0.001) 
38.6 
(p=0.002) 
GA at Blood sampling 
(days)  113  112 
(p<0.05)
 
111 
(p=0.001) 
114 
(p=0.699) 
112 
(p=0.671) Chapter 4: Results 
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groups was compared with the controls, women pregnant after IVF or ICSI with fresh eggs 
(Group 1) and after IVF or ICSI with frozen embryo (Group 2) had significantly higher 
(p<0.05) levels of hCG. There was no significant difference in hCG levels in the IVF with 
donor egg (Group 3) when compared with the controls.   
 
Table 4.17: Median multiples of the median (MoM) levels of AFP and hCG in ART and 
control pregnancies.  
1. IVF or ICSI with fresh eggs, 2. IVF or ICSI with frozen embryo and 3. IVF with donor’s egg 
The Mann-Whitney test was used to compare the median values. The median values (shown in 
bold) are significantly different (p<0.05) when compared with the median values of controls 
 
Markers  Controls 
ART pregnancies 
All  1  2  3 
AFP  1.0037 
(1.0011, 1.0064) 
0.9962 
(0.9347, 1.0616) 
(p=0.681) 
0.9631 
(0.9254, 1.0200) 
(p=0.677) 
1.0225 
(0.8294, 1.2606) 
(p=0.676) 
1.1909
 
(0.8960, 1.5796) 
(p=0.011) 
hCG  1.0189 
(1.0145, 1.0232) 
1.2203
 
(1.1201, 1.3292) 
(p<0.05) 
1.1967
 
(1.0850, 1.3199) 
(p=0.005) 
1.3014
 
(0.9712, 1.7430) 
(p=0.034) 
1.2149 
(0.8175, 1.8049) 
(p=0.128) Chapter 4: Results 
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4.5  RETROSPECTIVE  STUDY  ON  BIRTH  WEIGHT, 
DURATION  OF  PREGNANCY  AND  SECOND  TRIMESTER 
MATERNAL  SERUM  SCREENING  MARKERS  IN  NON-
SMOKERS AND SMOKERS 
4.5.1 ACCURACY OF SELF-REPORTED SMOKING INFORMATION 
AT BOOKING AND SCREENING APPOINTMENTS 
In antenatal care, self-reported smoking is commonly used to determine the smoking status 
of pregnant women. The accuracy of this information is still questionable. Inaccurate self 
report during pregnancy can result in inaccurate risk calculation for Down’s syndrome. In 
this study, the accuracy of self-reported smoking information at booking and screening 
appointments  in  West  of  Scotland  was  assessed  (refer  to  section  2.6).  The  smoking 
information  at  booking  was  obtained  from  the  SMR02  records  and  the  smoking 
information  at  screening  from  the  second  trimester  screening  records.    Of  the  29975 
women in the West of Scotland who gave birth in 2004 21,029 pregnant women opted for 
second trimester screening. Of these cotinine testing was performed on 3475 randomly 
selected maternal serum samples. The cotinine cut-off concentration used to distinguished 
smokers and non-smokers was 13.7ng/ml. Re-testing of cotinine  was performed on 71 
samples with cotinine values between 10-30ng/ml (close to the cut-off of 13.7ng/ml) and 
the average concentration taken as the final result. Table 4.18 shows the characteristics of 
the study population.  
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Table 4.18: Description of the study population.  
*STDUR: Stopped smoking during pregnancy, STPR: Stopped smoking prior to pregnancy 
 
Characteristic 
Whole sample 
(n=21029) 
Cotinine-validated sample 
(n=3475) 
Maternal age (years), median  29.8  29.9 
Infant birth weight (g), median  3420  3430 
Gestation at delivery (weeks), median  40  40 
Gestation at screening (weeks), median  16  16 
Self-reported  smoking  status  at  booking 
appointment (%): 
   
            Non – smokers  54.0  56.7 
            Current smokers  23.3  24.1 
            Former smokers  9.9  10.6 
            Unknown  9.3  8.6 
Self-reported  smoking  status  at  screening 
appointment (%): 
   
            Non – smokers  57.2  57.2 
            Current smokers  22.0  21.4 
            STDUR
*  4.8  4.9 
            STPR*  3.5  3.8 
            Unknown  12.5  12.7 Chapter 4: Results 
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From the smoking status at booking information, obtained from the SMR02 records 
(section 2.6), 1971 (56.7%) women self-reported as non-smokers, 839 (24.1%) as smokers 
and 367 (10.6%) as former smokers. The self-reported smoking information was not 
available for 298 (8.6%) women. The percentage of self-reported smokers (24.1%) at 
booking was significantly lower than the cotinine-validated estimate of 30.1%. At booking, 
4.9% and 25.6% of women who self-reported as non-smoker and former smoker 
respectively had cotinine level ≥13.7ng/ml (Table 4.19). Sixty-one (7.3%) women who 
self-reported as smokers had cotinine level below the cut-off. These women could have 
quit smoking between booking and screening appointment, be light smokers or this might 
be due to recording errors.  
 
Table 4.19: Number of women with cotinine levels above and below the cotinine cut-off of 
13.7 ng/ml in each self-reported smoking category at booking appointment 
 
 
Self-reported smoking status at booking  Total 
  Non-smokers  Smokers  Former smokers  Unknown 
Cotinine 
(ng/ml) 
 
<13.7  1875  61  273  220  2429 
≥13.7  96  778  94  78  1046 
Total  1971  839  367  298  3475 
 
Misclassification  4.9%  7.3%  25.6%  -   Chapter 4: Results 
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At the screening appointment, 1985 (57.2%) women self-reported as non-smokers, 745 
(21.4%) as smokers, 172 (4.9%) as stopped smoking during pregnancy and 131 (3.8%) as 
stopped  smoking  prior  to  pregnancy.  The  self-reported  smoking  information  was  not 
available for 442 (12.7%) women. The percentage of self-reported smokers (21.4%) at 
screening  was  significantly  lower  than  the  cotinine-validated  estimate  of  30.1%.  One-
hundred and thirteen (5.7%) women who self-reported as non-smokers had cotinine level 
≥13.7ng/ml (Table 4.20). Among those who self-reported as stopped smoking during or 
prior to pregnancy, 32.6% and 21.4% of these women had a cotinine level ≥13.7ng/ml 
respectively.  Twenty-eight  (3.8%)  women  who  self-reported  as  smokers  had  cotinine 
levels below the cut-off.  
 
Table 4.20: Number of women with cotinine levels above and below the cotinine cut-off of 
13.7 ng/ml in each self-reported smoking category at screening appointment 
 
*STDUR: Stopped smoking during pregnancy, STPR: Stopped smoking prior to pregnancy 
 
 
Self-reported smoking status at screening 
Total 
Non-smokers  Smokers  STDUR  STPR  Unknown 
Cotinine 
(ng/ml) 
<13.7  1872  28  116  103  310  2429 
≥13.7  113  717  56  28  132  1046 
Total  1985  745  172  131  442  3475 
Misclassification  5.7%  3.8%  32.6%  21.4%  -  - Chapter 4: Results 
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This study shows that, 25.6% and 31.5% cotinine-validated smokers were not detected by 
self-report at booking and screening appointment respectively. The highest proportion of 
inaccurate  reporting  was  amongst  women  who  stated  that  they  were  former  smokers 
(25.6% of former smokers at booking, 32.6% of those who stated at screening that they had 
stopped smoking during pregnancy and 21.4% of those who stated at screening that they 
had stopped smoking prior to pregnancy). In women who stated that they were smokers or 
non-smokers the level of accuracy was much higher.    
Since the cut-off used here was derived from a different assay method, the impact of using 
different  cotinine  cut-offs  on  the  percentage  of  misclassification  of  self-reported  non-
smokers and smokers at booking and screening appointments was evaluated (Table 4.21). 
The data from this study showed that there is very little variation in the findings when any 
cut-off between 10 and 30ng/ml is used. Chapter 4: Results 
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Table 4.21: The percentage of misclassification of non-smokers and smokers for various 
cut-off based on self-reported smoking status at booking and screening appointments 
Cut-off (ng/ml) 
Misclassification 
Booking appointment  Screening appointment 
Non-smokers (%)  Smokers (%)  Non-smokers (%)  Smokers (%) 
10  5.1  6.2  5.9  2.8 
11  4.9  6.3  5.8  3.0 
12  4.9  6.9  5.8  3.2 
13  4.9  7.3  5.8  3.8 
14  4.9  7.4  5.7  3.9 
15  4.8  7.7  5.6  3.9 
16  4.8  8.0  5.6  4.0 
17  4.7  8.1  5.5  4.2 
18  4.7  8.1  5.5  4.2 
19  4.6  8.3  5.5  4.6 
20  4.5  8.3  5.4  4.6 
21  4.5  8.3  5.4  4.6 
22  4.5  8.5  5.3  4.7 
23  4.5  8.5  5.3  4.7 
24  4.5  8.6  5.3  5.0 
25  4.5  8.7  5.2  5.1 
26  4.4  8.7  5.1  5.1 
27  4.4  8.8  5.1  5.1 
28  4.3  8.8  5.1  5.1 
29  4.3  8.8  5.1  5.1 
30  4.3  8.9  5.1  5.1 
13.7 (used in this study)  4.9  7.3  5.7  3.8 
 
4.5.2  FORMS  USED  FOR  COLLECTING  SELF  -  REPORTED 
SMOKING INFORMATION AT SCREENING 
The form used to collect self-reported smoking information was replaced with a new form 
in 2007. An analysis was performed to compare the efficiency between the old and new 
forms used to collect self-reported smoking information. Two datasets (March 2006 and 
March 2008) were used in this study (refer to section 2.6.2). The self-reported smoking 
information in March 2006 dataset was collected using the screening form where women 
were  given  four  options;  non-smoker,  smoker,  stopped  smoking  during  pregnancy  and 
stopped  smoking  prior  to  pregnancy.  The  self-reported  smoking  information  in  March 
2008 dataset was collected using the screening form where women were given only two Chapter 4: Results 
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options; non-smoker or smoker. Those women who stopped smoking during pregnancy 
and stopped smoking prior to pregnancy were classified as ‘non-smoker’. For both data-
sets, the smoking status information was also included in the screening report allowing the 
antenatal  clinic  to  contact  the  laboratory  if  there  was  any  mistake  in  the  smoking 
information. From each dataset maternal serum of 100 self-reported non-smokers and 100 
self-reported smokers were randomly selected for cotinine testing. The description of the 
study population is shown in Table 4.22. 
Table 4.22: Description of the study population.  
 
The accuracy of self-reported smoking information where women were given four options; 
non-smoker, smoker, stopped smoking during pregnancy and stopped smoking prior to 
pregnancy  on  the  screening  form  was  95.5%  (Table  4.23).  The  accuracy  of  smoking 
information  where  women  were  given  two  options;  non-smoker  and  smoker  on  the 
screening form and were allowed to correct their smoking status once they receive their 
screening  report  was  96%.  Therefore,  those  women  who  stopped  smoking  during 
pregnancy  and  stopped  smoking  prior  to  pregnancy  can  be  classified  as  ‘non-smoker’. 
Characteristic 
March 2006 
(n=1676) 
Cotinine-validated 
samples for March 
2006 (n=200) 
March 2008 
(n=1507) 
Cotinine-validated 
samples for March 
2008 (n=200) 
Maternal age (years), median  29.3  27.7  29.0  28.7 
Gestation at screening (weeks), 
median 
16  16  16  16 
Self reported smoking status at 
screening appointment (%): 
       
Non-smoker  72.1  50.0  78.4  50.0 
Smoker  21.7  50.0  21.1  50.0 
Not answered  6.2  -  0.5  - Chapter 4: Results 
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Allowing smoking status to be corrected after the issue of the screening report improves 
the  accuracy  of  self-reported  smoking  information.  Making  women  aware  that  mis-
reporting of smoking status may affect the accuracy of the risks that they are given from 
the screening test may also improve the quality of smoking status information at the time 
of screening. 
 
Table 4.23: Number of women with cotinine levels above and below the cotinine cut-off of 
13.7 ng/ml in each self-reported smoking category 
4.5.3 BIRTHWEIGHT, DURATION OF PREGNANCY AND SECOND 
TRIMESTER MARKERS 
From the 21,029 second trimester screening cohort, 15,973 singleton pregnancies which 
had full information on birth weight, gestation at delivery, AFP level, hCG level and self-
report as smoker or non-smoker were selected for this analysis. Those who responded with 
stopped during or prior to pregnancy were excluded from further analysis. 
 
March 2006  March 2008 
Non-smokers  Smokers  Total  Non-smokers  Smokers  Total 
Cotinine 
(ng/ml) 
 
<13.7  95  4  99  96  4  100 
≥13.7  5  96  101  4  96  100 
Total  100  100  200  100  100  200 Chapter 4: Results 
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4.5.3.1 BIRTH WEIGHT AND SECOND TRIMESTER MARKERS   
Table 4.24 shows the mean birth weight of all the infants according to AFP level for non-
smokers and smokers. As the AFP level increased from <0.5 MoM to ≥2.0 MoM there was 
an overall reduction of 448.3g (p<0.05) in the mean birth weight in non-smokers and by 
619.2g (p<0.05) in smokers. For AFP levels less than 0.5 MoM, the percentage of infants 
born weighing less than 2500g was 5.8% for non-smokers and 11% for smokers. As the 
AFP MoM increased from 0.5 to ³2.0, the percentage of infants born weighing less than 
2500g increased gradually from 2.9% to 18.3% for non-smokers and 8.7% to 39.8% for 
smokers (Table 4.24).  
As hCG levels increased from < 0.5 to 1.99 MoM there was an increase (50.9g) in the 
mean birth weight in non smokers but this failed to reach statistical significant (p=0.068). 
The group of women with hCG ³2.0 MoM for both non-smokers and smokers had the 
lowest  mean  birth  weight  (3385.4g  in  non  smokers  and  3068.7g  in  smokers)  and  the 
greatest  percentage  of  infants  born  weighing  less  than  2500g  (7.9%  and  17.5% 
respectively) (Table 4.25).  
In pregnant women who reported smoking there was a significant (p<0.05) reduction in 
mean birth weight of infants (average 270g) across all the AFP MoM and hCG MoM 
groups  when  compared  to  birth  weight  in  non-smoking  pregnant  women.  Regression 
analysis showed that the trends in birth weight for non-smokers and smokers according to 
AFP and hCG levels were significant, with the most marked changes associated with AFP 
(Figure 4.7).  
Since low birth weight can be associated with earlier delivery (Wilcox and Johnson, 1992), 
and  smokers  tend  to  have  earlier  deliveries  (McCowan  et  al.,  2009)  the  data  were  re-Chapter 4: Results 
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analysed in those pregnancies delivered at  39 to 41 weeks of gestation. . Table 4.26 shows 
the mean birth weights of all the infants according to AFP level for these pregnancies. 
Women with high AFP levels at screening had lower birth weight babies and were more 
likely to have low birth weight (<2500g) babies than those with lower AFP but this was 
less marked than that seen with the whole dataset when all gestations at delivery were 
included.  Table  4.27  shows  the  equivalent  data  for  hCG.  Unlike  AFP  levels  and  birth 
weight,  there  was  no  clear  association  between  birth  weight  and  hCG  either  in  non-
smokers or smokers (Figure 4.8).  
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Table 4.24: Birth weight according to maternal serum AFP level for non-smokers and smokers in the study group of 15973 cases 
AFP level 
(MoM) 
No. of non-
smokers 
Birth weight (NS) (g) 
Infants born weighting 
2500g or less (NS)  No. of 
smokers 
Birth weight (S) (g) 
Infants born weighting 
2500g or less (S) 
Mean  95% CI  No.  %  Mean  95% CI  No.  % 
<0.50  189  3566.4  3454.9, 3677.9  11  5.8  73  3254.0  3125.4, 3382.7  8  11.0 
0.50 -  0.74  2102  3522.0  3499.4, 3544.5  60  2.9  733  3259.0  3209.9, 3308.0  64  8.7 
0.75 - 0.99  3837  3509.8  3491.8, 3527.8  135  3.5  1423  3195.7  3165.0, 3226.3  142  10.0 
1.00 - 1.49  4358  3461.0  3443.5, 3478.4  193  4.4  1781  3110.3  3081.7, 3138.9  246  13.8 
1.50 - 1.99  782  3337.1  3291.9, 3382.2  62  7.9  358  3028.9  2962.8, 3094.9  67  18.7 
>=2.00  229  3118.1  3008.9, 3227.4  42  18.3  108  2634.8  2482.3, 2787.4  43  39.8 
 
* NS – non-smokers, S – smokers 
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Table 4.25: Birth weight according to maternal serum hCG level for non-smokers and smokers in the study group of 15973 cases. 
   
hCG level 
(MoM) 
No. of non-
smokers 
Birth weight (NS) (g) 
Infants born weighting 
2500g or less (NS)  No. of 
smokers 
Birth weight (S) (g) 
Infants born weighting 
2500g or less (S) 
Mean  95% CI  No.  %  Mean  95% CI  No.  % 
<0.50  807  3457.9  3419.0, 3496.8  30  3.7  850  3119.8  3077.9, 3161.8  112  13.2 
0.50 – 0.74  1906  3465.4  3439.7, 3491.1  73  3.8  1272  3153.8  3119.9, 3187.7  153  12.0 
0.75 – 0.99  2283  3482.7  3459.6, 3505.8  84  3.7  967  3185.8  3149.0, 3222.6  104  10.8 
1.00 – 1.49  3595  3493.4  3474.7, 3512.1  141  3.9  970  3132.6  3092.2, 3173.0  132  13.6 
1.50 – 1.99  1684  3508.8  3478.7, 3538.9  78  4.6  263  3143.5  3045.5, 3241.4  42  16.0 
>=2.00  1222  3385.4  3348.4, 3422.3  97  7.9  154  3068.7  2958.4, 3179.0  27  17.5 
* NS – non-smokers, S – smoker 
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Figure 4.7 - Trend of birth weight for non-smokers and smokers according to AFP and 
hCG levels in the study group of 15973 cases. The mean birth weight decreased as the AFP 
level increased from < 0.5 to ≥ 2.00 MoM in non-smokers and smokers. The mean birth 
weight in smokers was lower compared to non-smokers in all AFPMoM groups. As for the 
hCG levels, there were insignificant increase in the mean birth weight in non-smokers as 
hCG levels increased from <0.5 to 1.99MoM. The mean birth weight was reduced in the 
group of women with hCG MoM ≥ 2.0 for non-smokers and smokers  
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Table 4.26: Birth weight according to maternal serum AFP level for non-smokers and smokers for the cases  delivered at 39 – 41 weeks. 
 
* NS – non-smokers, S – smokers 
AFP level 
(MoM) 
No. of non-
smokers 
Birth weight (NS) (g) 
Infants born weighting 
2500g or less (NS)  No. of 
smokers 
Birth weight (S) (g) 
Infants born weighting 
2500g or less (S) 
Mean  95% CI  No.  %  Mean  95% CI  No.  % 
<0.50  136  3663.3  3575.4, 3751.2  2  1.5  58  3356.1  3234.3, 3477.9  2  3.4 
0.50 – 0.74  1627  3607.5  3586.0, 3629.0  8  0.5  547  3389.3  3343.4, 3435.3  14  2.6 
0.75 – 0.99  2888  3615.9  3599.6, 3632.3  10  0.3  1010  3344.8  3317.1, 3372.5  26  2.3 
1.00 – 1.49  3137  3595.5  3579.1, 3611.9  18  0.6  1176  3300.0  3273.4, 3326.6  48  4.1 
1.50 – 1.99  499  3543.7  3499.4, 3588.1  11  2.2  213  3315.7  3254.8, 3376.6  10  4.7 
>=2.00  129  3483.9  3397.2, 3570.6  5  3.9  48  3154.9  3002.3, 3307.5  9  18.8  
174 
 
 
Table 4.27: Birth weight according to maternal serum hCG level for non-smokers and smokers for the cases  delivered at 39 – 41 weeks. 
 
hCG level 
(MoM) 
No. of non-
smokers 
Birth weight (NS) (g) 
Infants born weighting 
2500g or less (NS)  No. of 
smokers 
Birth weight (S) (g) 
Infants born weighting 
2500g or less (S) 
Mean  95% CI  No.  %  Mean  95% CI  No.  % 
<0.50  591  3581.3  3546.1, 3616.6  1  0.2  575  3275.9  3238.5, 3313.2  23  4.0 
0.50 – 0.74  1434  3566.2  3542.8, 3589.7  10  0.7  887  3324.3  3293.1, 3355.5  34  3.8 
0.75 – 0.99  1673  3595.0  3573.5, 3616.6  13  0.8  692  3347.1  3313.6, 3380.6  20  2.9 
1.00 – 1.49  2676  3614.6  3596.9, 3632.3  12  0.4  634  3343.8  3308.6, 3379.0  22  3.5 
1.50 – 1.99  1217  3635.4  3608.8, 3662.0  9  0.7  164  3433.5  3326.3, 3540.6  7  4.3 
>=2.00  825  3594.3  3562.2, 3626.4  9  1.1  100  3338.7  3239.2, 3438.1  3  3.0 
* NS – non-smokers, S – smokers                                                                                                                                                     Chapter 4: Results 
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Figure 4.8 - Trend of birth weight for non-smokers and smokers according to AFP and 
hCG  levels  for  the  cases    delivered  at  39  –  41  weeks.  There  was  a  general  trend  of 
declining birth weight as AFP MoM increased from < 0.5 to ≥ 2.0 in non-smokers and 
smokers but there was no clear association between birth weight and hCG level either in 
non-smokers or smokers.                                                                                                                                                      Chapter 4: Results 
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4.5.3.2 GESTATION AT DELIVERY AND SECOND TRIMESTER MARKERS 
The median gestation at delivery was 40 weeks for non smokers and 39 weeks for smokers. 
Table 4.28 shows the median gestation at delivery and percentage of pregnancies delivered 
at 38 weeks and less according to AFP level for non-smokers and smokers. The percentage 
of pregnancies delivered at 38 weeks or less increased as AFP MoM increased in non-
smokers and smokers. In smokers with AFP levels greater than 2.0 MoM over half (55.6%) 
delivered at 38 weeks or earlier compared to 40.2% in non-smokers. There was no clear 
association between hCG level and the percentage of pregnancies delivered at 38 weeks or 
earlier in the non-smoking and smoking groups (table 4.29). As might be expected, given 
the known association between smoking and low birth weight and premature delivery, the 
percentage of pregnancies delivered at 38 weeks and earlier was higher in the smoking 
group compared to the non-smoking group in all but one of the AFP MoM groups and all 
hCG MoM groups (Figure 4.9).  
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 Table 4.28: Percentage of pregnancies delivered at 38 weeks or less for non-smokers and smokers according to AFP levels 
 
 
 
 
 
 
 
 
 
 
 * NS – non-smokers, S – smokers 
 
 
AFP level 
(MoM) 
No. of non-
smokers 
Median gestation at 
delivery (NS) 
Pregnancies delivered at 38 
weeks and less (NS)  No. of 
smokers 
Median gestation at 
delivery (S) 
Pregnancies delivered at 38 
weeks and less (S) 
No  %  No.  % 
<0.50  189  40  47  24.9  73  40  12  16.4 
0.50 – 0.74  2102  40  415  19.7  733  40  168  22.9 
0.75 – 0.99  3837  40  833  21.7  1423  39  385  27.1 
1.00 – 1.49  4358  40  1082  24.8  1781  39  565  31.7 
1.50 – 1.99  782  39  260  33.2  358  39  136  38.0 
>=2.00  229  39  92  40.2  108  38  60  55.6  
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Table 4.29: Percentage of pregnancies delivered at 38 weeks or less for non-smokers and smokers according to hCG levels 
          * NS – non-smokers, S – smokes
hCG level 
(MoM) 
No. of non-
smokers 
Median gestation at 
delivery (NS) 
Pregnancies delivered at 38 
weeks and less (NS)  No. of 
smokers 
Median gestation at 
delivery (S) 
Pregnancies delivered at 38 
weeks and less (S) 
No  %  No.  % 
<0.50  807  39  192  23.8  850  39  267  31.4 
0.50 – 0.74  1906  40  425  22.3  1272  39  357  28.1 
0.75 – 0.99  2283  40  543  23.8  967  40  253  26.2 
1.00 – 1.49  3595  40  805  22.4  970  39  312  32.2 
1.50 – 1.99  1684  40  401  23.8  263  39  90  34.2 
>=2.00  1222  39  363  29.7  154  39  47  30.5                                                                                                                                           Chapter 4: Results 
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Figure 4.9 – The percentage of pregnancies delivered at 38 weeks or less according to 
AFP and hCG levels for non-smokers and smokers. As AFP levels increased from 0.75 to 
≥ 2.0 MoM there was an increase in the percentage of pregnancies delivered at 38 weeks 
or less in non-smokers and smokers. There was no clear association between hCG levels 
and the percentage of pregnancies delivered at 38 weeks or less either in non-smokers or 
smokers. The percentage of pregnancies delivered at 38 weeks or less was higher in the 
smoking group compared to the non-smoking group                                                                                                                                      Chapter 5:Discussion 
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5.1  RETROSPECTIVE  STUDY  ON  WITHIN-TRIMESTER 
CONTINGENT SCREENING 
CUB screening using PAPP-A, fβhCG and NT measurement is proven to be an effective 
method of detecting Down syndrome pregnancies in the first trimester, with a detection 
rates of 85-91% at a 4-5% screen positive rate (Spencer et al., 2000a; Stenhouse et al., 
2004; Perni et al., 2006). However, this screening policy requires considerable investment 
in  ultrasound  equipment  and  operator  training  to  maintain  the  required  standard  when 
screening large numbers of pregnant women.  
In this model of first-trimester contingent screening, women who are found to have a high 
risk based on the initial biochemical test and maternal age are not offered NT measurement 
because  these  women  will  end  up  with  a  final  risk  ≥1:250  irrespective  of  the  NT 
measurement. Women with a low risk will also not be offered NT measurement as their 
risk is unlikely to be modified sufficiently to reach the final cut-off. Thus, this form of 
contingent screening allows those centres with limited resources to target the group of 
pregnant women whose screening results can be most usefully modified by information 
from  an  NT  measurement.  This  study  showed  that  this  contingent  screening  protocol 
would have achieved a detection rate of 88.7% at a false positive rate of 5.8% but with 
only 29% of women requiring an NT measurement. The results of the within-trimester 
contingent screening study are presented in Section 4.1. 
 This  form  of  within-trimester  contingent  testing  has  other  advantages.  Unlike  across-
trimester integrated testing (Wald et al., 1999a) where there is no disclosure of results after 
the first stage of testing, by the contingent method described here all women receive a risk 
result following their initial PAPP-A/fβhCG test. Decisions on whether to proceed to NT                                                                                                                                      Chapter 5:Discussion 
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measurement  or  not  are  therefore  based  on  the  woman’s  awareness  of  clearly  defined 
criteria, which aid counselling and are likely to help ensure that women do not default on 
their NT appointment. Further, all women complete screening before the end of the first 
trimester  and  more  than  two-thirds  (which  also  includes  60%  of  the  Down  syndrome 
pregnancies) complete screening at an even earlier stage when there is no requirement to 
carry out an NT measurement. 
To maximise the efficiency of this screening protocol it is important that women attend the 
initial blood sampling test as early as possible to allow time for those women requiring an 
NT scan to return no later than 14 weeks + 0 days of gestation. Although the number of 
women  requiring  an  NT  scan  is  reduced,  ultrasound  assessment  of  gestation  is 
indispensable in all cases as this information is essential for accurate interpretation of the 
serum marker results. Therefore, ultrasound assessment of gestation is essential in order to 
maintain the sensitivity and specificity of the screening policy. However a dating scan is 
generally less time consuming than an NT scan, and can be carried out by staff without 
specific training in NT measurement. 
Due to limited availability of ultrasound resources in some centres, gestational age is often 
determined by relying on LMP. The accuracy of LMP based gestational age is affected by 
the variation in menstrual cycle duration, non-menstrual vaginal bleeding, maternal recall 
error  and  clerical  error  (Wier  et  al.,  2007).  However,  in  areas  with  limited  ultrasound 
resources, LMP is the most practical method of determining gestational age. In this study, 
the performance of this screening policy was re-evaluated by using LMP based gestational 
age at the first stage of screening (refer to section 4.1). In pregnancies with certain LMP 
dates, this screening policy would have achieved a similar detection rate of 88.9% at the                                                                                                                                      Chapter 5:Discussion 
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cost of an increase in the false positive rate from 5.8% to 7.0%. Thus, using LMP based 
gestation in the first stage of screening for pregnancies with certain LMP dates degrades 
the performance of screening achievable by reliance on ultrasound estimation of gestation. 
However, performance remains acceptable and allows those centres with limited resources 
of ultrasound to provide risks for the group of pregnant women who are uncertain of their 
LMP dates.  
Although  the  performance  of  within-trimester  contingent  screening  using  LMP  based 
gestational  age  is  acceptable,  multiple  pregnany  will  not  be  identified.  Therefore, 
ultrasound scan in the first trimester remains essential to assess accurate gestational age 
and identify multiple pregnany.  
This form of contingent testing could be modified through the use of alternative serum 
markers  measured  earlier  in  pregnancy.  It  is  well  known  that  PAPP-A  has  better 
discriminatory power earlier in pregnancy at 8 weeks of gestation (Spencer et al., 2002) 
while other markers, notably total or intact hCG (Spencer et al., 2002), InhA (Christiansen 
and Nørgaard-Pederson, 2005) and ADAM12 (Laigaard et al., 2006b) may also perform 
better than fβhCG at this early stage. However, in routine CUB screening, PAPP-A and 
fβhCG are usually measured at the same gestation as NT at 11–13 weeks, and at that stage 
the reduced power of PAPP-A is compensated by the increased power of fβhCG. In this 
contingent model, a detection rate of 61.4% at a 3.1% false positive rate was predicted 
using  serum  markers  plus  maternal  age  alone  (i.e.  without  NT  measurement).  This  is 
similar to that estimated by Cuckle (2000) of 64.9% detection with a false positive rate of 
5%, and by Spencer et al. (2003d) of 64.7% detection with a false positive rate of 5%. It is 
likely that additional serum markers assayed in early pregnancy may improve the primary                                                                                                                                      Chapter 5:Discussion 
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screen detection rate even further. However, the selective addition of NT measurements as 
shown here, adds to screening performance and should be used wherever resources allow. 
Ultrasound based gestational age is also essential in order to meet the standard screening 
recommendations.  
5.2 CROSS-TRIMESTER CONTINGENT SCREENING 
The SURUSS trial reported that integrated testing is the most effective screening method 
for Down’s syndrome with detection rates of 93% at a 5% false positive rate (Wald et al., 
2003). However, this screening policy has many disadvantages. The results from the first 
trimester test will not be interpreted or informed to the patients until the second trimester 
test is performed. This could deprive many pregnant women the chance of getting early 
diagnostic tests and increases the anxiety due to the long wait for the test results until the 
second trimester.  
One  possible  compromise  solution  is  cross-trimester  contingent  screening.  In  this 
screening  policy  all  women  receive  an  initial  estimate  of  risk  but  only  women  with 
intermediate risks are offered a second trimester screening test. Women who are found to 
have a high risk based on the initial first trimester screening test and maternal age are not 
offered a second trimester screening test because these women will end up with a final risk 
≥1:150 irrespective of the second trimester screening test results. Women with a low risk 
will also not be offered a second trimester screening test as their risk is unlikely to be 
modified sufficiently to reach the final cut-off. This study has shown that this screening 
policy with repeat measure of PAPP-A could achieve a detection rate of 92.2% at a false 
positive rate of 1.4% but with only 9.7% of women requiring a second trimester screening 
test (refer to section 4.2.2). In this study, an early detection rate of 75.9% at a false positive                                                                                                                                      Chapter 5:Discussion 
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rate of 0.7% was estimated using NT, fβhCG and PAPP-A and maternal age in the first 
trimester.  This  is  similar  to  that  estimated  by  Cuckle  et  al  (2005)  using  statistical 
modelling of 70.0% early detection at a false positive rate of 0.7%, and by Cuckle et al 
(2008) of 60% detection with a false positive rate of 1.2% using FASTER trial data. Table 
5.1 shows the performance of cross-trimester contingent screening from various studies for 
the full cross-trimester screen and also after the initial (first trimester) test.  
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Table 5.1: Performance of cross-trimester contingent screening from various studies.
Studies  Marker combination 
Overall    1
st trimester 
DR (%)  FPR (%)  2
nd trimester 
frequency (%)* 
  DR (%)  FPR (%) 
Benn et al (2005) 
NT,  fβhCG, PAPP-A/  
AFP, fβhCG, uE3, InhA 
90.4  2.3  20.7 
 
60.4  0.3 
Cuckle et al (2005) 
NT,  fβhCG, PAPP-A/  
AFP, fβhCG, uE3, InhA 
92.0  3.0  15.0 
 
70.0  0.7 
Wald et al (2006) 
NT,  fβhCG, PAPP-A/  
AFP, fβhCG, uE3, InhA 
89.8  2.4  21.4 
 
66.0  0.5 
Cuckle et al (2008) 
NT,  fβhCG, PAPP-A/  
AFP, hCG, uE3, InhA 
91.0  4.5  23.0 
 
60.0  1.2 
This study 
NT,  fβhCG, PAPP-A/  
AFP, fβhCG, uE3, InhA 
90.6  1.8  9.7 
 
75.9  0.7 
This study 
NT,  fβhCG, PAPP-A/  
AFP, fβhCG, uE3, InhA, PAPP-A 
91.9  1.5  9.7 
 
75.9  0.7 
*Proportion of women requiring a second trimester test. Chapter 5:Discussion 
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The  cross-trimester  contingent  screening  policy  could  not  only  achieve  a  screening 
performance similar to the full integrated test, but also permits clinicians to disclose the 
first trimester screening results to the patient. This screening policy also allows women 
with an extremely high risk of carrying Down’s syndrome fetus to have an early diagnosis. 
Furthermore, more than two-third of women with unaffected pregnancies can avoid the 
second trimester screening test and thus, have early completion of screening. However, due 
to the complexity of this screening policy, it needs to be explained to women through 
counselling sessions why different risk cut-offs are used at each stage of screening. The 
acceptability or otherwise of this screening policy to pregnant women is unknown. 
The potential value of using highly correlated repeated measures of serum markers taken in 
the first and second trimester of pregnancy was first demonstrated by Wright and Bradbury 
(2005). The statistical modelling in this study shows that, in the cross-trimester contingent 
screening, there is a substantial benefit of adding repeated measurement of PAPP-A in the 
second trimester. At 11 weeks, adding repeated measurement of PAPP-A to a base test 
comprising NT, PAPP-A and fβhCG in the first trimester and AFP, hCG, uE3 and InhA in 
the second increases the detection rate by 1.1% from 91.1% to 92.2% and decreases the 
false positive rate by 0.2% from 1.6% to 1.4%. 
 
This study has also shown that the performance of this screening policy deteriorates when 
a larger SD is used for affected cases (Tables 4.11c and 4.11d). However, the differences 
in  the  overall  screening  performance  when  same  SDs  were  used  for  unaffected  and 
affected cases compared to using a larger SD for affected cases were small.     Chapter 5:Discussion 
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Most of the marker parameters used in this analysis are considered to be unbiased as these 
parameters were taken from a meta-analysis of several studies comprising several hundred 
Down’s syndrome cases (Aitken et al, 2007, Spencer et al., 2002, Cuckle et al., 2005). 
Although statistical modelling is a useful tool to evaluate the efficacy of Down’s syndrome 
screening policy, modelling is based on assumptions which may cause overestimation of 
the screening performance. For example, in this analysis, it is assumed that a Gaussian fit 
is reasonable in the tails of a multivariate distribution whereas in practice this will rarely be 
the case. Therefore, it is important to carry out prospective intervention studies in order to 
confirm the performance of testing and the practicality  and acceptability  of this cross-
trimester contingent screening policy.   
5.3  EFFECT  OF  SMOKING  AND  ETHNICITY  ON 
BIOCHEMICAL MARKERS 
This study (refer to section 3.3) confirmed previous findings that maternal smoking habits 
and ethnic origin affect the biochemical marker levels in Down’s syndrome screening. A 
unique aspect of this study was the use of paired first and second trimester serum samples 
in  939  women  allowing  for  an  assessment  of  the  trends  in  marker  levels  between 
gestations.  This  study  has  showed  that  the  pattern  of  change  caused  by  smoking  and 
ethnicity on biochemical markers varies from marker to marker and trimester to trimester. 
The results of the effect of smoking and ethnicity are presented in Section 4.3. 
In the data presented here markedly higher levels of AFP in the first trimester but only 
slightly higher in the second trimester were found in smokers with unaffected singleton 
pregnancies. A significant reduction in hCG and PAPP-A levels was also found in both the 
first and second trimesters in smokers. The fβhCG level was significantly decreased in Chapter 5:Discussion 
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smokers in the second trimester but not in first trimester. Similar patterns of change have 
been  reported  in  previous  studies.  Table  5.2  shows  the  summary  of  first  and  second 
trimester marker levels in non-smokers and smokers in this and previous studies.  
Overall, in this study, there was a 14.0% reduction in PAPP-A, a 1.6% reduction in fβhCG, 
a 16.3% elevation in AFP and a 27.6% reduction in hCG in the first trimester. In the 
second trimester, there was a 6.1% elevation in AFP, a 30.5% reduction in hCG, a 17.1% 
reduction  in  fβhCG  and  a  22.8%  reduction  in  PAPP-A.  Comparing  with  other  studies 
which  show  reduced  fβhCG  levels  ranging  from  3.0%  to  13.0%,  this  study  showed  a 
smaller reduction in fβhCG level in the first trimester in smokers but confirms the trend to 
larger reduction (20% to 30%) in the second trimester. This study has also shown that in 
smokers, with the exception of AFP, marker levels tend to show larger changes in the 
second trimester than in the first trimester. PAPP-A, hCG and fβhCG are produced by the 
placenta  whereas  AFP  is  of  fetal  origin  and  is  transported  across  the  placenta  to  the 
maternal circulation.   
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Table 5.2: Summary of first and second trimester marker levels in non-smokers and smokers in this and previous studies
Studies 
First trimester    Second trimester 
PAPP-A  FβhCG  AFP  hCG    PAPP-A  FβhCG  AFP  hCG 
Bartels et al (1993)                ↑ 4.5%  ↓ 20.1 
Spencer (1998)              ↓ 13.9%   ↑ 3.0%   
 de Graaf et al (2000)  ↓ 24.3%  ↓ 11%  ↑ 3.1%             
Crossley et al (2002b)                ↑ 5.1%  ↓ 29.2 
Rudnicka et al (2002)              ↓ 20.0%  ↑ 5.0%   
Spencer et al (2004)  ↓ 17.6%  ↓ 3.0%               
Kagan et al (2007)  ↓ 19.6%  ↓ 3.1%               
Miron et al (2008)  ↓ 16.5%  ↓ 13.0%               
Kagan et al (2009)  ↓ 17.0%  ↓ 4.0%               
Present study  ↓ 14.0%  ↓ 1.6%  ↑ 16.3%  ↓ 27.6%    ↓ 22.8%  ↓ 17.1%  ↑ 6.1%  ↓ 30.5% 
Weighted average  ↓ 18.3%  ↓ 5.6%  ↑ 6.4%  ↓ 27.6%    ↓ 22.8%  ↓ 15.3%  ↑ 3.7%  ↓ 23.3% 
Correction factor  0.82  0.94  1.06  0.72    0.77  0.85  1.04  0.77 Chapter 5:Discussion  
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The reason behind these changes in the marker concentration is not clearly understood.  
Jauniaux and Burton (1992) demonstrated that smoking causes morphological changes in 
the  trophoblast  which  might  explain  the  disturbance  in  hCG  production  or  increased 
permeability  of  the  placenta  promoting  increased  transfer  of  AFP  across  the  placental 
barrier. PAPP-A is another placental protein produced by syncytiotrophoblast and studies 
have shown that there is an increase in syncytiotrophoblast necrosis in smokers (Jauniaux 
and Burton, 1992; Zdravkovic et al., 2005). The further decrease in hCG, PAPP-A and 
fβhCG levels evident in the second trimester suggest that there is an increased effect on the 
placenta  in  women  who  continued  smoking  during  pregnancy  which  causes  further 
reduction in production of these markers. Therefore, it is important to derive appropriate 
correction factors for smoking for each trimester for individual biochemical markers.  
Those who are smokers among the pregnant population tend to be younger than those who 
are non-smokers. Due to the marked difference in the age distribution of those pregnant 
women  who  smoke  compared  with  those  who  do  not,  the  expected  rate  of  Down’s 
syndrome in pregnant women who smoke will be lower (Spencer et al., 1998, Crossley et 
al.,  2002b,  Spencer  et  al.,  2004).  Therefore,  it  is  important  to  take  into  account  the 
maternal  age  effect  when  studying  the  incidence  of  Down’s  syndrome  in  women  who 
smoke.  
Ethnic origin has an impact on the biochemical marker levels, which cannot be explained 
by differences in maternal weight. Results from this study based on 939 pairs of first and 
second trimester samples along with the results from other studies are summarised in Table 
5.3. In this study (see section 3.3), after maternal weight adjustment, South Asian women 
had a significantly higher level of first trimester hCG compared to Caucasians. In the first Chapter 5:Discussion  
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trimester, although the fβhCG and PAPP-A levels were slightly decreased compared to 
Caucasian, the differences were not significant. This finding is in contrast to Spencer et al 
(2005b)  who  reported  that  South  Asian  women  had  higher  PAPP-A  and  lower  fβhCG 
levels compared to Caucasians. This difference might be due to a larger South Asian data 
in Spencer et al (2005b) compared to this study. 
In this study the Oriental women had higher levels of first trimester hCG, fβhCG and 
PAPP-A compared to Caucasian. This finding is similar to that of Spencer et al (2005b) 
that Oriental women had higher levels of PAPP-A and fβhCG compared to Caucasians. In 
the data presented in this study, after weight correction, Black women had higher levels of 
first trimester hCG and PAPP-A but slightly lower fβhCG levels compared to Caucasian. 
These findings are in contrast to Krantz et al (2005), Spencer et al (2005b) and Spencer et 
al  (2000e)  who  found  that  fβhCG  level  was  higher  in  Black  women  compared  to 
Caucasian. In this study a cohort of Middle East women were identified who had lower 
levels of AFP in the first trimester after weight adjustment compared to Caucasian. 
South Asian women had significantly lower levels of second trimester fβhCG and PAPPA 
but similar AFP and hCG levels compared to Caucasian. These findings were in contrast to 
Watt et al (1996) who found higher hCG and lower AFP levels in South Asian women 
compared to Caucasian. However, Watt et al (1996) also found similar decrease in fβhCG 
levels in South Asian women compared to Caucasian.  
Oriental women had higher levels of second trimester hCG compared to Caucasians. The 
AFP levels were slightly lower and fβhCG were higher in Oriental women compared to 
Caucasian but the difference was not significant. Hseih et al (1995) reported 2.9% higher 
fβhCG  and  10%  lower  AFP  in  the  Taiwan  population  compared  to  Caucasians.  Black Chapter 5:Discussion  
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women had significantly higher PAPP-A levels in the second trimester but similar levels of 
AFP, hCG and fβhCG compared to Caucasian women. These finding are in contrast to 
previous  studies  which  reported  higher  AFP,  hCG  and  fβhCG  levels  in  Black  women 
compared to Caucasian (Benn et al., 1997, Watt et al., 1996, Kulch et al., 1993).  
It  is  possible  that  some  of  the  findings  from  this  study  which  are  at  odds  with  those 
reported in other studies may be due to the small number of women in each ethnic group 
(especially the Black population) and the difficulty of ensuring that ethnic categories are 
the same between studies. However, the use of paired first and second trimester serum 
samples allows an assessment of the relative change in marker levels between trimesters 
and the results suggest that the changes are more marked for PAPP-A and fβhCG in the 
second trimester, but greater for hCG in the first trimester. Table 5.3 shows the summary 
of first and second trimester marker levels in different ethnic origins in this and previous 
studies.   
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Table 5.3: Summary of first and second trimester marker levels in different ethnic groups in this and previous studies. 
 
Studies  Ethnic origin 
First trimester    Second trimester 
PAPP-A  FβhCG  AFP  hCG    PAPP-A  FβhCG  AFP  hCG 
Kulch et al (1993)  Black (n = 134)                  ↑ 16.0% 
Watt et al (1996)  Black (n = 4215)              ↑ 12.0%  ↑ 22.0%  ↑ 19.0% 
  South Asian (n = 4392)              ↓ 9.0%  ↓ 6.0%  ↑ 6.0% 
Spencer et al (2000e)  Black (n = 752)  ↑ 57.0%  ↑ 21.0%               
  Asian (n = 170)  ↑ 17.0%  ↑ 4.0%               
Spencer et al (2005b)  Black (n = 2943)  ↑ 55.0%  ↑ 11.0%               
  South Asian (n = 4835)  ↑ 8.0%  ↓ 7.5%               
  Oriental (n = 3925)  ↑ 9.0%  ↑ 6.0%               
Krantz et al (2005)  African Americans (n = 2682)  ↑ 35.0%  ↑ 16.0%               
  Asians (n = 2228)    ↑ 6.0%               
  Hispanic (n = 2795)    ↓ 9.0%               
Kagan et al (2009)  Black (n = 2144)  ↑ 57.0%  ↑ 12.0%               
Present study  South Asian (n=268)  ↓ 3.0%  ↓ 10.7  ↓ 0.7%  ↑ 6.7%    ↓ 8.1%  ↓ 13.6%  ↓ 3.5%  ↓ 2.2% 
  Oriental (n=66)  ↑ 20.9%  ↑ 5.9%  ↓ 1.6%  ↑ 37.8%    ↑ 12.4%  ↑ 6.9%  ↓ 3.2%  ↑ 18.4% 
  Middle Easterner (n=42)  ↓ 7.2%  ↓ 0.1%  ↓ 11.6%  ↑ 10.0%    ↓ 3.6%  ↓ 0.6%  ↓ 5.4%  ↑ 8.2% 
  Black (n=35)  ↑ 43.2%  ↓ 4.0%  ↑ 7.3%  ↑ 23.1%    ↑ 60.1%  ↓ 10.0%  ↓ 0.2%  ↓ 9.2% 
Weighted average  Black  ↑ 49.4%  ↑ 13.6%  ↑ 7.3%  ↑ 23.1%    ↑ 60.1%  ↑11.8%  ↑21.8%  ↑18.7% 
  South Asian  ↑ 7.4%  ↓ 7.7%  ↓ 0.7%  ↑ 6.7%    ↓ 8.1%  ↓ 9.3%  ↓ 5.9%  ↑ 5.5% 
  Oriental  ↑ 9.2%  ↑ 6.0%  ↓ 1.6%  ↑ 37.8%    ↑ 12.4%  ↑ 6.9%  ↓ 3.2%  ↑ 18.4% 
Correction factors  Black  1.49  1.14  1.07  1.23    1.60  1.12  1.22  1.19 
  South Asian  1.07  0.92  0.99  1.07    0.92  0.91  0.94  1.06 
  Oriental  1.09  1.06  0.98  1.38    1.12  1.07  0.97  1.18 Chapter 5: Discussion  
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Watt et al (1996) proposed a method to derive the median MoM of second trimester serum 
markers in a multiethnic population. In this approach, the ratios of median MoM in an 
ethnic group (e.g Black population) to that in the main ethnic group (e.g. Caucasian) were 
used to correct the marker concentration in different ethnic groups. Such an approach is 
useful if there is insufficient data for a particular ethnic group. If there is an adequate 
number of women in each ethnic group, separate MoM equations can be derived for each 
ethnic group. 
 In terms of screening for Down’s syndrome by first and second trimester markers, it is 
important to take into account maternal smoking habit and ethnic origin when a risk is 
calculated.  Correcting  for  smoking  and  ethnicity  can  be  performed  by  dividing  the 
appropriate  MoM  by  the  correction  factors  given  in  Tables  5.2  and  5.3.  Although 
correcting for smoking and ethnicity has little impact on the overall Down’s syndrome 
screening performance,  it will provide individual women with more accurate risks and 
contribute  to  reduction  in  the  screen  positive  rate.  Reducing  the  number  of  women 
requiring diagnostic testing is generally desirable and particularly so in ART pregnancies 
where there is increased reluctance to expose the pregnancy to the risk of procedure-related 
miscarriage.    More  data  are  required  to  explore  the  combined  effect  of  smoking  and 
ethnicity on marker levels.  Chapter 5: Discussion  
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5.4  EFFECT  OF  ASSISTED  REPRODUCTIVE  TECHNOLOGY 
ON FIRST AND SECOND TRIMESTER SERUM MARKERS 
In this screened population, approximately 50% of women conceived by ART are aged 35 
years or more. Due to their age-related risk, these women are often classified as ‘at risk’ 
following a Down’s syndrome screening. The effect of ART on Down’s syndrome markers 
still remains to be clarified. In this study, in the overall ART group, PAPP-A and fβhCG 
levels  were  not  significantly  different  from  the  levels  found  in  naturally  conceived 
pregnancies. The first trimester screening marker PAPP-A was significantly decreased in 
pregnancies conceived through IVF or ICSI with fresh eggs compared with pregnancies 
which were conceived spontaneously. This is in line with previous findings (Gjerris et al., 
2009, Anckaert et al., 2008, Tul and Novak-Antolic, 2006, Hui et al., 2005, Liao et al., 
2001). In pregnancies conceived after IVF or ICSI with frozen embryo, there were no 
significant differences in the PAPP-A level. Gjerris et al (2009) and Anckaert et al (2008) 
also  reported  similar  findings  that  the  median  PAPP-A  MoM  was  not  significantly 
different in the pregnancies conceived after frozen embryo transfer from that in naturally 
conceived pregnancies. The results are presented in section 4.4 and summarised along with 
the results of other studies in tables 5.4 and 5.5. 
In this study no significant difference in the concentration of fβhCG between ART and 
normally conceived pregnancies was found. This is in agreement with most of previous 
studies (Gjerris et al., 2009, Anckaert et al., 2008, Tul and Novak-Antolic, 2006, Lambert-
Messerlian et al., 2006) although a few papers have reported an increase in the fβhCG 
concentration (Ghisoni et al., 2003, Wojdemann et al., 2001).  
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In this study in the overall ART group, NT measurements were significantly increased over 
the  measurements  found  in  naturally  conceived  pregnancies.  NT  measurement  was 
significantly increased in the pregnancies conceived after IVF with fresh eggs. However, 
the majority of previous studies found no significant difference in the NT measurement in 
ART pregnancies compared with spontaneously conceived pregnancies (Liao et al., 2001, 
Orlandi et al., 2002, Maymon and Shulman, 2002 and Tul and Novak-Antolic, 2006). But 
Maymon and Shulman (2004) and Hui et al (2005) reported that NT measurement was 
significantly  increased  in  pregnancies  with  fresh  embryos  from  IVF,  frozen-thawed 
embryos from IVF and fresh embryos from ICSI. 
In 2009, Amor and co-workers conducted one of the largest and comprehensive studies on 
the  effect  of  ART  on  first  trimester  Down’s  syndrome  markers.  This  study,  which 
comprised  more  than  1,700  ART  pregnancies,  showed  that  PAPP-A  levels  were 
significantly lower in ART pregnancies compared with non-ART pregnancies. There were 
no significant differences in NT measurement and fβhCG levels between ART and non-
ART pregnancies. Another prospective study of 1000 ART pregnancies by Gjerris et al 
(2009)  showed  that  PAPP-A  levels  were  significantly  decreased  in  IVF  and  ICSI 
pregnancies compared to naturally conceived pregnancies. 
  
In this study, the concentration of second trimester AFP was significantly increased but not 
the concentration of hCG in pregnancies conceived after IVF with donor’s egg compared 
with naturally conceived pregnancies. There was no significance differences in the AFP 
levels in pregnancies conceived after IVF with fresh eggs or frozen embryos. This is in 
agreement with previous studies (Lambert-Messerlian et al., 2006, Shulman and Maymon, 
2003,  Perheentupa  et  al.,  2002;  Maymon  and  Shulman,  2001).  In  this  study  the Chapter 5: Discussion  
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concentration of total hCG was significantly increased in pregnancies treated with IVF 
with fresh and frozen eggs compared with naturally conceived pregnancies, in line with 
most previous studies (Lambert-Messerlian et al., 2006, Maymon and Shulman, 2001). In 
contrast to these findings, Muller et al (2003) and Rice et al (2005) reported that there 
were  no  significant  differences  in  the  second  trimester  markers  in  ART  pregnancies 
compared with naturally conceived pregnancies. Tables 5.4 and 5.5 show the overview of 
studies on the first and second trimester markers levels in ART pregnancies. 
 
The changes in the marker level in ART pregnancies might have an effect on the false 
positive rate. Numerous studies have confirmed that ART increases the second trimester 
serum marker false positive rate (Barkai et al., 1996b, Ribbert et al., 1996, Heinonen et al., 
1996, Frishman et al., 1997, Maymon et al., 1999, Raty et al., 2002). Lambert-Messerlian 
et al (2006) reported that the decrease in uE3 levels and increase in hCG and InhA levels 
in IVF pregnancies causes significant increase in the second trimester screen positive rate. 
But in the first trimester, Lambert-Messerlian et al (2006) reported that the differences in 
the first trimester serum marker levels were not sufficient to affect the screen positive rate. 
This is in agreement with previous other studies (Tul and Novak-Antolic, 2006; Bellver et 
al., 2005). However two other studies (Gjerris  et al., 2009; Orlandi et  al., 2002) have 
reported  higher  false  positive  rate  in  ART  pregnancies  when  compared  with  naturally 
conceived pregnancies in the first trimester.    
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Table 5.4: Comparison of studies on the first trimester Down’s syndrome markers in pregnancies achieved naturally and by assisted reproduction 
 
Studies  Natural conception  ART pregnancies  PAPP-A  FβhCG  NT measurement 
Liao et al (2001)  1233  220 (IVF)  ↓  ↑  = 
    30 (ICSI)  ↓  =  = 
Orlandi et al (2002)  370  32 (IVF)  ↓  =  = 
    42 (ICSI)  =  =  = 
Ghisoni et al (2003)  426  50 (IVF)  =  ↑  = 
    92 (ICSI)  =  ↑  = 
Maymon and Shulman (2004)  1781  99 (IVF)  ↓  N/A  ↑ 
Tul and Novak-Antolic (2006)  914  130 IVF  ↓  =  = 
    54 ICSI  ↓  =  = 
Lambert-Messerlian et al. (2006)  37,070  277 IVF  =  =  = 
    56 (IVF with egg donation)  =  =   
Anckaert et al. (2008)  4088  59 IVF  ↓  =  N/A 
    163 ICSI  ↓  =  N/A 
Gjerris et al (2009)  2532  512 (IVF)  ↓  =  = 
    396 (ICSI)  ↓  =  = 
Kagan et al., (2009)   18829  784 (IVF)  ↓  ↑  N/A 
This study  10891  91 (IVF or ICSI with fresh eggs)  ↓  =  ↑ 
    29 (IVF or ICSI with frozen embryos)  =  =  = 
    7 ( IVF with donor’s eggs)  =  =  =  
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Table 5.5: Comparison of studies on the second trimester Down’s syndrome markers in pregnancies achieved naturally and by assisted reproduction 
 
Studies  Natural conception  ART pregnancies  AFP  hCG 
Maymon and Shulman (2002)  285  71 (IVF)  ↑  = 
Muller et al (2003)  21014  970 (IVF)  =  = 
    545 (ICSI + IVF)  =  = 
Maymon and Shulman (2004)  1781  99 (IVF)  =  = 
Rice et al (2005)  596  88 (IVF)  =  = 
Lambert-Messerlian et al (2006)  37,070  277 IVF  =  ↑ 
    56 (IVF with egg donation)  ↑  = 
This study  61448  105 (IVF or ICSI with fresh eggs)  =  ↑ 
    15 (IVF or ICSI with frozen embryos)  =  ↑ 
    9 ( IVF with donor’s eggs)  ↑  = Chapter 5: Discussion  
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The contradictory results from previous studies are possibly due to different underlying 
causes  of  infertility  and  different  treatment  methods.  Tul  and  Novak-Antolic  (2006) 
reported that with an increasing number of retrieved oocytes, the concentration of PAPP-A 
was significantly decreasing and InhA was increasing but not statistically significantly. 
Based on their finding that InhA, which is secreted by the corpus luteum, was increased 
with decreasing PAPP-A, the authors hypothesized that the number of oocytes retrieved 
reflected the number of corpora lutea in pregnancy. The authors proposed that the secretion 
of PAPP-A is hampered by InhA. Hui et al (2005) suggested that a delay in placental 
maturation causes decreased PAPP-A level. The author also suggested that ICSI itself as 
well  as  the  freezing  and  thawing  procedure  produce  different  effects  on  placental 
development, supported by their finding that additional ICSI procedures cause the largest 
reduction in PAPP-A levels especially after freezing and thawing of embryos. In this study, 
PAPP-A were close to normal levels in pregnancies after IVF with frozen eggs but was 
decreased in pregnancies after IVF with fresh eggs. Hui et al (2005) also reported that 
there was a negative correlation between the number of transferred embryos and PAPP-A. 
With  the  increasing  number  of  embryo  transferred,  the  concentration  of  PAPP-A  was 
decreasing.   
Several  theories  have  been  proposed  to  explain  the  elevated  hCG  levels  in  ART 
pregnancies. An earlier study by Wald et al (1999b) suggested that increased hCG in ART 
pregnancies is not due to the administration of hCG as part of the IVF protocol but due to 
the continuing high progesterone concentration in IVF pregnancies. In IVF pregnancies, 
multiple follicle development causes the formation of multiple corpora lutea. This would 
lead to further production of progesterone and thus increase the production of hCG from 
the developing placenta (Wald et al., 1999b). This theory seemed unlikely when Raty et al. Chapter 5: Discussion  
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(2002) reported increased hCG levels in frozen embryo transfer (FET) pregnancies. In FET 
and oocyte donation pregnancies, there is no excessive follicles or corpora lutea. However, 
this study showed that the levels of hCG were not elevated in IVF pregnancies with donor 
egg. Perheentupa et al. (2002) showed that the second trimester hCG levels were similar in 
pregnancies following stimulated and un-stimulated cycles and therefore, super-ovulation 
therapy is unlikely to be the cause of the elevated hCG levels in ART pregnancies.  
Therefore,  although  many  theories  have  been  proposed,  the  biological  basis  of  altered 
screening  markers  levels  in  pregnancies  conceived  after  ART  remains  unknown.  The 
treatments or drugs used in ART protocols or infertility conditions might be the cause of 
the altered marker concentrations (Maymon and Jauniaux, 2002; Raty et al., 2002; Hui et 
al., 2003). Whatever the biologic basis, the effect of ART on Down’s syndrome screening 
markers must not be overlooked. Correcting for ART would provide women with more 
accurate individual risks and reduces the increased screen positive rate.  
Some of the findings from this study were not consistent with previous studies. This might 
be due to the small number of cases in each ART group especially in the IVF with donor’s 
egg group. Further research need to be conducted using a larger database to investigate the 
effect of current IVF procedure on Down’s syndrome screening markers.   Chapter 5: Discussion  
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5.5  RETROSPECTIVE  STUDY  ON  BIRTH  WEIGHT, 
DURATION  OF  PREGNANCY  AND  SECOND  TRIMESTER 
MATERNAL  SERUM  SCREENING  MARKERS  IN  NON-
SMOKERS AND SMOKERS 
5.5.1  ACCURACY  OF  SELF-REPORTED  SMOKING  STATUS  AT 
BOOKING AND SCREENING APPOINTMENT 
At most prenatal screening centres, self-reported smoking information is usually used to 
correct  the  biochemical  marker  levels  for  maternal  smoking  habit.  Using  cotinine-
validation, this study has estimated the prevalence of smoking among pregnant women as 
30.1%. This figure is 24.9% and 40.6% higher than figures based on self-report at booking 
and screening appointment respectively. In 2008, Usmani et al reported that at least 10% of 
pregnant women in Glasgow population likely not telling the truth about their smoking 
habits which causing under estimation of smoking prevalence in the Scottish population. In 
this  study,  approximately  one-quarter  of  validated  smoking  pregnant  women  were 
undetected through self-report at booking and screening. This finding is similar to that is 
seen in previous studies (Lindqvist et al., 2002, Klebanoff et al., 2001, Ford et al., 1997). 
Webb et al (2003) reported over 50% of cotinine-validated smokers were undetected by 
self report in the US.  
This study has also found that there is no change in the sensitivity and specificity of the 
self-reported  smoking  information  when  the  ‘former  smokers’  are  classified  as  ‘non-
smokers’. However, allowing pregnant women to correct their smoking status once they 
receive their screening report improves the accuracy of self-reported smoking information. Chapter 5: Discussion  
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Previous  studies  have  shown  that  the  concentration  of  cotinine,  whether  measured  in 
serum, plasma, saliva or urine, is the best biomarker for measuring smoking status due to 
its long half life and optimised sensitivity and specificity (Russell et al., 2004, Dempsey et 
al., 2002, Jarvis et al., 1987). The cotinine cut-off used between current smokers and non-
smokers is arbitrary. This is because there is an over-lap between non-smokers who are 
highly exposed to ETC with occasional smokers or those inhale very little. There is little 
variation  in  the  cotinine  cut-off  used  in  different  previous  studies.  Some  studies  used 
10ng/ml (Klebanoff et al., 2001, McDonald et al., 2005) as cotinine cut-off in pregnant 
women where as some other studies used 24ng/ml (Lindqvist et al., 2002, Boyd et al., 
1998). The cotinine cut-off of 13.7ng/ml used in this study was based on a previous study 
by Jarvis et al (1987) who used gas chromatography to measure cotinine concentration. 
The data from this study showed that there is very little variation in the findings when any 
cut-off between 10 and 30ng/ml is used (Table 4.21).  
Both nicotinine replacement therapy (NRT) and exposure to environmental tobacco smoke 
(ETS)  is  known  to  increase  the  cotinine  levels.  However,  the  median  cotinine  level 
measuring the impact for ETS exposure was reported as 4ng/ml and 8ng/ml for office staff 
and bar staff respectively (Hammond et al., 1995, Jarvis et al., 1992).Therefore, the chosen 
cut-off of 13.7ng/ml in this study would unlikely misclassify women exposed to ETS as 
smokers. Furthermore, in the dataset used in this study, 69.0% of pregnant women had 
cotinine levels below 10ng/ml and 29.0% of women had cotinine level 30ng/ml and above. 
Therefore, any cut-off between 10 and 30ng/ml would not make much difference to the 
findings in this study as 98% of pregnant women had cotinine level either below 10ng/ml 
or above 30ng/ml. The pregnant women in this study were not routinely recommended 
NRT. Community Action on Tobacco for Children’s Health (CATCH) (Bryce et al., 2008) Chapter 5: Discussion  
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was the only service offering NRT during the time the study women were pregnant which 
was in 2003/4. However, NRT was offered to only 65 women. Therefore, it is unlikely to 
bias the finding in this study due to the small number of women involved in NRT.   
The findings in this study are based on assumptions that the screened population represents 
the West of Scotland population and the differences between the West of Scotland and the 
Scottish  population  are  accounted  for  in  generating  the  projected  figures.  The  random 
selection of the sample from the screened population is successful as all characteristics 
tested in the study sample are similar to that of the screened samples. The high screening 
rate  (70%  of  all  women  are  screened)  in  this  population  reduces  the  possibilities  for 
differences between the screened population and target population.  
As anticipated, there were some errors in the recording or transcribing of the self-reported 
smoking information at booking and screening appointment. For an example, when the 
duration between the booking date and screening date was calculated, for 182 pregnant 
women the booking date was after the screening date (some of them were more than 3 
months after the screening date) and for 9 pregnant women the screening date was more 
than 84 days after the booking date. In order to check if there was an error in the booking 
date or screening date, the days between gestation at screening and gestation at birth were 
compared with the days between date of screening and baby’s date of birth. For 93.7% of 
these  women,  their  gestation  at  screening  and  gestation  at  birth  matched  with  date  of 
screening and baby’s date of birth. Therefore, the date of booking was not accurate in these 
cases. In the remaining cases, one of the other dates (DOB or screening date) was not 
correct. However, such errors are unlikely to bias the findings in this study as the recording 
error would not be systematic (e.g. by smoking status). Chapter 5: Discussion  
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The self-report smoking information collected at the maternity booking and screening visit 
is usually used to refer smoking pregnant women to specialist smoking cessation services 
and  for  refining  the  estimation  of  women’s  individual  risks  of  Down’s  syndrome  by 
prenatal screening, since maternal smoking causes changes in the levels of the biochemical 
markers used in the screening test. Therefore, accurate self-report smoking information is 
important.  However,  this  study  and  other  previous  studies  (O'Gorman,  2008)  have 
demonstrated  poor  quality  of  the  routinely  collected  self-report  smoking  data.  Better 
methods of routinely identifying smokers during pregnancy are required to improve the 
quality  of  smoking  information.  Currently  in  Glasgow,  all  women  attending  antenatal 
clinic have to provide both self-report smoking status and undergo carbon monoxide breath 
test. Usmani et al (2008) reported that the use of both self-report smoking information and 
carbon  monoxide  validated  measurement  would  be  able  to  identify  95.8%  of  pregnant 
smokers.  
In summary, the use of self-report to collect smoking information among pregnant women 
significantly  underestimates  the  number  of  pregnant  smokers  in  Scotland.  Therefore,  a 
more reliable method is required to accurately identify pregnant smokers in Scotland.  
5.5.2 BIRTHWEIGHT, DURATION OF PREGNANCY AND SECOND 
TRIMESTER MARKERS 
Although the association between birth weight, early delivery and AFP level has been 
previously reported, this study shows the impact of smoking on these variables. In this 
study,  women  who  smoke  and  have  AFP  levels  greater  than  2.0  MoM  have  a  39.8% 
chance of delivering a low birth weight infant and a 55.6% chance of delivery prior to 39 
weeks. This compares to a 4.4% chance of delivering a low birth weight infant and a Chapter 5: Discussion  
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23.8% chance of  delivery prior to 39 weeks in non-smokers with AFP levels less than 2.0 
MoM. This study shows that women who smoke and have an elevated AFP level (³2.0 
MoM) give birth to babies which are on average around 900g lighter than those born to 
non-smoking women with AFP values <1.00 MoM.  
Although smoking has a significantly greater effect on maternal serum hCG levels than on 
AFP levels, in this study, there was little association with high or low hCG levels and 
either birth weight or early delivery. The association between birth weight,  delivery prior 
to 39 weeks and second trimester markers is presented in section 4.5. The findings from 
this study are consistent with previous studies showing that pregnant women who smoke 
tend  to  deliver  low  birth  weight  infants  (Brooke  et  al.,  1989,  May,  2007,  Schell  and 
Hodges, 1985). In this study, the birth weights of infants born to women who smoke and 
had  deliveries at 39 to 41 weeks were, on average 270g less than infants born to non-
smoking women.  
The reasons of decreased birth weight in smoking mothers are still debatable. Some studies 
have suggested that carbon monoxide from smoking cause placental hypoxia and limits 
oxygen-carrying  capacity  of haemoglobin  (Longo, 1970, Cole et al., 1972 and Astrup, 
1972). Pathological placental hypoxia leads to decrease in cytotrophoblast proliferation 
and abnormal differentiation during the cell cycle in the placenta which causes restricted 
fetal growth (Zdravkovic et al., 2005, Albuquerque et al., 2004). One study proposed that 
nicotine  causes  vasoconstriction  of  uterine  arteries  and  uteroplacental  arteries  which 
subsequently leads to restricted fetal growth (Andrews and McGarry, 1972). van der Velde 
et al (1983) suggested that the structural changes in the placenta of smoking pregnant 
women  which  causes  restricted  fetal  growth  is  due  to  cadmium  from  tobacco  smoke. Chapter 5: Discussion  
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Cadmium content has been shown to be higher in smokers’ blood circulation compare to 
non-smokers (De Voogt et al., 1980) and causes reduction in birth weight (Sutou et al., 
1980).  
While this and other studies show that there is a clear association between elevated AFP 
level and low birth weight, AFP is a poor screening test for low birth weight in the whole 
pregnant population due to its low sensitivity and specificity (Smith, 1980). Chard et al. 
(1986), in a prospective study on 887 randomly selected pregnant women, found that if 
elevated AFP is used as a predictor of low birth weight, five out of every six cases will be 
missed and for every case correctly identified there would be nine false-positives. This 
study shows that if AFP is used as a screening test in smokers its predictive value is 
doubled over that in non-smokers but remains poor: maternal serum AFP levels ³2.0 MoM 
can predict only around 7.5% of low birth weight (<2500g) pregnancies at a false positive 
rate of 2.4%.  
Part of the association between AFP level and birth weight can be due to preterm delivery. 
The association between  delivery prior to 39 weeks and AFP level has also been shown in 
this study. In this study, women who smoke tend to have  deliveries prior to 39 weeks with 
a median gestation at delivery of 40 weeks in non smokers and 39 weeks in smokers. 
Although there is a clear association between early delivery and AFP level, part of this 
association might be due to bias. Abnormally high AFP level and early delivery can be also 
due to under-estimation of gestational week at the time of screening (Brock et al., 1980). A 
study by Wald et al (1977) showed that by using gestational age based on ultrasound, some 
of the association between high AFP level and early delivery was eliminated.  Chapter 5: Discussion  
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Gitlin (1975) reported that AFP, a fetal protein produced by the yolk sac and fetal liver, is 
transported  from  the  fetus  to  mother  mainly  across  the  placenta.  The  amount  of  AFP 
transported  from  the  fetus  to  the  mother  via  the  transplacental  route  depends  on  the 
permeability  of  the  placenta,  the  villous  surface  area  and  the  fetal  AFP  concentration 
(Gitlin,  1975,  Boyd  and  Keeling,  1986,  Boyd,  1992).  Boyd  and  Keeling  (1986)  also 
reported  that  increase  in  the  amount  of  AFP  transported  from  the  fetus  to  the  mother 
causing  elevated  maternal  serum  AFP  level  can  be  associated  with  infarcted  placental 
tissue and feto-maternal haemorrhage. 
The birth weight of a fetus depends on the functionality of different mechanism in the 
placenta. Any biological relevant stress on the fetoplacenta can cause changes in the birth 
weight (Salafia et al., 2008).  Ferguson-Smith et al (1979) suggested that the association of 
elevated AFP level and low birth weight can be explained by fetal haemorrhage due to 
placental lesion causing increase transport of AFP from fetus to mother.  
Although hCG level was thought to reflect the early placental pathology, in this study there 
was no any association between low birth weight,  delivery prior to 39 weeks and hCG 
level. HCG, a placental protein produced by  cytotrophoblast and excreted directly into 
maternal circulation, reflects placental function. Elevated second trimester hCG level is 
normally  associated  with  preeclampsia,  Down’s  syndrome,  still  birth  and  spontaneous 
abortion (Onderoglu and Kabukcu, 1997, Duric et al., 2003). 
In summary, although AFP is a poor screening test for low birth weight, pregnant women 
who have high AFP levels and who smoke should be monitored more carefully than non-
smoking pregnant women with normal AFP levels.   Chapter 5: Discussion  
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5.6 GENERAL DISCUSSION 
The UK NSC advises that first trimester CUB screening should be the preferred screening 
policy for Down’s syndrome. This is because in this screening policy, pregnant women 
only  need  to  visit  the  antenatal  clinic  once  and  a  risk  for  Down’s  syndrome  will  be 
provided before 14 weeks of gestation allowing earlier decision making for the parents. 
Although CUB screening is proven to be an effective method of detecting Down syndrome 
pregnancies  in  the  first  trimester,  with  a  detection  rates  of  85-91%  at  a  4-5%  screen 
positive rate (Spencer et al., 2000; Stenhouse et al., 2004, Perni et al., 2006), one of the 
critical factors in maintaining the performance of CUB screening is consistent and accurate 
NT measurement. This requires ultrasonographers with specific training and a system of 
on-going monitoring within a quality assured programme. This has hampered the adoption 
of  CUB  screening  in  some  screening  centres  which  lack  the  ultrasound  resources  to 
provide high quality NT measurements to the entire booking population. Therefore, an 
alternative  screening  policy  was  proposed  by  Christiansen  and  Larsen  (2002)  where 
women were selected for NT measurement based on PAPP-A and FβhCG measurements. 
This study showed that within-trimester contingent screening policy offers the prospect of 
reducing  the  NT  measurement  workload  to  around  25–30%  whilst  maintaining  high 
sensitivity  and  specificity.  Therefore,  this  screening  policy  allows  those  centres  with 
limited resources to target the group of pregnant women whose screening results can be 
most usefully modified by information from an NT measurement. 
Although  CUB  screening  is an efficient screening method to detect Down’s syndrome 
pregnancy, this screening policy would not be able to achieve the mission of the UK NSC; 
detection rate of greater than 90% with a screen positive rate of less than 2%. Repeat Chapter 5: Discussion  
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measure testing, one of the strategies currently being reviewed by the Health Technology 
Assessment  programme  (Wright  et  al.,  2010),  is  expected  to  further  improve  the 
performance of Down’s syndrome screening programmes if implemented in the period 
after  2010.  In  this  study,  the  performance  of  cross-trimester  contingent  screening  with 
repeat measure was assessed. Contingent screening policy with repeat measure of PAPP-A 
in the second trimester (NT, PAPP-A, fβhCG / AFP, hCG, InhA, uE3, PAPP-A) could 
potentially meet the 2010 recommended outcome with a detection rate of 92.2% at a false 
positive rate of 1.4% but with only 9.7% of women requiring a second trimester screening 
test.  In  screening  centres  where  there  is  lack  of  ultrasound  resources  to  provide  NT 
measurements, this screening policy without NT measurement could achieve a detection 
rate of 86.2% at a false positive rate of 3.0% but with only 22.3% of women requiring a 
second trimester screening test.  The cost of the additional marker (PAPP-A) to be added to 
the second trimester quadruple test has to be evaluated. However, only a slight increase in 
the screening cost would be expected as 90.0% (without NT measurement - 78.0%) of 
women would complete their screening in the first trimester without the need for a second 
trimester screening test.  
These findings using statistical modelling are based on assumption that a Gaussian fit is 
reasonable in the tails of a multivariate distribution which might cause overestimation of 
the screening performance. Further prospective intervention studies need to be carried out 
in  order  to  confirm  these  findings  and  the  practicality  of  cross-trimester  contingent 
screening policy. The evaluation of this screening policy would require large number of 
blood samples both from affected and unaffected pregnancies collected at two different 
stages of pregnancy. Therefore, a multi-centre prospective study would be recommended 
to confirm the results from this study. Chapter 5: Discussion  
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Although  previous  studies  have  reported  that  correcting  for  factors  such  as  maternal 
smoking habits, ethnic origin and ART has a little impact on the overall Down’s syndrome 
screening  performance,  the  effect  of  these  factors  on  the  biochemical  markers  used  in 
Down’s syndrome screening should not be overlooked. This study on the effect of ethnicity 
and  smoking  on  Down’s  syndrome  biochemical  markers  is  unique  as  paired  first  and 
second trimester serum samples were used to assess the trends in marker levels between 
gestations. The findings from this study have shown that the pattern of change caused by 
smoking  and  ethnicity  on  biochemical  markers  vary  depending  on  the  trimester  of 
screening and marker used. Therefore, the correction factors also vary between trimesters 
for  certain  biochemical  markers.  Further  studies  on  larger  numbers  of  women  in  each 
ethnic group are indicated to refine the correction factor found in this study and these may 
need to be specific for individual weeks of gestation. Correcting for these factors would 
provide  women  with  more  accurate  individual  risks  and  reduces  the  increased  screen 
positive  rate.  This  would  certainly  reduce  the  number  of  women  requiring  diagnostic 
testing.  
In Glasgow, PAPP-A levels are corrected for smoking before the risk of Down’s syndrome 
is  calculated.  The  self-reported  smoking  information  collected  during  the  screening 
appointment  is  usually  used  to  determine  maternal  smoking  habit.  Using  cotinine-
validation, this study has estimated the prevalence of smoking among pregnant women as 
30.1% which is 40.6% higher than figures based on self-report at screening appointment. 
Therefore,  approximately  30.0%  cotinine-validated  smokers  were  not  detected  by  self-
report at screening appointment. The individual risk for Down’s syndrome calculated for 
these women would not be accurate. This calls for a better method of collecting smoking 
information  at  antenatal  clinics.  Therefore,  it  is  important  that  detailed  and  accurate Chapter 5: Discussion  
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information  on  maternal  smoking  status,  ethnic  origin  and  the  type  of  ART  used  are 
recorded at the antenatal clinic. Appropriate MoM adjustment for these factors should be 
included in the screening software. 
In summary, this study  has shown that it is possible to meet the UK NSC mission to 
achieve a detection rate of 90% with a screen positive rate of less than 2% by April 2010. 
The contingent screening policy with repeat measure appears to hold much promise to 
meet the 2010 recommended Down’s syndrome screening outcome. Correcting for factors 
such as maternal smoking habits, ethnicity and ART would further improve the Down’s 
syndrome screening programme in the UK.   Chapter 6:Conclusion  
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In the past decade, there have been great developments in Down’s syndrome screening. 
Much research is still being carried out to further improve detection at lower false positive 
rates and meet the UK NSC goal to achieve a detection rate of 90% with a screen positive 
rate of less than 2% by April 2010. Considerable emphasis has been placed on screening in 
the first trimester, driven in part by women expressing a preference for early testing. Early 
screening  for  Down’s  syndrome  allows  early  reassurance  or  diagnosis  and  elective 
termination of affected pregnancies, which is simpler, safer and less traumatic than at a 
later stage. 
However,  although  this  study  and  others  have  demonstrated  that  within-trimester 
contingent  screening  can  deliver  useful  benefits  through  minimising  the  proportion  of 
women  requiring  an  NT  scan,  the  scope  to  increase  detection  rates  and  reduce  false 
positive rates in the first trimester is limited.  
Great potential for better screening performance seems possible through the use of samples 
collected at two different stages of pregnancy – cross trimester testing. As shown in this 
study, these policies  can be designed to allow  a proportion of women  a proportion of 
women to complete screening early, in the first trimester, but give overall higher detection 
rates and  lower false positive rates when repeat measures are incorporated into the model. 
The  studies  in  this  thesis  have  shown  that  a  contingent  screening  policy  with  repeat 
measures appear to meet the UK NSC performance goal. Correcting for factors such as 
maternal smoking habits, ethnicity and ART would further improve the Down’s syndrome 
screening programme in the UK.  Chapter 6:Conclusion  
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The results on cross-trimester contingent screening presented in this thesis are based on 
statistical modelling. Therefore, prospective intervention studies need to be carried out in 
order  to  confirm  these  findings  and  the  practicality  of  a  cross-trimester  contingent 
screening policy. The evaluation of this screening policy would require a large series of 
blood samples both from affected and unaffected pregnancies collected at two different 
stages of pregnancy, first and second trimester. Therefore, a multi-centre prospective study 
would  be  recommended  for  further  research  on  cross-trimester  contingent  screening.Reference List 
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